US20220031944A1 - Techniques to reduce risk of occlusions in drug delivery systems - Google Patents
Techniques to reduce risk of occlusions in drug delivery systems Download PDFInfo
- Publication number
- US20220031944A1 US20220031944A1 US16/945,246 US202016945246A US2022031944A1 US 20220031944 A1 US20220031944 A1 US 20220031944A1 US 202016945246 A US202016945246 A US 202016945246A US 2022031944 A1 US2022031944 A1 US 2022031944A1
- Authority
- US
- United States
- Prior art keywords
- liquid drug
- pump mechanism
- output
- dosage
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
- G05B15/00—Systems controlled by a computer
- G05B15/02—Systems controlled by a computer electric
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05D—SYSTEMS FOR CONTROLLING OR REGULATING NON-ELECTRIC VARIABLES
- G05D7/00—Control of flow
- G05D7/06—Control of flow characterised by the use of electric means
- G05D7/0617—Control of flow characterised by the use of electric means specially adapted for fluid materials
- G05D7/0623—Control of flow characterised by the use of electric means specially adapted for fluid materials characterised by the set value given to the control element
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05D—SYSTEMS FOR CONTROLLING OR REGULATING NON-ELECTRIC VARIABLES
- G05D7/00—Control of flow
- G05D7/06—Control of flow characterised by the use of electric means
- G05D7/0617—Control of flow characterised by the use of electric means specially adapted for fluid materials
- G05D7/0629—Control of flow characterised by the use of electric means specially adapted for fluid materials characterised by the type of regulator means
- G05D7/0676—Control of flow characterised by the use of electric means specially adapted for fluid materials characterised by the type of regulator means by action on flow sources
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/18—General characteristics of the apparatus with alarm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
Definitions
- Subcutaneous insulin delivery is the most commonly utilized, minimally invasive method of insulin delivery for people with Type-1 diabetes mellitus (T1DM) that utilize insulin pumps.
- T1DM Type-1 diabetes mellitus
- subcutaneous insulin infusion incurs a wide range of risks that must be mitigated to ensure safety of the users.
- pump occlusion can be defined as insulin delivery from the pump being impeded from actual delivery into the body, potentially caused by site pressure, scar tissue formation, incorrect cannula insertion, and others.
- Non-transitory computer readable medium embodied with programming code executable by a processor.
- the processor may be operable to receive a control instruction to deliver a dosage of insulin.
- the control instruction may include an amount of insulin to be output as the dosage of insulin.
- a pump rate for delivery of the dosage of insulin may be modified by adding additional time to a preset time period to provide an extended time period for outputting the dosage of insulin.
- An actuation command may be to output to actuate a pump mechanism to output the dosage of insulin included in the control instruction at the modified pump rate.
- An example of a drug delivery device includes a reservoir, a cannula, a pump mechanism, a memory, a controller and a communication device.
- the reservoir may be configured to hold a liquid drug.
- the cannula may be coupled to the reservoir via a fluid delivery path and operable to output the liquid drug to a user.
- the pump mechanism may be coupled to the reservoir and operable to output the liquid drug from the reservoir via the fluid delivery path and out of the cannula.
- the memory may be operable to store programming code, applications including a delivery control application, and data.
- the controller may be coupled to the pump mechanism and the memory, and operable to execute programming code and the applications including the delivery control application.
- the communication device may be operable to wirelessly communicate with an external device and communicatively coupled to the controller.
- the controller when executing the delivery control application, may be operable to receive, from the external device, a control instruction including a dosage of insulin to be output by the pump mechanism.
- the received control instruction may indicate an amount of insulin to be output for a control cycle.
- the controller may be operable to calculate an output distribution of the dosage of insulin by the pump mechanism.
- the output distribution may be a series of partial insulin doses output at discrete times distributed over the control cycle.
- An actuation command may be output by the controller to actuate the pump mechanism to deliver a partial each insulin dose in the series of partial insulin doses.
- An example of a method may include receiving a control instruction to deliver a dosage of insulin.
- the control instruction may include a dosage of insulin to be output as a pump mechanism.
- a number of doses of insulin may be determined to be delivered based on a duration of a control cycle.
- the sum of the number of doses of insulin may equal the dosage of insulin, to be delivered based on a duration of a control cycle.
- a series of actuation commands may be output.
- the series of actuation commands may include a number of actuation commands equal to a number of doses of insulin in the plurality of doses of insulin.
- Each actuation command in the series of actuation commands may actuate a pump mechanism to output a respective dose of insulin of the plurality of doses of insulin, and each actuation command may be applied after passage of a selected additional time period based on the duration of the control cycle.
- FIG. 1 illustrates an example of a process for modifying a pump rate for delivery of a dosage of insulin.
- FIG. 2 illustrates an example of a functional block diagram of drug delivery system suitable for implementing the example processes and techniques described herein.
- FIG. 2A illustrates an example of a drug delivery system suitable for implementing the example processes and techniques described herein.
- FIG. 3A illustrates an example of a process for determining a series of insulin dosages to be output over a control cycle.
- FIG. 3B illustrates an example of a process for modifying a pump rate suitable for use in the device examples of FIGS. 2 and 2A .
- FIG. 4 shows a graphic illustrating time segmentation of a control cycle during the modification of a pump rate.
- FIG. 5A illustrates an example of a process for detecting a pump occlusion that may result in a modification of a pump rate.
- FIG. 5B illustrates an example of a process for detecting a pump occlusion that may result in a modification of a pump rate.
- FIG. 6 illustrates an example of system suitable to implement the processes and techniques described herein.
- An example provides a process that may be used with additional algorithms or computer applications that may provide information and enable management of blood glucose levels and insulin therapy.
- Such algorithms may include an “artificial pancreas” algorithm-based system, or more generally, an artificial pancreas (AP) application or automatic insulin delivery (AID) algorithm, that provides automatic delivery of insulin based on a blood glucose sensor input, such as that received from a CGM or the like.
- AP artificial pancreas
- AID automatic insulin delivery
- the artificial pancreas (AP) application when executed by a processor may enable a system to monitor a user's glucose values, determine an appropriate level of insulin for the user based on the monitored glucose values (e.g., blood glucose concentrations or blood glucose measurement values) and other information, such as user-provided information, such as carbohydrate intake, exercise times, meal times or the like, and take actions to maintain a user's blood glucose value within an appropriate range.
- the appropriate blood glucose value range may be considered within a threshold value of a target blood glucose value of the particular user.
- a target blood glucose value may be acceptable if it falls within the range of 80 mg/dL to 120 mg/dL, which is a range satisfying the clinical standard of care for treatment of diabetes.
- an AP application as described herein may be able to establish a target blood glucose value more precisely and may set the target blood glucose value at, for example, 110 mg/dL, or the like.
- the AP application may utilize the monitored blood glucose measurement values and other information to determine an optimal pump rate that mitigates potential causes of insulin device pump occlusions, or the like.
- a pump rate may be the amount of insulin that may be output by a pump over a set period of time.
- a wearable drug delivery device may be affixed at a site on a user's body, such as, for example, the abdomen or upper arm.
- the drug delivery device may include a needle insertion component, a needle and a flexible cannula within the needle, a reservoir containing insulin, a pump that is a mechanism operable to expel various amounts of insulin from the reservoir, and control logic circuitry that is operable to control the pump and delivery of insulin from the reservoir to the flexible cannula.
- a needle may be used to puncture the user's skin to the depth of subcutaneous tissue, and within the needle is a flexible cannula.
- Insulin may be delivered from the reservoir based on the pump causing insulin to be expelled from the reservoir to a fluid delivery path that leads to the flexible cannula that has been inserted in the user's body.
- the wearable drug delivery device may be operable to deliver a basal dosage of insulin and a bolus amount of insulin.
- the basal dosage of insulin is a small amount of insulin that is gradually delivered to a user over the course of a day (i.e., 24 hours).
- a bolus is an amount of insulin greater than the basal dosage that is delivered in a much shorter period of time than the extended period of time over which the basal dosage is delivered.
- a bolus dosage may be requested or required for various reasons, most typically, a bolus dosage is delivered in response to the consumption of a meal by the user, but also in response to exercise or as a way to correct excursions of the user's blood glucose measurements.
- the sum of the insulin amounts delivered as a basal dosage and in the bolus dosages may be referred to as the user's total daily insulin (TDI).
- the AID algorithm may be operable to deliver basal dosages, bolus dosages as well as other dosages, that are greater than a basal dosage but less than a typical bolus dosage. These other dosages may be referred to as “microboluses.”
- a microbolus may be an amount of insulin greater than basal but less than a bolus.
- the amount of insulin in a microbolus may include the amount of insulin in the basal dosage.
- the amount of insulin contained in the microbolus may be substantially equal to the basal dosage of insulin. Microboluses may be less likely to be occluded because it is smaller than a typical bolus dosage.
- a situation may arise during which a proper amount of insulin is not delivered to a user within a predetermined time period.
- the predetermined time period may be referred to as “a control cycle.”
- a common cause of the non-delivery (e.g., an improper delivery) of the intended amount of insulin within the predetermined amount of time is the presence of what is generally referred to as a pump occlusion.
- a pump occlusion may be defined as insulin delivery from the pump being impeded from actual delivery into the body.
- the occlusion may be within a pump mechanism, a fluid delivery path of the medical device, a needle or cannula, or the user's body.
- a non-delivery of insulin is intended to mean that an intended amount of insulin was not delivered to the user for some reason, such as a pump occlusion.
- a control cycle may be approximately 5 minutes.
- the control cycle may be a period of time that is longer or shorter than approximately 5 minutes, such as 3 minutes, 6.5 minutes or the like.
- control logic circuitry in a pump may initiate delivery of a predetermined amount of insulin that is to be delivered to the user within a set period of time, e.g., 30 seconds.
- the control logic circuitry may direct the pump to deliver the predetermined amount of insulin within the set period of time, but due to a pump occlusion, the pump may be unable to complete the delivery of the predetermined amount of insulin within the set period of time.
- the drug delivery device may be deployed with the flexible cannula inserted in the user.
- the deployed drug delivery device while initially affixed to a site on a user may shift which may result in movement of the drug delivery device.
- the flexible cannula cannot move since the flexible cannula is inserted in the user. This relative movement between the drug delivery device and the flexible cannula may cause a kink in the flexible cannula. As a result of the kink, the full amount of the predetermined amount of insulin may not be delivered within the set period of time.
- pressure may be applied on a surface of the drug delivery device (such as the top or the side) and consequently to the site of the body at which the drug delivery device is located.
- interstitial fluid may build up within a part of the fluid delivery path of the pump which may cause a back pressure into the cannula (or even further up the fluid delivery path toward the reservoir and pump).
- the pump has to work harder to expel both the built-up interstitial fluid and the predetermined amount of insulin.
- the needle insertion component is operable to puncture the skin of the user with the needle to a depth of the subcutaneous region of the user's skin.
- the needle is hollow and within the needle is the flexible cannula.
- the needle insertion component is further operable to retract the needle from the user's skin and leave the flexible cannula within the skin to allow delivery of insulin.
- the needle may leave punctured tissue below the open end of cannula from which insulin is output to the user's subcutaneous region. The punctured tissue allows the end of the cannula to freely move up and down and not be occluded.
- the body's immune system may attack the location of the needle insertion (i.e., insulin infusion site).
- the human body's immune response causes inflammation in the area around the cannula within the body and scar tissue may form, which causes an occlusion around the cannula and an occlusion of the pump.
- Occlusions may also occur when insulin is not absorbed quickly enough by the subcutaneous tissues of the user.
- the delay in absorption may be related to a number of issues, such as the buildup of scar tissue if the pump is placed at a frequently used location on the user's body.
- Pump occlusion may be caused by different conditions. Any method or device operable to mitigate the occurrence of a pump occlusion is an improvement of the presently available wearable drug delivery systems.
- FIG. 1 illustrates an example of a process for mitigating the potential causes of pump occlusion.
- the process 100 may be implemented by a controller coupled to a pump mechanism.
- the controller may be operable to receive a control instruction to deliver a dosage of insulin ( 110 ).
- the controller may be operable to modify a pump rate for delivery of the dosage by at least adding additional time to a preset time period for delivering the dosage of insulin ( 120 ).
- a pump rate may be a rate at which a pump on a wearable drug delivery device is operable to deliver insulin to a user.
- the controller may be further operable to output an actuation command to actuate a pump to output the dosage of insulin included in the control instruction at the modified pump rate ( 130 ).
- the medical device 202 may include a controller 221 , a pressure sensor 222 , a memory 223 , an AP application 229 and delivery control application 299 stored in the memory 223 , a pump mechanism 224 , a communication device 226 , user interface 227 , and a power source 228 .
- a memory 223 may be operable to store programming code and applications including a delivery control application 299 , an AP application 229 and data.
- the delivery control application 299 and an AP application 229 may optionally be stored on other devices, as shown in another examples.
- the controller 221 may be coupled to the pump mechanism 224 and the memory 223 .
- the controller 221 may include logic circuits, a clock, a counter or timer as well as other processing circuitry, and be operable to execute programming code and the applications stored in the memory 223 including the delivery control application.
- a communication device 226 may be communicatively coupled to the controller 221 and may be operable to wirelessly communicate with an external device, such as personal diabetes management device, a smart device (both shown in a system example), or the like.
- the pressure sensor 222 ′ may be a mechanical, electronic, or electromechanical sensor that is operable to measure changes in pressure of a fluid delivery path between the reservoir 225 and a cannula (not shown in this example) inserted into a user.
- the pump mechanism may be operable to deliver a drug, like insulin, at a fixed rate.
- pump mechanisms are commanded by the controller 221 to deliver insulin at the fixed rate.
- a fixed rate for the pump mechanism 224 may be a rate of approximately 0.05 Units per 2 seconds, or 0.025 per second, or 6 Units per 5 minutes, where insulin is measured in Units.
- These mechanical rates are different from physiological dosage rates that may be determined for a patient.
- an AP application or AID algorithm executing on a personal diabetes management device or a smart phone may determine that a user's total daily insulin is 24 units per 24 hours, which may translate to an exemplary physiological dosage rate of 1 unit per hour that may be determined according to a diabetes treatment plan.
- the pump mechanism 224 may be operable to deliver insulin at rates different from the example physiological dosage rate of 1 unit per hour.
- dosage rate e.g., either the example physiological dosage rate or the example mechanical rate of the pump mechanism
- additional and different control algorithms may be implemented or applied to enable delivery of an appropriate insulin dosage by the pump mechanism 224 .
- the medical device 202 may be attached to the body of a user, such as a patient or diabetic via, for example, an adhesive, and may deliver any therapeutic agent, including any drug or medicine, such as insulin, morphine, or the like, to the user.
- the medical device 202 may, for example, be a wearable device worn by the user.
- the medical device 202 may be directly coupled to a user (e.g., directly attached to the skin of the user via an adhesive or the like).
- a surface of the medical device 202 may include an adhesive (not shown) to facilitate attachment to a user.
- the medical device 202 may be an automatic, wearable drug delivery device.
- the medical device 202 may include a reservoir 225 configured to hold a liquid drug (such as insulin), a needle or cannula 233 (not shown) for delivering the drug into the body of the user (which may be done subcutaneously, intraperitoneally, or intravenously), and a pump mechanism (mech.) 224 , or other drive mechanism, for transferring the drug from the reservoir 225 , through a needle or cannula 233 , and into the user.
- a liquid drug such as insulin
- a needle or cannula 233 not shown
- a pump mechanism or other drive mechanism
- the pump mechanism 224 may be fluidly coupled to reservoir 225 , and communicatively coupled to the medical device controller 221 .
- the pump mechanism 224 may be coupled to the reservoir 225 and operable to output the liquid drug from the reservoir 225 via a fluid delivery path and out of the cannula (shown in the example of FIG. 2A ).
- the pump mechanism 224 may have mechanical parameters and specifications, such as a pump resolution, that indicate mechanical capabilities of the pump mechanism.
- the pump resolution is a fixed amount of insulin the pump mechanism 224 delivers in a pump mechanism pulse, which is an actuation of the pump mechanism for a preset time period. Actuation may be when power from the power source 228 is applied to the pump mechanism 224 and the pump mechanism 224 operates to pump a fixed amount of insulin in a preset amount of time from the reservoir 225 .
- the cannula 233 of FIG. 2 may be coupled to the reservoir 225 via a fluid delivery path 234 (and shown in the example of FIG. 2A ).
- the cannula 233 may be operable to output the liquid drug to a user when the cannula 233 is inserted in the user.
- the medical device 202 may also include a power source 228 , such as a battery, a piezoelectric device, or the like, that is operable to supply electrical power to the pump mechanism 224 and/or other components (such as the controller 221 , memory 223 , and the communication device 226 ) of the medical device 202 .
- a power source 228 such as a battery, a piezoelectric device, or the like, that is operable to supply electrical power to the pump mechanism 224 and/or other components (such as the controller 221 , memory 223 , and the communication device 226 ) of the medical device 202 .
- the drug delivery device 200 may include a plunger 102 positioned within the reservoir 225 ′.
- An end portion or stem of the plunger 102 can extend outside of the reservoir 225 ′.
- the pump mechanism shown generally as 224 ′ may, under control of the controller 221 ′, be operable to cause the plunger 102 to expel the fluid, such as a liquid drug (not shown) from the reservoir 225 ′ and into the fluid component 104 and cannula 108 by advancing into the reservoir 225 ′.
- the pressure sensor 222 ′ may be integrated anywhere along the overall fluid delivery path of the drug delivery device 200 , which includes the reservoir 225 ′, a fluid delivery path component 104 , the cannula 108 ) that is at the same approximate pressure as the outlet into the patient.
- An intervening membrane (not shown in FIG. 2A for simplicity) can be used to isolate the pressure sensor 222 ′ from the fluid within the reservoir 225 ′, the fluid delivery path component 104 , and/or the cannula 108 .
- a pliable gel or sufficiently soft rubber can be used to isolate the pressure sensor 222 ′ from the fluid.
- the pressure sensor 222 ′ may be integrated into the reservoir 225 ′.
- the pressure sensor 222 ′ can have a round body to simplify sealing against the reservoir 102 , the fluid delivery path component 104 and the cannula 108 .
- an integral lip seal can be used to seal the interface between the body of the pressure sensor 222 ′ and the reservoir 225 ′, the fluid delivery path component 104 , and the cannula 108 .
- the pressure sensor 222 ′ may be coupled to a controller 221 ′ via connection 22 A.
- the pressure sensor 222 ′ can measure the absolute pressure of the reservoir 102 and/or the fluid delivery path component 104 (e.g., the overall fluid delivery path of the drug delivery device 200 ) and can provide an output signal to the controller 221 ′.
- the pressure sensor 222 ′ can take continuous readings of the absolute pressure.
- the output signal from the pressure sensor 222 ′ can indicate the measured or detected absolute pressure and/or any other measured, detected, or derived pressure value.
- the controller 221 ′ can process the received signal from the pressure sensor 222 ′.
- the controller 221 ′ may be implemented in hardware, software, or any combination thereof.
- the controller 221 ′ can be implemented as dedicated hardware (e.g., as an application specific integrated circuit (ASIC)).
- ASIC application specific integrated circuit
- the controller 221 ′ may be a constituent part of the drug delivery device 200 , can be implemented in software as a computational model, or can be implemented external to the drug delivery device 200 (e.g., remotely).
- the pressure sensor 222 ′ can be an absolute pressure sensor that can detect both ambient pressure (e.g., absolute or atmospheric pressure) and relative pressure (e.g., gage or pumping pressure) introduced as the drug delivery device 200 displaces fluid (e.g., the fluid stored in the reservoir 225 ′) in the overall fluid delivery path of the drug delivery device (e.g., including the reservoir 102 the fluid delivery path component 104 and the cannula 108 ).
- ambient pressure e.g., absolute or atmospheric pressure
- relative pressure e.g., gage or pumping pressure
- the pressure sensor 222 ′ may be operable to respond to pressure changes in the fluid delivery path and cause a signal to be provided to the controller 221 ′.
- the pressure sensor 222 ′ may, for example, be one or more sensors positioned along the fluid delivery path that are operable to respond to changes in pressure of the fluid within the fluid delivery path.
- the pressure sensor may be an electromechanical sensor that includes a transducer. The transducer may be positioned to detect pressure within the fluid delivery path, for example, adjacent to a wall of the fluid delivery path or the like. In response to fluid being output from the reservoir, the walls of the fluid delivery path may become more rigid due to the increased pressure of the dispensed fluid.
- the transducer positioned adjacent to a fluid delivery path wall may cause the transducer positioned adjacent to a fluid delivery path wall to generate an electrical signal in response to an increased pressure.
- the increased pressure in the fluid delivery path of the reservoir 225 ′ to the cannula 108 may cause the pressure sensor 222 ′ to generate an output signal indicative of the pressure in the fluid delivery path.
- the controller 221 ′ may be operable to determine an increase in a delivery pressure value when outputting insulin in comparison to a respective delivery pressure value associated with a respective earlier output of insulin.
- the controller may be operable to measure pressure by using the time it takes for the pump mechanism to push a specified amount of insulin (e.g., 0.1 Units) out of the reservoir. If the delivery of the specified amount of insulin takes longer than a threshold, the controller may cause a first alarm to notify the user of a possible problem with the pump.
- a pump resolution is 0.05 Units per 2 seconds
- a pump occlusion back pressure into the reservoir may cause the pump to fail to deliver the amount of insulin designated in a control instruction, which may result in extra pulses of the pump mechanism.
- the pump piston is moved so an amount of 0.05 U is displaced from the reservoir 225 ′. If there is occlusion, it may take longer than 2 seconds to complete the pulse, which means that, in this example, there is not a fractional pulse (i.e., a pulse less than two seconds or a delivery of less than 0.05 U.
- the controller 221 ′ may give an occlusion alarm that may be delivered to a user interface of a smart phone or PDM.
- the controller 221 ′ may be operable to report back to the AP algorithm how many pulses were delivered.
- the output signal generated by the pressure sensor 222 ′ can be a voltage signal, a current signal, and/or an electrical charge signal that may be provided to the controller 221 ′ via a connection, such as 222 A.
- the output signal from the pressure sensor 222 ′ can indicate a measured pressure.
- the output signal generated by the pressure sensor 222 ′ may be an analog or digital data signal output by, for example, an inter-integrated circuit (I2C), serial peripheral interface (SPI), or any other known or customized synchronous or asynchronous data communication stream.
- I2C inter-integrated circuit
- SPI serial peripheral interface
- the pressure sensor 222 ′ and the controller 221 ′ can communicate over any known signaling protocol or standard including any known wired or wireless communication or signaling protocol.
- the signal generated by the pressure sensor 222 ′ for output and delivery to the controller 221 ′ may be compensated for various environmental conditions, such as altitude, humidity or temperature, to remove or mitigate any error due to environmental changes.
- the controller 221 ′ may be operable to convert the output signal received from the pressure sensor 222 ′ into an indication of absolute pressure (e.g., pounds per square inch absolute (psia)) or the like.
- the controller 221 ′ may be operable to process the output signal received from the pressure sensor 222 ′ to determine whether a modification of the pump rate of the pump mechanism 224 is necessary, and, if determined to be necessary, may make the appropriate pump modification or modifications.
- FIG. 3A illustrates an example of a process for determining a series of insulin dosages to be output over a control cycle.
- a control cycle may be a time period during which an AP application or an AID algorithm may process received data and information, such as a blood glucose measurement value provided by a continuous blood glucose measurement sensor or other devices, services, such as a cloud service, or the like.
- the duration of the control cycle may vary between different brands of AP applications and different sensors coupled to the respective AP applications.
- a blood glucose sensor may periodically output a blood glucose measurement value.
- an AP application may process the received blood glucose measurement value and generate a control instruction.
- the control cycle may be the time from when an AP application receives a blood glucose measurement value and an immediately subsequent blood glucose measurement value. In the present examples, the control cycle is approximately 5 minutes.
- the process 300 is an algorithm for determining a series of insulin dosages to be output over a control cycle may be performed either by a personal diabetes management device (PDM) or by a medical device that delivers insulin to a user.
- a control instruction may be received that includes a dosage of insulin to be output by the pump mechanism.
- an AP application or AID algorithm may determine that a bolus dosage is required to be delivered or has been requested by a user to be delivered.
- the AP application or AID algorithm may generate a control instruction for output to a medical device that is operable to deliver insulin to the user.
- the medical device may deliver the requested or required bolus of insulin as rapidly as possible given the pump resolution of the pump mechanism.
- the AP application may output a series of control instructions that cause medical device to actuate the pump mechanism without pausing between actuations until the entire amount of insulin indicated in the control instruction is output from the reservoir.
- a controller of a medical device may be operable to modify a pump rate for delivery of the dosage of insulin provided using different techniques.
- a delivery control application may be executed by a controller of the medical device.
- a controller of the medical device may receive a control instruction from an AP application.
- the received control instruction may include a dosage of insulin to be delivered by the medical device.
- the delivery control application executed by the controller of the medical device may be operable to deliver a number of microboluses continuously over the control cycle (e.g., 5 minutes).
- the following examples describe a pre-existing AID system that may utilize the devices, products, processes and techniques described herein to deliver its recommended dose of insulin every control cycle over a pre-defined period, such as the full control cycle, instead of attempting this delivery at a fixed pump rate without pausing to allow some absorption of the delivered insulin.
- an AID algorithm may recommend as a bolus insulin delivery ID(t).
- a delivery control application executing on a medical device may be operable to, instead of delivering this ID(t) immediately, may deliver a portion of this delivery over an evenly distributed interval throughout its control cycle to minimize the buildup of pressure to thereby mitigate the rate of occlusion.
- the calculation of an evenly-distributed delivery amount of insulin over a control period may be described with reference to the following equations:
- I D (t) is the algorithm's requested amount of insulin to be delivered for the current control cycle
- R is the pump resolution that is an expression of an amount of insulin that is delivered by a pulse of the pump mechanism
- I n (t) is the number of times the pump actuates every t i (t) time intervals to deliver insulin at the pump resolution R
- t c (t) is the time interval t i (t) divided by the number of pump actuations are needed to deliver an insulin delivery quantity (i.e., I D (t)/R).
- FIG. 3A illustrates an example of a process for determining a series of insulin dosages to be output over a control cycle of an automatic insulin delivery (AID) system.
- AID automatic insulin delivery
- a controller of the medical device may receive a control instruction including a dosage of insulin to be output by the pump mechanism ( 310 ) from an external device.
- An example of an external device may be a PDM, a smart phone, a smart wearable accessory, such as a smart watch, a fitness device, or the like, or some other type of computing device able to communicate with the medical device.
- the controller may evaluate the received control instruction to determine a dosage of insulin to be delivered over a control cycle of the AID system.
- an AID algorithm of the AID system may request a microbolus of 0.4 U (of insulin) at the beginning of a current control cycle.
- the pump mechanism 224 of the medical device 202 as described with reference to the following examples may have a pump resolution of 0.05 Units of insulin that is delivered in 2 seconds, which means that in response to a control actuation command the pump mechanism delivers 0.05 Units of insulin over a time of 2 seconds.
- different pump resolutions are possible based on a type of electric motor, control mechanisms or logic used in the respective pump mechanism.
- the 2 seconds of the pump resolution may be viewed as a preset time period and the 0.05 Units may be viewed as the minimum dosage that the pump mechanism may deliver in response to a control actuation command.
- the pump mechanism may “pulse” for 2 seconds during which the pump mechanism outputs the 0.05 Units of insulin. So, each pulse of the pump mechanism may be equated to either 0.05 Units of insulin or 2 seconds. may also be referred to the amount of insulin output by each pulse
- the controller may evaluate the dosage of insulin in the received control instruction with reference to the pump resolution and the time period of the control cycle. Based on the evaluation, the controller may determine a number of doses that equal the dosage of insulin to be delivered based on over a time period equal to the time of a control cycle ( 320 ). Once the dosage of insulin is determined by the controller, the controller may output an actuation command to the pump mechanism to deliver a set amount of insulin. The actuation command may actuate the pump mechanism to deliver a set amount of insulin for each insulin dosage in a series of insulin doses ( 330 ). Actuation of the pump mechanism is a pump mechanism pulse generated in response to the actuation command that causes the output of a drug from the reservoir.
- control instruction from the external device may include a dosage of insulin equal to 0.4 Units of insulin.
- FIG. 3B illustrates an example of a process for modifying a pump rate that may be implemented by the device shown in the examples of FIGS. 2 and 2A .
- FIG. 4 shows a graphic illustrating segmentation of a control cycle during the modification of a pump rate. This graphic may be helpful in understanding the process 303 described in FIG. 3B .
- the controller may be operable to accumulate (or carry over) the determined remainder of insulin to a next time period. In which case, the amounts of insulin to be delivered may not be evenly distributed across the respective time segments.
- the controller may be operable to either deliver the accumulated remainder of insulin and the scheduled insulin delivery during the next time segment or to revise the distribution so that the accumulated remainder is distributed with the scheduled delivery amounts over the remaining time segments.
- a revised distribution to include the accumulated remainder may be determined by summing the accumulated remainder and the total amount of insulin to be delivered over the remaining time segments and dividing the sum total by the remaining time segments.
- time segment #1 includes pulse 411 and a selected additional time period 421 .
- the pulse 411 may be equal to the pump resolution or a preset time period.
- the pump resolution, or the resolution of the pump mechanism may be an amount or volume of insulin that the pump mechanism delivers upon each actuation. Note the pump resolution may also be referred to as the pump mechanism resolution, the resolution of the pump, or resolution of the pump mechanism and the terms may be used interchangeably.
- the preset time period 411 may be equal to the period of time that the pump mechanism of the medical device takes to output the volume of fluid (i.e., the pump resolution), such as pump mechanism 224 of the medical device 202 of FIG. 2 , outputs in response to a control actuation command.
- the controller may be operable to divide the dosage of insulin by a resolution of the pump mechanism to produce the number of times the pump needs to actuate to output the insulin dosages as shown by the respective time segments in the example graphic 400 of FIG. 4 .
- the pump mechanism 224 of the medical device 202 as may be assumed to have a pump resolution of 0.05 Units of insulin that is delivered in 2 seconds, which means that in response to a control actuation command, a pulse of the pump mechanism delivers 0.05 Units of insulin over a time of 2 seconds.
- the pulse of the pump mechanism may be complete at the end of 2 seconds if no resistance is encountered (such as back pressure from an occlusion or the like).
- the pulse may last longer than 2 seconds due to a mechanical travel limit on the pump mechanism.
- the 2 seconds may be equal to the preset time period 411 in FIG. 4 and the 0.05 Units may be viewed as the fixed dosage that the pump mechanism may deliver in response to a control actuation command during the preset time period.
- the mechanical limit may be based on the travel of a ratchet gear (not shown) as the ratchet gear moves from one gear tooth to another, from one notch to another between gear teeth, or the like.
- the fastest time that the ratchet gear can move moves from one gear tooth to another, from one notch to another between gear teeth, or the like may be 2 seconds.
- the movement in the presence of an occlusion or back pressure may be 5 seconds, 9 seconds or the like.
- each time segment #1-#8 is formed by a preset time period or pulse 411 , and a selected additional time period, such as 421 .
- the pulse or preset time period 411 is equal to 2 seconds which is the time that the pump mechanism takes to output a dose of insulin equal to 0.05 Units.
- Each pulse 411 - 418 has a fixed time period that is equal to the time period of the pump resolution.
- the selected additional time period 421 is an amount of time that the controller has calculated to wait until issuing a subsequent actuation command.
- the selected additional time periods 421 - 428 may be of equal duration to allow sufficient absorption of the outputted insulin.
- each of the time segments #1-#8 is of equal duration.
- the controller may be operable to calculate an output distribution of the dosage of insulin by the pump mechanism by dividing a duration of a control cycle by the number of pump mechanism pulses to obtain an output distribution, such as output distribution 449 of FIG. 4 .
- the output distribution 449 may be, for example, a series of discrete time segments distributed over the duration of control cycle 444 and during which a partial insulin dose is output by the pump mechanism.
- the output distribution 449 may be a series of partial doses of insulin dosages output at discrete times distributed over the control cycle 444 .
- the output distribution 449 illustrates the distributed output of the dosage of insulin indicated in the control instruction as partial doses of insulin distributed over the control cycle 444 of FIG. 4 .
- the output distribution 449 may be used by the controller to determine timing of delivery of the partial doses of the dosage of insulin. For example, each pulse 411 - 418 may output of a dose of insulin that is an of the dosage of insulin indicated in the control instruction.
- the controller determines the timing of the partial doses of the dosage of insulin ( 380 ).
- the timing of the partial doses of the dosage of insulin may be represented by the selected additional time periods 421 - 428 .
- Each additional time period 421 - 428 is a period of time that serves as a delay or a waiting period after completion of a corresponding pulse 411 - 418 .
- the controller upon determining the number of pump mechanism pulses needed to deliver the 0.4 Units is 8 may divide the duration of the control cycle 444 by 8 to determine the duration of each time segment #1-8.
- a control cycle such as 444 may be 5 minutes or 300 seconds (5 ⁇ 60 seconds) in duration.
- the duration of each time segment #1-#8, in this example may be equal to the time period of the control cycle in seconds (i.e., 300) divided by the number of pump mechanism pulses (i.e., 8). In this example, the duration of each time segment #1-#8 may be equal to 37.5 seconds.
- the controller Based on this determination the controller generate a respective actuation command to actuate the pump mechanism to output each partial dose of the partial doses distributed over the output distribution ( 390 ). For example, the controller may generate a respective actuation command that corresponds to pulse 411 of time segment #1, and at after the 37.5 seconds allocated to time segment #1, the controller may generate another respective actuation command that corresponds to pulse 412 of time segment #2. A timer within the controller may be reset or may indicate a start of time segment #2. The respective generation of subsequent actuation commands for time segment #3, time segment #4, time segment #5, time segment #6, time segment #7 and time segment #8 may be performed until the control cycle 444 is completed. By the completion of time segment #8 and the corresponding completion of the control cycle 444 , the 0.4 Units of insulin in the dosage of insulin included in the control instruction is output by the pump mechanism.
- the controller may generate actuation signals that cause the delivery of the instructed 0.4 Units immediately without any pauses at the pump resolution.
- the controller may generate actuation signals every 2 seconds at the start of a control cycle, the pump mechanism may need to receive 8 actuation signals to deliver the instructed 0.4 Units within 16 seconds (i.e., 2 seconds times the 8 actuation signals).
- the control cycle 444 may be as long as 5 minutes and the 16 second delivery of insulin may be less than the total time duration of time segment #1.
- controller it is also possible for the controller to take different approaches to determining the output distribution 449 and the time segments #1-#8.
- the controller may be operable to determine a number of times the pump mechanism needs to actuate to output the dosage of insulin included in the control instruction (e.g., 8 ). Using the determined number of times the pump mechanism needs to actuate to output the dosage of insulin, the controller may segment the control cycle 444 into time segments #1-#8 by dividing a duration of the control cycle 44 by the determined number of times the pump mechanism ought to actuate. The segmentation of the 300 seconds of the control cycle 444 provides eight time segments #1-#8 of 37.5 seconds. As noted, each time segment #1-#8 may include a pump resolution or preset time period and a respective additional time period 421
- each time segment #1-#8 is 37.5 seconds in duration.
- the controller is operable to generate a respective actuation command that actuates the pump mechanism for each time segment #1-#8.
- the pump mechanism pulses 411 - 418 occur at the start of each respective time segment #1-#8.
- Each pump mechanism pulse such as pulse 411 of time segment #1, pumps 0.05 Units of insulin for 2 seconds and stops, the controller delays the generation of an actuation command for application at the start of time segment #2 for 35.5 seconds (i.e., 37.5 seconds minus 2 seconds).
- the 35.5 seconds may be measured by a clock, a counter or timer accessible by or within the controller.
- the 35.5 seconds may be the selected additional time period 421 .
- An advantage of the selected additional time period 421 is that this delay enables the partial dose of insulin to be absorbed within the user and thereby mitigate the effects of any pump occlusion.
- the controller causes the actuation of the pump mechanism, which pulses at 412 to output another 0.05 Units of insulin. Since the pump mechanism does not have the ability to gradually deliver 0.05 U, the pump outputs 0.05 Units over the 2 seconds of the preset time period or pulse, then pauses for 35.5 seconds, then repeats.
- the controller causes the actuation of the pump mechanism, which pulses at 412 to output another 0.05 Units of insulin. Since the pump mechanism does not have the ability to gradually deliver 0.05 U, the pump outputs 0.05 Units over the 2 seconds of the preset time period or pulse, then pauses for 35.5 seconds, then repeats.
- 1, 3A and 3B enable spreading the 0.4 Units of insulin to be output over a time of the control cycle that is greater much more than the 16 seconds (i.e., 8 pulses to deliver 0.4 units ⁇ 2 seconds per pulse) that would happen if the selected additional time period was not incorporated to enable absorption of a partial dose of insulin.
- the pump rate modification may be applied to other insulin deliveries than automated insulin deliveries.
- user requested boluses can also be delivered at a lower than maximal rate.
- the delivery control application may be operable to cause this delivery can occur via several pump mechanism pulses (i.e., 6) that have a selected additional time period of, for example, 3 seconds between pulses.
- the 3 seconds may be combined with the 2 seconds of the pump resolution to provide a time segment of 5 seconds which delivers the requested bolus of 3 Units within 3 seconds to allow for a pump occlusion.
- the pulse in response to an output of the actuation command at a beginning of each respective time segment of the control cycle is shown in FIG. 4
- the pulses 411 - 418 are shown as occurring at the beginning of each time segment #1-#8 in FIG. 4 .
- the actuation command may be delivered at other times within the respective time segments so long as the selected additional time periods 421 - 428 are of sufficient time to allow for absorption of the insulin and mitigate the effects of any pump occlusion or other absorption problems after output of the dosage of insulin.
- FIG. 5A illustrates an example of a process for detecting a pump occlusion that may result in a modification of a pump rate.
- a controller of a medical device may be operable to receive a pressure sensor signal from a pressure sensor in a fluid delivery path through which the dosage of insulin is delivered ( 510 ).
- the pressure sensor signal may include a pressure value.
- the controller may be further operable to determine whether the pressure value exceeds a pressure threshold ( 520 ).
- the pressure threshold for example, may be equal to an amount of pressure that the pump mechanism experiences when outputting a drug when no form of pump occlusion is present, and the drug is substantially absorbed by bodily tissue at or near an output of a cannula or needle. This may be determined from testing prior to manufacturing of the pump mechanism, for example.
- the threshold may be stored in a memory of the medical device during manufacture, may be set (or updated) and stored after an initial use of the medical device, or the like.
- the controller may access a lookup table stored in the memory or may communicate with and external device for an additional time increment.
- the lookup table may contain a number of pressure values that exceed the pressure threshold with corresponding additional time increments.
- the additional time increments may select an additional time increment to be added to the preset time period of the pump mechanism.
- the controller may be operable to use the additional time increment in the modification of the pump rate ( 540 ).
- a preset time period is an amount of time it takes the pump mechanism to output the dosage of insulin after receipt of the actuation command.
- the controller may be operable to calculate the extended time period or time segment (as in the example of FIGS. 3A, 3B and 4 ) by adding the selected additional time increment to the preset time period to arrive at the time segment and the modified pump rate.
- FIG. 5B illustrates another example of a process for detecting a pump occlusion that may result in a modification of a pump rate.
- the process 503 may be implemented by the execution of programming code by the controller of the pump mechanism in response to pressure sensor signals received from a pressure sensor that may be coupled to the pump mechanism and the controller.
- the controller may be operable to receive, at 563 , a pressure sensor signal from the pressure sensor, which is coupled to a fluid delivery path of the pump mechanism through which the dosage of insulin is output.
- the controller may calculate an amount of delivery back pressure based on the received pressure sensor signal. For example, the controller may monitor the pressure sensor signal received from the pressure sensor at the beginning, during, and/or end of each pulse of the pump mechanism.
- the controller may be operable to determine whether the calculated amount of delivery back pressure exceeds a threshold ( 583 ).
- the controller may use the respective pressure sensor signals to determine whether the pressure sensor signal is indicating increases in back pressure that are greater than an operation without a pump occlusion.
- the controller may generate an indication that the deliver pressure value has increased ( 593 ).
- the programming code executed by the controller may, for example, in response the generated indication may perform pump rate modification processes, such as those discussed with reference to the examples of FIGS. 3A, 3B and 4 .
- the presence of the pressure sensor and the functions provided by delivery control application as described with reference to the earlier examples serves to reduce the buildup of back pressure and thus reduces the increased risk of occlusion that may be caused by a fixed rate of insulin delivery, which improves the safety of the AID system to the users.
- FIG. 6 illustrates an example of system suitable to implement the processes and techniques described herein.
- the example processes may be implemented by programming code, such as a delivery control application, an AP application or automatic insulin deliver (AID) application, or a combination of applications that are executed by a processor.
- the AP application or the AID application when executed by a processor may utilize inputs and calculations as described with respect to the foregoing examples.
- FIG. 6 illustrates an example of a drug delivery system suitable for implementing the example processes and techniques described herein including those described with reference to FIGS. 1, 3A, 3B, 5A and 5B .
- a medical device such as 202 of FIG. 2 or 200 of FIG. 2A
- a wearable drug delivery device such as an OmniPod® delivery device provided by Insulet Corp, or the like
- an OmniPod® delivery device provided by Insulet Corp, or the like
- the drug delivery system 600 may be an automatic drug delivery system that may include a medical device 602 (also referred to as “a drug delivery device”, “a wearable drug delivery device,” or “a drug delivery device”), a blood glucose sensor 604 (also referred to as “a continuous glucose monitor” or “a blood glucose measurement device”), and a personal diabetes management (PDM) device 606 .
- the system 600 may also include a smart device 607 , which may be operable to communicate with the PDM 606 and other components of system 600 either via a wired or wireless communication link, such as 691 , 692 or 693 .
- the smart device 607 is coupled to the PDM 606 only via a wireless communication link 693 , which may be a wireless communication link that utilizes the Bluetooth communication protocol or the like.
- the medical device 602 may include a controller 621 , a pressure sensor 622 , a memory 623 , an AP application 629 and a delivery control application 699 stored in the memory 623 , a pump mechanism 624 , a communication device 626 , user interface 627 , and a power source 628 .
- the pump mechanism may be operable to deliver a drug, like insulin, at fixed rate of the mech.
- pumps are commanded by a controller to deliver insulin at the fixed rate.
- an ordinary rate for the pump mechanism 624 may be 0.05 Units per 2 seconds or 0.025 Units per second or 6 Units per 5 minutes, where insulin is measured in Units. These mechanical rates are different from physiological rates that may be determined for a patient.
- the AP algorithm may determine that a user's total daily insulin is 24 Units per 24 hours, which may translate to a physiological rate of 1 unit per hour that may be determined according to a diabetes treatment plan.
- the pump mechanism may be operable to deliver insulin at rates greater than or less than 1 unit per hour.
- the medical device 602 may be attached to the body of a user, such as a patient or diabetic via, for example, an adhesive, and may deliver any therapeutic agent, including any drug or medicine, such as insulin, morphine or the like, to the user.
- the medical device 602 may, for example, be a wearable device worn by the user.
- the medical device 602 may be directly coupled to a user (e.g., directly attached to a body part and/or skin of the user via an adhesive or the like).
- a surface of the medical device 602 may include an adhesive (not shown) to facilitate attachment to a user.
- the medical device 602 may include a number of components to facilitate automatic delivery of a drug (also referred to as a therapeutic agent) to the user.
- the medical device 602 may be operable to store the drug (i.e., insulin) and to provide the drug to the user.
- the medical device 602 is often referred to as a pump, or an insulin pump, in reference to the operation of expelling insulin from the reservoir 625 for delivery to the user. While the examples refer to the reservoir 625 storing insulin, the reservoir 625 may be operable to store other drugs or therapeutic agents, such as morphine or the like, that are suitable for automatic delivery.
- the medical device 602 may be an automatic, wearable drug delivery device.
- the medical device 602 may include a reservoir 625 for storing the drug (such as insulin), a needle or cannula (not shown) for delivering the drug into the body of the user (which may be done subcutaneously, intraperitoneally, or intravenously), and a pump mechanism (mech.) 624 , or other drive mechanism, for transferring the drug from the reservoir 625 , through a needle or cannula (not shown), and into the user.
- the pump mechanism 624 may be fluidly coupled to reservoir 625 , and communicatively coupled to the medical device controller 621 .
- the medical device 602 may also include a power source 628 , such as a battery, a piezoelectric device, or the like, for supplying electrical power to the pump mechanism 624 and/or other components (such as the controller 621 , memory 623 , and the communication device 626 ) of the medical device 602 .
- a power source 628 such as a battery, a piezoelectric device, or the like, for supplying electrical power to the pump mechanism 624 and/or other components (such as the controller 621 , memory 623 , and the communication device 626 ) of the medical device 602 .
- an electrical power supply for supplying electrical power may similarly be included in each of the sensor 604 , the smart device 607 and the PDM device 606 .
- the blood glucose sensor 604 may be a device communicatively coupled to the PDM processor 661 or controller 621 and may be operable to measure a blood glucose value at a predetermined time interval, such as every 5 minutes, or the like.
- the blood glucose sensor 604 may provide a number of blood glucose measurement values to the AP applications (e.g., 629 , 649 , 669 , or 679 ) operating on the respective devices (e.g., 602 , 604 , 606 , or 607 ).
- the AP applications 629 , 649 , 669 and 679 may be replaced with an AID algorithm that is also operable to control and communicate with connected devices, such as medical device 602 and sensor 604 , and manage a personal diabetes treatment program, and provide the functions and services as described herein.
- the medical device 602 may provide the insulin stored in reservoir 625 to the user based on information (e.g., blood glucose measurement values, predicted future blood glucose measurements, evaluations based on a user request for a bolus, pressure sensor signals received from the pressure sensor 622 ), and the other information provided by the sensor 604 , smart device 607 , and/or the management device (PDM) 606 .
- the medical device 602 may contain analog and/or digital circuitry that may be implemented as a controller 621 for controlling the delivery of the drug or therapeutic agent.
- the circuitry used to implement the controller 621 may include discrete, specialized logic and/or components, an application-specific integrated circuit, a microcontroller or processor that executes software instructions, firmware, programming instructions or programming code (enabling, for example, the artificial pancreas application (AP App) 629 as well as the process examples of FIGS. 1, 3A, 3B, 5A and 5B ) stored in memory 623 , or any combination thereof.
- the controller 621 may execute a control algorithm, such as the artificial pancreas application 629 , and other programming code that may make the controller 621 operable to cause the pump to deliver doses of the drug or therapeutic agent to a user at predetermined intervals or as needed to bring blood glucose measurement values to a target blood glucose value.
- the AP application (App) 629 may include programming code that is operable upon execution by the controller 621 to provide the example processes for adjusting or modifying total daily insulin settings, or the like as described with reference to FIGS. 1, 3A, 3B, 5A and 5B .
- the user preferences for total daily insulin settings may be programmed, for example, into an artificial pancreas application 629 by the user or by a third party (such as a health care provider, medical device manufacturer, or the like) using a wired or wireless link, such as 631 , between the medical device 602 and a personal diabetes management device 606 or other device, such as a computing device at a healthcare provider facility.
- the pump or medical device 602 is communicatively coupled to the PDM processor 661 of the personal diabetes management device via the wireless link 631 or via a wireless link, such as 691 from smart device 607 or 608 from the sensor 604 .
- the pump mechanism 624 of the medical device 602 may be operable to receive an actuation signal from the PDM processor 661 , and in response to receiving a command signal or an actuation signal, expel insulin from the reservoir 625 based on the commands from an AP application, such as 669 .
- the drug delivery system 600 may be operable to implement the process examples illustrated in FIGS. 1, 3A, 3B, 5A and 5B by executing a delivery control application in cooperation with an AP application.
- the delivery control application 699 or AP application 629 may be operable to receive a signal from the pressure sensor 622 .
- the AP application 669 executing in the personal diabetes management device 606 may be operable to control delivery of insulin to a user.
- the AP application 669 may be operable to determine timing of an insulin dose and may output a command signal to the medical device 602 that actuates the pump mechanism 624 to deliver an insulin dose.
- the AP application (or AID algorithm) 669 when loaded with programmed code that provides instructions for the functionality of FIGS. 1, 3A, 3B, 5A and 5B .
- the AP application or AID algorithm may have requested, via a command signal to the medical device 602 , delivery of an insulin delivery dosage for a current cycle, say every 5 minutes, which is equal to the control cycle of the AP application or AID algorithm.
- the controller 621 of the medical device 602 may evaluate the requested insulin delivery using the delivery control application 699 .
- the delivery control application 699 may receive the requesting insulin delivery.
- the requested insulin delivery dosage (referred to as ID(t)) may be equal to 0.4 Units of insulin as discussed above.
- the controller 621 of the medical device 602 may actuate the pump mechanism 624 to deliver the ID(t) dosage immediately at the mechanical pump rate of 0.05 units every 2 seconds (which will deliver the 0.4 units of insulin in approximately 16 seconds).
- the pressure sensor signal received from the pressure sensor 622 may have indicated a degree of back pressure, which the deliver control application 699 may be operable to interpret as indicating a partial pump occlusion.
- the pressure sensor 622 may be operable to provide a signal to the controller 621 indicating the partial pump occlusion.
- the controller 621 in the presence of the indicated partial pump occlusion, may be operable to modify the delivery of the requested insulin delivery by modifying the mechanical pump rate of the pump mechanism 624 . Alternatively, the controller 621 may automatically extend all requested insulin deliveries over the control cycle regardless of whether there is a pump occlusion or not.
- the controller 621 may modify the delivery of insulin by extending a time interval to deliver the requested insulin delivery (ID(t)) amount.
- the controller 621 may be operable to extend the time interval to fit the control cycle or control cycle, such as 5 minutes, 10 minutes or the like, of the AP application or AID algorithm. Using a 5 minute control cycle and the ID(t) amount as 0.4 Units in an example in which the controller receives a signal from the pressure sensor 622 indicating a pump occlusion, the controller 621 may determine a pump rate modification is needed.
- the controller modifies the delivery and extends the delivery over the 5 minutes (or 300 seconds (5 minutes ⁇ 60 seconds/minute)) of the control cycle.
- the controller may divide the 300 seconds of the control cycle by the number of pump resolution cycles for delivering the 0.4 U of insulin.
- the controller 621 may actuate the pump mechanism 624 to deliver 0.05 U of insulin every 37.5 seconds for the 300 seconds (i.e., the 5 minute control cycle) after which substantially all of the entire amount of the requested insulin delivery ID(t) is output by the pump mechanism 624 .
- the controller may be able to overcome, or at least mitigate, the effects of the pump occlusion. For example, if the pump occlusion is caused by a slow absorption rate of the insulin due to a buildup of scar tissue in or around the infusion site, the slower rate of delivery over the extended time period may enable the insulin to be absorbed in or around the infusion site.
- Bolus dosages may be handled in a similar manner by the medical device 602 .
- a user in response to a meal or other event that may cause an increase in blood glucose, a user may request a bolus dosage of insulin.
- the user may request the delivery of 3 Units of insulin as the bolus dosage.
- the AP application or AID algorithm in the PDM 606 or the like may deliver a control signal to the medical device 602 indicated that a bolus delivery of 3 units is requested.
- the controller 621 may receive and interpret the control signal to instruct the pump mechanism 624 to deliver a requested insulin delivery (ID(t)) amount of 3 U.
- ID(t) requested insulin delivery
- the pump mechanism 624 may deliver the ID(t) of 3 U within 120 seconds or 2 minutes (i.e., 60 times 2 seconds).
- the controller 621 may extend the time interval for delivery of the ID(t).
- the time for the control cycle may be 5 minutes
- the 300 seconds is divided by the number of pulses (60) so 5 seconds is the time for the pump to deliver 0.05 U of insulin.
- the controller 621 commands the pump mechanism 624 to deliver the 0.05 U of insulin over a 5 second period instead of the 2 seconds.
- the other devices in the system 600 may also be operable to perform various functions including controlling the medical device 602 .
- the personal diabetes management device 606 may include a communication device 664 , a PDM processor 661 , and a personal diabetes management device memory 663 .
- the personal diabetes management device memory 663 may store an instance of the AP application 669 that includes programming code, that when executed by the PDM processor 661 provides the process examples described with reference to the examples of FIGS. 1, 3A, 3B, 5A and 5B .
- the personal diabetes management device memory 663 may also store programming code for providing the process examples described with reference to the examples of FIGS. 1, 3A, 3B, 5A and 5B .
- the smart device 607 may be, for example, a smart phone, an Apple Watch®, another wearable smart device, including eyeglasses, provided by other manufacturers, a global positioning system-enabled wearable, a wearable fitness device, smart clothing, or the like. Similar to the personal diabetes management device 606 , the smart device 607 may also be operable to perform various functions including controlling the medical device 602 .
- the smart device 607 may include a communication device 674 , a processor 671 , and a memory 673 .
- the memory 673 may store an instance of the AP application 679 and/or an instance of an AID application (not shown) that includes programming code for providing the process examples described with reference to the examples of FIGS.
- the memory 673 may also as store programming code and be operable to store data related to the AP application 679 or an instance of an AID application (not shown).
- the AP application 679 may be operable to provide functionality similar to or the same the functionality as described with reference to the instance of the AP application 669 .
- the sensor 604 of system 600 may be a continuous glucose monitor (CGM) as described above, that may include a processor 641 , a memory 643 , a sensing or measuring device 644 , and a communication device 646 .
- the memory 643 may, for example, store an instance of an AP application 649 as well as other programming code and be operable to store data related to the AP application 649 and process examples described with reference to FIGS. 1, 3A, 3B, 5A and 5B .
- the AP application 649 may also include programming code for providing the process examples described with reference to the examples of FIGS. 1, 3A, 3B, 5A and 5B .
- Instructions for determining the delivery of the drug or therapeutic agent (e.g., as a bolus dosage) to the user may originate locally by the medical device 602 or may originate remotely and be provided to the medical device 602 .
- programming instructions such as an instance of the artificial pancreas application 629 , stored in the memory 623 that is coupled to the medical device 602 may be used to make determinations by the medical device 602 .
- the medical device 602 may be operable to communicate with the cloud-based services 611 via the communication device 626 and the communication link 688 .
- the system 600 may include one or more components operable to implement the process examples of FIGS. 1, 3A, 3B, 5A and 5B .
- the remote instructions may be provided to the medical device 602 over a wired or wireless link (such as 631 ) by the personal diabetes management device (PDM) 606 , which has a PDM processor 661 that executes an instance of the artificial pancreas application 669 , or the smart device 607 (via communication link 691 ), which has a processor 671 that executes an instance of the artificial pancreas application 669 as well as other programming code for controlling various devices, such as the medical device 602 , smart device 607 and/or sensor 604 .
- PDM personal diabetes management device
- the smart device 607 via communication link 691
- processor 671 that executes an instance of the artificial pancreas application 669 as well as other programming code for controlling various devices, such as the medical device 602 , smart device 607 and/or sensor 604 .
- PDM personal diabetes management
- the medical device 602 may execute any received instructions (originating internally or from the personal diabetes management device 606 ) for the delivery of the drug or therapeutic agent to the user. In this way, the delivery of the drug or therapeutic agent to a user may be automatic.
- the medical device 602 may communicate via a wireless link 631 with the personal diabetes management device 606 .
- the personal diabetes management device 606 may be an electronic device such as, for example, a smart phone, a tablet, a dedicated diabetes therapy personal diabetes management device, or the like.
- the personal diabetes management device 606 may be a wearable wireless accessory device.
- the wireless communication links 608 , 631 , 632 , 691 , 692 and 693 may be any type of wireless link provided by any known wireless standard.
- the wireless communication links 608 , 631 , 632 , 691 , 692 and 693 may enable communications between the medical device 602 , the personal diabetes management device 606 and sensor 604 based on, for example, Bluetooth®, Wi-Fi®, a near-field communication standard, a cellular standard, or any other wireless optical or radio-frequency protocol.
- the sensor 604 may be a glucose sensor operable to measure blood glucose and output a blood glucose value or data that is representative of a blood glucose value.
- the sensor 604 may be a glucose monitor or a continuous glucose monitor (CGM).
- the sensor 604 may include a processor 641 , a memory 643 , a sensing/measuring device 644 , and communication device 646 .
- the communication device 646 of sensor 604 may include one or more sensing elements, an electronic transmitter, receiver, and/or transceiver for communicating with the personal diabetes management device 606 over a wireless link 632 or with medical device 602 over the link 608 .
- the sensing/measuring device 644 may include one or more sensing elements, such as a glucose measurement, heart rate monitor, or the like.
- the processor 641 may include discrete, specialized logic and/or components, an application-specific integrated circuit, a microcontroller or processor that executes software instructions, firmware, programming instructions stored in memory (such as memory 643 ), or any combination thereof.
- the memory 643 may store an instance of an AP application 649 that is executable by the processor 641 .
- the sensor 604 is depicted as separate from the medical device 602 , in various examples, the sensor 604 and medical device 602 may be incorporated into the same unit. That is, in various examples, the sensor 604 may be a part of the medical device 602 and contained within the same housing of the medical device 602 (e.g., the sensor 604 may be positioned within or embedded within the medical device 602 ).
- Glucose monitoring data e.g., measured blood glucose values
- the sensor 604 may be provided to the medical device 602 , smart device 607 and/or the personal diabetes management device 606 and may be used to perform the functions and deliver doses of insulin for automatic delivery of insulin by the medical device 602 as described with reference to the examples of FIGS. 1, 3A, 3B, 5A and 5B .
- the sensor 604 may also be coupled to the user by, for example, adhesive or the like and may provide information or data on one or more medical conditions and/or physical attributes of the user.
- the information or data provided by the sensor 604 may be used to adjust drug delivery operations of the medical device 602 .
- the personal diabetes management device 606 may be a mobile computing device operable to manage a personal diabetes treatment plan via an AP application or an AID algorithm.
- the personal diabetes management device 606 may be used to program or adjust operation of the medical device 602 and/or the sensor 604 .
- the personal diabetes management device 606 may be any portable electronic, computing device including, for example, a dedicated controller, such as PDM processor 661 , a smartphone, or a tablet.
- the personal diabetes management device (PDM) 606 may include a PDM processor 661 , a personal diabetes management device memory 663 , and a communication device 664 .
- the personal diabetes management device 606 may contain analog and/or digital circuitry that may be implemented as a PDM processor 661 (or controller) for executing processes to manage a user's blood glucose levels and for controlling the delivery of the drug or therapeutic agent to the user.
- the PDM processor 661 may also be operable to execute programming code stored in the personal diabetes management device memory 663 .
- the personal diabetes management device memory 663 may be operable to store an artificial pancreas (AP) application 669 that may be executed by the PDM processor 661 .
- the PDM processor 661 may when executing the artificial pancreas application 669 may be operable to perform various functions, such as those described with respect to the examples in FIGS. 1, 3A, 3B, 5A and 5B .
- the wireless communication device 664 may be a device, such as a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols.
- the communication device 664 may include a cellular transceiver and a Bluetooth transceiver that enables the personal diabetes management device 606 to communicate with a data network (not shown) via the cellular transceiver and with the sensor 604 and the medical device 602 .
- the respective transceivers of communication device 664 may be operable to transmit signals containing information useable by or generated by the AP application or the like.
- the communication devices 626 , 646 and 676 of respective medical device 602 , sensor 604 and Smart device 607 may also be operable to transmit signals containing information useable by or generated by the AP application or the like.
- the medical device 602 may communicate with the sensor 604 over a wireless link 608 and may communicate with the personal diabetes management device 606 over a wireless link 631 .
- the sensor 604 and the personal diabetes management device 606 may communicate over a wireless link 632 .
- the smart device 607 when present, may communicate with the medical device 602 , the sensor 604 and the personal diabetes management device 606 over wireless communication links 691 , 692 and 693 , respectively.
- the wireless communication links 608 , 631 , 632 , 691 , 692 and 693 may be any type of wireless link operating using known wireless standards or proprietary standards.
- the wireless communication links 608 , 631 , 632 , 691 , 692 and 693 may provide communication links based on Bluetooth®, Wi-Fi, a near-field communication standard, a cellular standard, or any other wireless protocol via the respective communication devices 626 , 646 and 664 .
- the medical device 602 and/or the personal diabetes management device 606 may include a user interface 627 , 678 and 668 , respectively, such as a keypad, a touchscreen display, levers, buttons, a microphone, a speaker, a light, a display, or the like, that is operable to allow a user to enter information and allow the personal diabetes management device to output information for presentation to the user.
- the respective user interface devices 627 , 678 and 668 may serve with the associated hardware, such as a touchscreen display, as both an input device and an output device.
- the user interface devices may present graphical user interfaces that guide a user, for example, through the presentation of prompts, to input information or provide data to the user as well as other functions.
- the drug delivery system 600 may implement the artificial pancreas (AP) algorithm (and/or provide AP functionality) to govern or control automatic delivery of insulin to a user (e.g., to maintain euglycemia—a normal level of glucose in the blood).
- the AP application (or an AID algorithm) may be implemented by the medical device 602 and/or the sensor 604 .
- the AP application may be operable to determine an initial total daily insulin dosage as described with reference to the examples of FIGS. 1, 2, 4 and 5 , as well as the times and incremental dosages of insulin delivery.
- the AP application may determine the times and dosages for delivery based on information known about the user, such as the user's sex, age, weight, or height, and/or on information gathered about a physical attribute or condition of the user (e.g., from the sensor 604 ). For example, the AP application may determine an appropriate delivery of insulin based on glucose level monitoring of the user through the sensor 604 . The AP application may also allow the user to adjust insulin delivery. For example, the AP application may allow the user to issue (e.g., via an input) commands to the medical device 602 , such as a command to deliver an insulin bolus.
- different functions of the AP application may be distributed among two or more of the personal diabetes management device 606 , the medical device 602 or the sensor 604 . In other examples, the different functions of the AP application may be performed by one device, such the personal diabetes management device 606 , the medical device 602 or the sensor 604 .
- the drug delivery system 600 or any component thereof, such as the medical device may be considered to provide AP functionality or to implement an AP application.
- references to the AP application e.g., functionality, operations, or capabilities thereof
- the drug delivery system 600 may be considered to be a drug delivery system or an AP application-based delivery system that uses sensor inputs (e.g., data collected by the sensor 604 ).
- one or more of the devices, 602 , 604 , 606 or 607 may be operable to communicate via a wireless communication link 688 with cloud-based services 611 .
- the cloud-based services 611 may utilize servers and data storage (not shown).
- the communication link 688 may be a cellular link, a Wi-Fi link, a Bluetooth link, or a combination thereof, that is established between the respective devices 602 , 604 , 606 or 607 of system 600 .
- the data storage provided by the cloud-based services 611 may store insulin delivery history related to the user, cost function data related to general delivery of insulin to users, or the like.
- the cloud-based services 611 may process anonymized data from multiple users to provide generalized information related to the various parameters used by the AP application.
- the device 602 includes a communication device 664 , which as described above may be a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols, such as Bluetooth, Wi-Fi, a near-field communication standard, a cellular standard, that may enable the respective device to communicate with the cloud-based services 611 .
- a communication device 664 which as described above may be a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols, such as Bluetooth, Wi-Fi, a near-field communication standard, a cellular standard, that may enable the respective device to communicate with the cloud-based services 611 .
- radio-frequency protocols such as Bluetooth, Wi-Fi, a near-field communication standard, a cellular standard
- outputs from the sensor 604 or the medical device 602 may be transmitted to the cloud-based services 611 for storage or processing via the transceivers of communication device 664 .
- the respective receiver or transceiver of each respective device, 602 , 606 or 607 may be operable to receive signals containing respective blood glucose measurement values of the number of blood glucose measurement values that may be transmitted by the sensor 604 .
- the respective processor of each respective device 602 , 606 or 607 may be operable to store each of the respective blood glucose measurement values in a respective memory, such as 623 , 663 or 673 .
- the respective blood glucose measurement values may be stored as data related to the artificial pancreas algorithm, such as 629 , 649 , 669 or 679 .
- the AP application operating on any of the personal diabetes management device 606 , the Smart device 607 , or sensor 604 may be operable to transmit, via a transceiver implemented by a respective communication device, 664 , 674 , 646 , a control signal for receipt by a medical device.
- the control signal may indicate an amount of insulin to be expelled by the medical device 602 .
- system 600 may be operable to implement the process examples of FIGS. 1, 4A, 4B, 5A and 5B .
- set a total daily insulin dosage using the attained information and obtain blood glucose measurement values over a period of time. Based on the obtained blood glucose measurement values, a level of glycated hemoglobin of a user may be determined.
- the set total daily insulin dosage may be modified to provide a modified total daily insulin dosage in response to the determined level of glycated hemoglobin.
- a control signal including the modified total daily insulin dosage may be output instructing a controller to actuate delivery of insulin according to the modified total daily insulin dosage.
- the system 600 or any component thereof may be implemented in hardware, software, or any combination thereof.
- Software related implementations of the techniques described herein may include, but are not limited to, firmware, application specific software, or any other type of computer readable instructions that may be executed by one or more processors.
- Hardware related implementations of the techniques described herein may include, but are not limited to, integrated circuits (ICs), application specific ICs (ASICs), field programmable arrays (FPGAs), and/or programmable logic devices (PLDs).
- ICs integrated circuits
- ASICs application specific ICs
- FPGAs field programmable arrays
- PLDs programmable logic devices
- the techniques described herein, and/or any system or constituent component described herein may be implemented with a processor executing computer readable instructions stored on one or more memory components.
- the examples may have been described with reference to a closed loop algorithmic implementation, variations of the disclosed examples may be implemented to enable open loop use.
- the open loop implementations allow for use of different modalities of delivery of insulin such as smart pen, syringe or the like.
- the disclosed delivery control application, AP application and algorithms may be operable to perform various functions related to open loop operations, such as modification of a pump mechanism rate or the like.
- a dosage amount of insulin may be received by the AP application or algorithm from a user via a user interface.
- Other open-loop actions may also be implemented by adjusting user settings or the like in an AP application or algorithm.
- Some examples of the disclosed device may be implemented, for example, using a storage medium, a computer-readable medium, or an article of manufacture which may store an instruction or a set of instructions that, if executed by a machine (i.e., processor or microcontroller), may cause the machine to perform a method and/or operation in accordance with examples of the disclosure.
- a machine i.e., processor or microcontroller
- Such a machine may include, for example, any suitable processing platform, computing platform, computing device, processing device, computing system, processing system, computer, processor, or the like, and may be implemented using any suitable combination of hardware and/or software.
- the computer-readable medium or article may include, for example, any suitable type of memory unit, memory, memory article, memory medium, storage device, storage article, storage medium and/or storage unit, for example, memory (including non-transitory memory), removable or non-removable media, erasable or non-erasable media, writeable or re-writeable media, digital or analog media, hard disk, floppy disk, Compact Disk Read Only Memory (CD-ROM), Compact Disk Recordable (CD-R), Compact Disk Rewriteable (CD-RW), optical disk, magnetic media, magneto-optical media, removable memory cards or disks, various types of Digital Versatile Disk (DVD), a tape, a cassette, or the like.
- memory including non-transitory memory
- removable or non-removable media erasable or non-erasable media, writeable or re-writeable media, digital or analog media
- hard disk floppy disk
- CD-ROM Compact Disk Read Only Memory
- CD-R Compact Disk Recordable
- the instructions may include any suitable type of code, such as source code, compiled code, interpreted code, executable code, static code, dynamic code, encrypted code, programming code, and the like, implemented using any suitable high-level, low-level, object-oriented, visual, compiled and/or interpreted programming language.
- the non-transitory computer readable medium embodied programming code may cause a processor when executing the programming code to perform functions, such as those described herein.
- Program aspects of the technology may be thought of as “products” or “articles of manufacture” typically in the form of executable code and/or associated data that is carried on or embodied in a type of non-transitory, machine readable medium.
- Storage type media include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Automation & Control Theory (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Primary Health Care (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- General Engineering & Computer Science (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
- Subcutaneous insulin delivery is the most commonly utilized, minimally invasive method of insulin delivery for people with Type-1 diabetes mellitus (T1DM) that utilize insulin pumps. Unfortunately, subcutaneous insulin infusion incurs a wide range of risks that must be mitigated to ensure safety of the users. One of the most critical risks is pump occlusion, which can be defined as insulin delivery from the pump being impeded from actual delivery into the body, potentially caused by site pressure, scar tissue formation, incorrect cannula insertion, and others.
- It is known that a high rate of insulin infusion is strongly correlated with increased incidence of pump occlusions. This is due to issues in subcutaneous insulin infusion sites potentially reducing in the rate of absorption of the subcutaneously delivered insulin into the bloodstream and increasing the resistance (back pressure) against additional insulin delivery. This resistance against additional insulin delivery is exacerbated with high insulin delivery rates, as the back pressure does not have sufficient time to be absorbed by a user's body before additional insulin is delivered into the infusion site.
- This back pressure issue is especially apparent during a user-initiated “bolus” insulin delivery of pump users, where the pump attempts to deliver an insulin dosage greater than normal and at a fixed rate possible upon user request.
- It would be advantageous to provide techniques and devices operable to mitigate the effects a pump occlusion on the delivery of drugs to a user.
- Disclosed is an example of a non-transitory computer readable medium embodied with programming code executable by a processor. When the programming code is executed by the processor, the processor may be operable to receive a control instruction to deliver a dosage of insulin. The control instruction may include an amount of insulin to be output as the dosage of insulin. A pump rate for delivery of the dosage of insulin may be modified by adding additional time to a preset time period to provide an extended time period for outputting the dosage of insulin. An actuation command may be to output to actuate a pump mechanism to output the dosage of insulin included in the control instruction at the modified pump rate.
- An example of a drug delivery device is disclosed that includes a reservoir, a cannula, a pump mechanism, a memory, a controller and a communication device. The reservoir may be configured to hold a liquid drug. The cannula may be coupled to the reservoir via a fluid delivery path and operable to output the liquid drug to a user. The pump mechanism may be coupled to the reservoir and operable to output the liquid drug from the reservoir via the fluid delivery path and out of the cannula. The memory may be operable to store programming code, applications including a delivery control application, and data. The controller may be coupled to the pump mechanism and the memory, and operable to execute programming code and the applications including the delivery control application. The communication device may be operable to wirelessly communicate with an external device and communicatively coupled to the controller. The controller, when executing the delivery control application, may be operable to receive, from the external device, a control instruction including a dosage of insulin to be output by the pump mechanism. The received control instruction may indicate an amount of insulin to be output for a control cycle. The controller may be operable to calculate an output distribution of the dosage of insulin by the pump mechanism. The output distribution may be a series of partial insulin doses output at discrete times distributed over the control cycle. An actuation command may be output by the controller to actuate the pump mechanism to deliver a partial each insulin dose in the series of partial insulin doses.
- An example of a method is also disclosed that may include receiving a control instruction to deliver a dosage of insulin. The control instruction may include a dosage of insulin to be output as a pump mechanism. A number of doses of insulin may be determined to be delivered based on a duration of a control cycle. The sum of the number of doses of insulin may equal the dosage of insulin, to be delivered based on a duration of a control cycle. A series of actuation commands may be output. The series of actuation commands may include a number of actuation commands equal to a number of doses of insulin in the plurality of doses of insulin. Each actuation command in the series of actuation commands may actuate a pump mechanism to output a respective dose of insulin of the plurality of doses of insulin, and each actuation command may be applied after passage of a selected additional time period based on the duration of the control cycle.
-
FIG. 1 illustrates an example of a process for modifying a pump rate for delivery of a dosage of insulin. -
FIG. 2 illustrates an example of a functional block diagram of drug delivery system suitable for implementing the example processes and techniques described herein. -
FIG. 2A illustrates an example of a drug delivery system suitable for implementing the example processes and techniques described herein. -
FIG. 3A illustrates an example of a process for determining a series of insulin dosages to be output over a control cycle. -
FIG. 3B illustrates an example of a process for modifying a pump rate suitable for use in the device examples ofFIGS. 2 and 2A . -
FIG. 4 shows a graphic illustrating time segmentation of a control cycle during the modification of a pump rate. -
FIG. 5A illustrates an example of a process for detecting a pump occlusion that may result in a modification of a pump rate. -
FIG. 5B illustrates an example of a process for detecting a pump occlusion that may result in a modification of a pump rate. -
FIG. 6 illustrates an example of system suitable to implement the processes and techniques described herein. - An example provides a process that may be used with additional algorithms or computer applications that may provide information and enable management of blood glucose levels and insulin therapy. Such algorithms may include an “artificial pancreas” algorithm-based system, or more generally, an artificial pancreas (AP) application or automatic insulin delivery (AID) algorithm, that provides automatic delivery of insulin based on a blood glucose sensor input, such as that received from a CGM or the like. In an example, the artificial pancreas (AP) application when executed by a processor may enable a system to monitor a user's glucose values, determine an appropriate level of insulin for the user based on the monitored glucose values (e.g., blood glucose concentrations or blood glucose measurement values) and other information, such as user-provided information, such as carbohydrate intake, exercise times, meal times or the like, and take actions to maintain a user's blood glucose value within an appropriate range. The appropriate blood glucose value range may be considered within a threshold value of a target blood glucose value of the particular user. For example, a target blood glucose value may be acceptable if it falls within the range of 80 mg/dL to 120 mg/dL, which is a range satisfying the clinical standard of care for treatment of diabetes. Alternatively, in addition, an AP application (or AID algorithm) as described herein may be able to establish a target blood glucose value more precisely and may set the target blood glucose value at, for example, 110 mg/dL, or the like. As described in more detail with reference to the examples of
FIGS. 1-5 , the AP application (or AID algorithm) may utilize the monitored blood glucose measurement values and other information to determine an optimal pump rate that mitigates potential causes of insulin device pump occlusions, or the like. A pump rate may be the amount of insulin that may be output by a pump over a set period of time. - In operation, a wearable drug delivery device (also referred to as “a drug delivery device” herein) may be affixed at a site on a user's body, such as, for example, the abdomen or upper arm. The drug delivery device may include a needle insertion component, a needle and a flexible cannula within the needle, a reservoir containing insulin, a pump that is a mechanism operable to expel various amounts of insulin from the reservoir, and control logic circuitry that is operable to control the pump and delivery of insulin from the reservoir to the flexible cannula. A needle may be used to puncture the user's skin to the depth of subcutaneous tissue, and within the needle is a flexible cannula. After puncturing the user's skin, the needle is withdrawn leaving the flexible cannula in place. Insulin may be delivered from the reservoir based on the pump causing insulin to be expelled from the reservoir to a fluid delivery path that leads to the flexible cannula that has been inserted in the user's body.
- In operation, the wearable drug delivery device may be operable to deliver a basal dosage of insulin and a bolus amount of insulin. The basal dosage of insulin is a small amount of insulin that is gradually delivered to a user over the course of a day (i.e., 24 hours). A bolus is an amount of insulin greater than the basal dosage that is delivered in a much shorter period of time than the extended period of time over which the basal dosage is delivered. A bolus dosage may be requested or required for various reasons, most typically, a bolus dosage is delivered in response to the consumption of a meal by the user, but also in response to exercise or as a way to correct excursions of the user's blood glucose measurements. The sum of the insulin amounts delivered as a basal dosage and in the bolus dosages may be referred to as the user's total daily insulin (TDI). The AID algorithm may be operable to deliver basal dosages, bolus dosages as well as other dosages, that are greater than a basal dosage but less than a typical bolus dosage. These other dosages may be referred to as “microboluses.” A microbolus may be an amount of insulin greater than basal but less than a bolus. In an example, the amount of insulin in a microbolus may include the amount of insulin in the basal dosage. If the user's blood glucose is within the “safe range,” such as 70 mg/dL-120 mg/dL, the amount of insulin contained in the microbolus may be substantially equal to the basal dosage of insulin. Microboluses may be less likely to be occluded because it is smaller than a typical bolus dosage.
- In some instances, a situation may arise during which a proper amount of insulin is not delivered to a user within a predetermined time period. The predetermined time period may be referred to as “a control cycle.” A common cause of the non-delivery (e.g., an improper delivery) of the intended amount of insulin within the predetermined amount of time is the presence of what is generally referred to as a pump occlusion. A pump occlusion may be defined as insulin delivery from the pump being impeded from actual delivery into the body. The occlusion may be within a pump mechanism, a fluid delivery path of the medical device, a needle or cannula, or the user's body. A non-delivery of insulin is intended to mean that an intended amount of insulin was not delivered to the user for some reason, such as a pump occlusion. In the disclosed examples, a control cycle may be approximately 5 minutes. Of course, the control cycle may be a period of time that is longer or shorter than approximately 5 minutes, such as 3 minutes, 6.5 minutes or the like. In an example, control logic circuitry in a pump may initiate delivery of a predetermined amount of insulin that is to be delivered to the user within a set period of time, e.g., 30 seconds. The control logic circuitry may direct the pump to deliver the predetermined amount of insulin within the set period of time, but due to a pump occlusion, the pump may be unable to complete the delivery of the predetermined amount of insulin within the set period of time.
- However, there may be times that an intended amount, or proper dosage, of insulin is not delivered to the user, which may be referred to as a non-delivery or improper delivery. A pump occlusion may be caused by various conditions. In a first example, the drug delivery device may be deployed with the flexible cannula inserted in the user. The deployed drug delivery device while initially affixed to a site on a user may shift which may result in movement of the drug delivery device. However, the flexible cannula cannot move since the flexible cannula is inserted in the user. This relative movement between the drug delivery device and the flexible cannula may cause a kink in the flexible cannula. As a result of the kink, the full amount of the predetermined amount of insulin may not be delivered within the set period of time.
- In a second example, pressure may be applied on a surface of the drug delivery device (such as the top or the side) and consequently to the site of the body at which the drug delivery device is located. In response to the increased pressure on the drug delivery device and the site of the body, interstitial fluid may build up within a part of the fluid delivery path of the pump which may cause a back pressure into the cannula (or even further up the fluid delivery path toward the reservoir and pump). As a result, the pump has to work harder to expel both the built-up interstitial fluid and the predetermined amount of insulin.
- As a third example, the needle insertion component is operable to puncture the skin of the user with the needle to a depth of the subcutaneous region of the user's skin. The needle is hollow and within the needle is the flexible cannula. The needle insertion component is further operable to retract the needle from the user's skin and leave the flexible cannula within the skin to allow delivery of insulin. However, when the needle is inserted in the skin, the needle may leave punctured tissue below the open end of cannula from which insulin is output to the user's subcutaneous region. The punctured tissue allows the end of the cannula to freely move up and down and not be occluded. However, external pressure to the skin in the area of the drug delivery device may inadvertently push the cannula against the non-punctured skin around or below the open end of the cannula. As a result, the cannula may be forced into contact with the non-punctured skin around or below the cannula which may occlude the cannula. Alternatively, or in addition, the punctured skin may heal around the cannula and seal the cannula, thereby causing the occlusion.
- In a fourth example, the body's immune system may attack the location of the needle insertion (i.e., insulin infusion site). The human body's immune response causes inflammation in the area around the cannula within the body and scar tissue may form, which causes an occlusion around the cannula and an occlusion of the pump.
- Occlusions may also occur when insulin is not absorbed quickly enough by the subcutaneous tissues of the user. The delay in absorption may be related to a number of issues, such as the buildup of scar tissue if the pump is placed at a frequently used location on the user's body. Pump occlusion may be caused by different conditions. Any method or device operable to mitigate the occurrence of a pump occlusion is an improvement of the presently available wearable drug delivery systems.
-
FIG. 1 illustrates an example of a process for mitigating the potential causes of pump occlusion. Theprocess 100 may be implemented by a controller coupled to a pump mechanism. For example, the controller may be operable to receive a control instruction to deliver a dosage of insulin (110). In response to the received control instruction, the controller may be operable to modify a pump rate for delivery of the dosage by at least adding additional time to a preset time period for delivering the dosage of insulin (120). A pump rate may be a rate at which a pump on a wearable drug delivery device is operable to deliver insulin to a user. The controller may be further operable to output an actuation command to actuate a pump to output the dosage of insulin included in the control instruction at the modified pump rate (130). - An example of a medical device operable to implement the
process 100 is shown inFIGS. 2 and 2A . Themedical device 202 may include acontroller 221, apressure sensor 222, amemory 223, anAP application 229 anddelivery control application 299 stored in thememory 223, apump mechanism 224, acommunication device 226,user interface 227, and apower source 228. amemory 223 may be operable to store programming code and applications including adelivery control application 299, anAP application 229 and data. Thedelivery control application 299 and anAP application 229 may optionally be stored on other devices, as shown in another examples. - The
controller 221 may be coupled to thepump mechanism 224 and thememory 223. Thecontroller 221 may include logic circuits, a clock, a counter or timer as well as other processing circuitry, and be operable to execute programming code and the applications stored in thememory 223 including the delivery control application. Acommunication device 226 may be communicatively coupled to thecontroller 221 and may be operable to wirelessly communicate with an external device, such as personal diabetes management device, a smart device (both shown in a system example), or the like. - The
pressure sensor 222′ may be a mechanical, electronic, or electromechanical sensor that is operable to measure changes in pressure of a fluid delivery path between thereservoir 225 and a cannula (not shown in this example) inserted into a user. - The pump mechanism may be operable to deliver a drug, like insulin, at a fixed rate. Typically, pump mechanisms are commanded by the
controller 221 to deliver insulin at the fixed rate. For example, a fixed rate for thepump mechanism 224 may be a rate of approximately 0.05 Units per 2 seconds, or 0.025 per second, or 6 Units per 5 minutes, where insulin is measured in Units. These mechanical rates are different from physiological dosage rates that may be determined for a patient. For example, an AP application or AID algorithm executing on a personal diabetes management device or a smart phone may determine that a user's total daily insulin is 24 units per 24 hours, which may translate to an exemplary physiological dosage rate of 1 unit per hour that may be determined according to a diabetes treatment plan. However, thepump mechanism 224 may be operable to deliver insulin at rates different from the example physiological dosage rate of 1 unit per hour. Depending upon which dosage rate (e.g., either the example physiological dosage rate or the example mechanical rate of the pump mechanism), additional and different control algorithms may be implemented or applied to enable delivery of an appropriate insulin dosage by thepump mechanism 224. In an example, themedical device 202 may be attached to the body of a user, such as a patient or diabetic via, for example, an adhesive, and may deliver any therapeutic agent, including any drug or medicine, such as insulin, morphine, or the like, to the user. Themedical device 202 may, for example, be a wearable device worn by the user. For example, themedical device 202 may be directly coupled to a user (e.g., directly attached to the skin of the user via an adhesive or the like). In an example, a surface of themedical device 202 may include an adhesive (not shown) to facilitate attachment to a user. - In various examples, the
medical device 202 may be an automatic, wearable drug delivery device. For example, themedical device 202 may include areservoir 225 configured to hold a liquid drug (such as insulin), a needle or cannula 233 (not shown) for delivering the drug into the body of the user (which may be done subcutaneously, intraperitoneally, or intravenously), and a pump mechanism (mech.) 224, or other drive mechanism, for transferring the drug from thereservoir 225, through a needle orcannula 233, and into the user. - The
pump mechanism 224 may be fluidly coupled toreservoir 225, and communicatively coupled to themedical device controller 221. Thepump mechanism 224 may be coupled to thereservoir 225 and operable to output the liquid drug from thereservoir 225 via a fluid delivery path and out of the cannula (shown in the example ofFIG. 2A ). Thepump mechanism 224 may have mechanical parameters and specifications, such as a pump resolution, that indicate mechanical capabilities of the pump mechanism. The pump resolution is a fixed amount of insulin thepump mechanism 224 delivers in a pump mechanism pulse, which is an actuation of the pump mechanism for a preset time period. Actuation may be when power from thepower source 228 is applied to thepump mechanism 224 and thepump mechanism 224 operates to pump a fixed amount of insulin in a preset amount of time from thereservoir 225. - The
cannula 233 ofFIG. 2 may be coupled to thereservoir 225 via a fluid delivery path 234 (and shown in the example ofFIG. 2A ). Thecannula 233 may be operable to output the liquid drug to a user when thecannula 233 is inserted in the user. - The
medical device 202 may also include apower source 228, such as a battery, a piezoelectric device, or the like, that is operable to supply electrical power to thepump mechanism 224 and/or other components (such as thecontroller 221,memory 223, and the communication device 226) of themedical device 202. - As shown in
FIG. 2A , thedrug delivery device 200 may include aplunger 102 positioned within thereservoir 225′. An end portion or stem of theplunger 102 can extend outside of thereservoir 225′. The pump mechanism shown generally as 224′ may, under control of thecontroller 221′, be operable to cause theplunger 102 to expel the fluid, such as a liquid drug (not shown) from thereservoir 225′ and into thefluid component 104 andcannula 108 by advancing into thereservoir 225′. In various examples, thepressure sensor 222′ may be integrated anywhere along the overall fluid delivery path of thedrug delivery device 200, which includes thereservoir 225′, a fluiddelivery path component 104, the cannula 108) that is at the same approximate pressure as the outlet into the patient. An intervening membrane (not shown inFIG. 2A for simplicity) can be used to isolate thepressure sensor 222′ from the fluid within thereservoir 225′, the fluiddelivery path component 104, and/or thecannula 108. Alternatively, a pliable gel or sufficiently soft rubber can be used to isolate thepressure sensor 222′ from the fluid. In an example, thepressure sensor 222′ may be integrated into thereservoir 225′. The - In various embodiments, the
pressure sensor 222′ can have a round body to simplify sealing against thereservoir 102, the fluiddelivery path component 104 and thecannula 108. In various embodiments, an integral lip seal can be used to seal the interface between the body of thepressure sensor 222′ and thereservoir 225′, the fluiddelivery path component 104, and thecannula 108. - The
pressure sensor 222′ may be coupled to acontroller 221′ via connection 22A. Thepressure sensor 222′ can measure the absolute pressure of thereservoir 102 and/or the fluid delivery path component 104 (e.g., the overall fluid delivery path of the drug delivery device 200) and can provide an output signal to thecontroller 221′. In various embodiments, thepressure sensor 222′ can take continuous readings of the absolute pressure. The output signal from thepressure sensor 222′ can indicate the measured or detected absolute pressure and/or any other measured, detected, or derived pressure value. - The
controller 221′ can process the received signal from thepressure sensor 222′. Thecontroller 221′ may be implemented in hardware, software, or any combination thereof. In various examples, thecontroller 221′ can be implemented as dedicated hardware (e.g., as an application specific integrated circuit (ASIC)). Thecontroller 221′ may be a constituent part of thedrug delivery device 200, can be implemented in software as a computational model, or can be implemented external to the drug delivery device 200 (e.g., remotely). - The
pressure sensor 222′ can be an absolute pressure sensor that can detect both ambient pressure (e.g., absolute or atmospheric pressure) and relative pressure (e.g., gage or pumping pressure) introduced as thedrug delivery device 200 displaces fluid (e.g., the fluid stored in thereservoir 225′) in the overall fluid delivery path of the drug delivery device (e.g., including thereservoir 102 the fluiddelivery path component 104 and the cannula 108). By using an absolute pressure sensor as thepressure sensor 222′, it may also be possible to measure the effects of external ambient pressure on air within thereservoir 102. - In an example, the
pressure sensor 222′ may be operable to respond to pressure changes in the fluid delivery path and cause a signal to be provided to thecontroller 221′. Thepressure sensor 222′ may, for example, be one or more sensors positioned along the fluid delivery path that are operable to respond to changes in pressure of the fluid within the fluid delivery path. In a specific example, the pressure sensor may be an electromechanical sensor that includes a transducer. The transducer may be positioned to detect pressure within the fluid delivery path, for example, adjacent to a wall of the fluid delivery path or the like. In response to fluid being output from the reservoir, the walls of the fluid delivery path may become more rigid due to the increased pressure of the dispensed fluid. In response to the increased pressure caused by the dispensed fluid, which may cause the transducer positioned adjacent to a fluid delivery path wall to generate an electrical signal in response to an increased pressure. As the fluid in the dosage is delivered to the user, the increased pressure in the fluid delivery path of thereservoir 225′ to thecannula 108 may cause thepressure sensor 222′ to generate an output signal indicative of the pressure in the fluid delivery path. - The
controller 221′, for example, may be operable to determine an increase in a delivery pressure value when outputting insulin in comparison to a respective delivery pressure value associated with a respective earlier output of insulin. In another example, the controller may be operable to measure pressure by using the time it takes for the pump mechanism to push a specified amount of insulin (e.g., 0.1 Units) out of the reservoir. If the delivery of the specified amount of insulin takes longer than a threshold, the controller may cause a first alarm to notify the user of a possible problem with the pump. For example, even though, a pump resolution is 0.05 Units per 2 seconds, if there is a pump occlusion back pressure into the reservoir may cause the pump to fail to deliver the amount of insulin designated in a control instruction, which may result in extra pulses of the pump mechanism. For example, for each pulse, the pump piston is moved so an amount of 0.05 U is displaced from thereservoir 225′. If there is occlusion, it may take longer than 2 seconds to complete the pulse, which means that, in this example, there is not a fractional pulse (i.e., a pulse less than two seconds or a delivery of less than 0.05 U. If the time to complete a tick exceeds some threshold (e.g., 5 seconds, 9 seconds, or the like) thecontroller 221′ may give an occlusion alarm that may be delivered to a user interface of a smart phone or PDM. In a further example, thecontroller 221′ may be operable to report back to the AP algorithm how many pulses were delivered. - In various examples, the output signal generated by the
pressure sensor 222′ can be a voltage signal, a current signal, and/or an electrical charge signal that may be provided to thecontroller 221′ via a connection, such as 222A. In general, the output signal from thepressure sensor 222′ can indicate a measured pressure. In various examples, the output signal generated by thepressure sensor 222′ may be an analog or digital data signal output by, for example, an inter-integrated circuit (I2C), serial peripheral interface (SPI), or any other known or customized synchronous or asynchronous data communication stream. Further, thepressure sensor 222′ and thecontroller 221′ can communicate over any known signaling protocol or standard including any known wired or wireless communication or signaling protocol. In various examples, the signal generated by thepressure sensor 222′ for output and delivery to thecontroller 221′ may be compensated for various environmental conditions, such as altitude, humidity or temperature, to remove or mitigate any error due to environmental changes. In a specific example, thecontroller 221′ may be operable to convert the output signal received from thepressure sensor 222′ into an indication of absolute pressure (e.g., pounds per square inch absolute (psia)) or the like. Thecontroller 221′ may be operable to process the output signal received from thepressure sensor 222′ to determine whether a modification of the pump rate of thepump mechanism 224 is necessary, and, if determined to be necessary, may make the appropriate pump modification or modifications. - An operational example may be helpful to further explain the pump rate and the determination of delivering a dosage of insulin over a period of time.
FIG. 3A illustrates an example of a process for determining a series of insulin dosages to be output over a control cycle. - A control cycle may be a time period during which an AP application or an AID algorithm may process received data and information, such as a blood glucose measurement value provided by a continuous blood glucose measurement sensor or other devices, services, such as a cloud service, or the like. The duration of the control cycle may vary between different brands of AP applications and different sensors coupled to the respective AP applications. In the present example, a blood glucose sensor may periodically output a blood glucose measurement value. Upon receipt of each periodic blood glucose measurement value, an AP application may process the received blood glucose measurement value and generate a control instruction.
- The control cycle may be the time from when an AP application receives a blood glucose measurement value and an immediately subsequent blood glucose measurement value. In the present examples, the control cycle is approximately 5 minutes.
- For example, the
process 300 is an algorithm for determining a series of insulin dosages to be output over a control cycle may be performed either by a personal diabetes management device (PDM) or by a medical device that delivers insulin to a user. In theprocess 300, a control instruction may be received that includes a dosage of insulin to be output by the pump mechanism. For example, an AP application or AID algorithm may determine that a bolus dosage is required to be delivered or has been requested by a user to be delivered. In response, the AP application or AID algorithm may generate a control instruction for output to a medical device that is operable to deliver insulin to the user. - In an operation that does not account for the possibility of a pump occlusion, the medical device may deliver the requested or required bolus of insulin as rapidly as possible given the pump resolution of the pump mechanism. In order to provide the requested or required bolus rapidly during the operation that does not account for the possibility of a pump occlusion, the AP application may output a series of control instructions that cause medical device to actuate the pump mechanism without pausing between actuations until the entire amount of insulin indicated in the control instruction is output from the reservoir.
- In contrast to the operation that does not account for the possibility of a pump occlusion, the present examples account for the possibility of a pump occlusion. As in the example of
FIG. 1 and the following examples, a controller of a medical device may be operable to modify a pump rate for delivery of the dosage of insulin provided using different techniques. As discussed with reference to the example medical device ofFIG. 2 , a delivery control application may be executed by a controller of the medical device. - In an example, a controller of the medical device may receive a control instruction from an AP application. The received control instruction may include a dosage of insulin to be delivered by the medical device. Instead of delivering the requested bolus of insulin in a rapid delivery without pausing between actuations until the entire amount of insulin indicated in the control instruction is delivered, the delivery control application executed by the controller of the medical device may be operable to deliver a number of microboluses continuously over the control cycle (e.g., 5 minutes). The following examples describe a pre-existing AID system that may utilize the devices, products, processes and techniques described herein to deliver its recommended dose of insulin every control cycle over a pre-defined period, such as the full control cycle, instead of attempting this delivery at a fixed pump rate without pausing to allow some absorption of the delivered insulin.
- In more detail, an AID algorithm may recommend as a bolus insulin delivery ID(t). In response, a delivery control application executing on a medical device may be operable to, instead of delivering this ID(t) immediately, may deliver a portion of this delivery over an evenly distributed interval throughout its control cycle to minimize the buildup of pressure to thereby mitigate the rate of occlusion. The calculation of an evenly-distributed delivery amount of insulin over a control period may be described with reference to the following equations:
-
- In
Equations -
FIG. 3A illustrates an example of a process for determining a series of insulin dosages to be output over a control cycle of an automatic insulin delivery (AID) system. - In the
example process 300 ofFIG. 3A , a controller of the medical device may receive a control instruction including a dosage of insulin to be output by the pump mechanism (310) from an external device. An example of an external device may be a PDM, a smart phone, a smart wearable accessory, such as a smart watch, a fitness device, or the like, or some other type of computing device able to communicate with the medical device. The controller may evaluate the received control instruction to determine a dosage of insulin to be delivered over a control cycle of the AID system. - For example, an AID algorithm of the AID system may request a microbolus of 0.4 U (of insulin) at the beginning of a current control cycle. Briefly referring back to
FIG. 2 , thepump mechanism 224 of themedical device 202 as described with reference to the following examples may have a pump resolution of 0.05 Units of insulin that is delivered in 2 seconds, which means that in response to a control actuation command the pump mechanism delivers 0.05 Units of insulin over a time of 2 seconds. Of course, different pump resolutions are possible based on a type of electric motor, control mechanisms or logic used in the respective pump mechanism. - In the present example of
FIG. 3A andFIG. 4 , the 2 seconds of the pump resolution may be viewed as a preset time period and the 0.05 Units may be viewed as the minimum dosage that the pump mechanism may deliver in response to a control actuation command. In response to the control actuation command, the pump mechanism may “pulse” for 2 seconds during which the pump mechanism outputs the 0.05 Units of insulin. So, each pulse of the pump mechanism may be equated to either 0.05 Units of insulin or 2 seconds. may also be referred to the amount of insulin output by each pulse - Returning to the example of
FIG. 3A , when determining the dosage of insulin to be delivered, the controller may evaluate the dosage of insulin in the received control instruction with reference to the pump resolution and the time period of the control cycle. Based on the evaluation, the controller may determine a number of doses that equal the dosage of insulin to be delivered based on over a time period equal to the time of a control cycle (320). Once the dosage of insulin is determined by the controller, the controller may output an actuation command to the pump mechanism to deliver a set amount of insulin. The actuation command may actuate the pump mechanism to deliver a set amount of insulin for each insulin dosage in a series of insulin doses (330). Actuation of the pump mechanism is a pump mechanism pulse generated in response to the actuation command that causes the output of a drug from the reservoir. - It may be helpful to describe an example of a process performed by the controller when evaluating dosage of insulin in the received control instruction with reference to the pump resolution and the time period of the control cycle. The
process 303 ofFIG. 3B is described with reference toFIG. 4 for more easily illustrating and explaining theprocess 303 as well as other processes that may be utilized. In the operational example ofFIG. 3B , the control instruction from the external device may include a dosage of insulin equal to 0.4 Units of insulin. - In the example of the evaluation by the controller in response to the control instruction, the controller may process the dosage of insulin in the control instruction.
FIG. 3B illustrates an example of a process for modifying a pump rate that may be implemented by the device shown in the examples ofFIGS. 2 and 2A .FIG. 4 shows a graphic illustrating segmentation of a control cycle during the modification of a pump rate. This graphic may be helpful in understanding theprocess 303 described inFIG. 3B . - The
evaluation process 303 ofFIG. 3B includes the controller calculating a number of pump mechanism pulses need to deliver the dosage of insulin (360). Since the pump mechanism has a pump resolution in which a fixed amount of insulin (e.g., 0.05 U) is output over a preset time period (e.g., 2 seconds) during each pulse of the pump mechanism, the controller may determine a number of pulses of the pump mechanism needed to output the dosage of insulin included in the control instruction by, for example, dividing the 0.4 U (from the control instruction) by the 0.05 U. In the example, the number of pump mechanism pulses needed to deliver the dosage of insulin is (0.4/0.05=) 8. When a remainder of insulin is determined to be undelivered during a preset time period by a controller (such ascontroller 221′), the controller may be operable to accumulate (or carry over) the determined remainder of insulin to a next time period. In which case, the amounts of insulin to be delivered may not be evenly distributed across the respective time segments. The controller may be operable to either deliver the accumulated remainder of insulin and the scheduled insulin delivery during the next time segment or to revise the distribution so that the accumulated remainder is distributed with the scheduled delivery amounts over the remaining time segments. A revised distribution to include the accumulated remainder may be determined by summing the accumulated remainder and the total amount of insulin to be delivered over the remaining time segments and dividing the sum total by the remaining time segments. - In the example graphic 400 of
FIG. 4 , thecontrol cycle 444 is shown as extending over 8 time segments or extended time periods (i.e. time segment #1-time segment # 8 or extended time period #1-#8). Each of the time segments #1-#8 are further divided into 2 additional time segments. As shown,time segment # 1 includespulse 411 and a selectedadditional time period 421. Thepulse 411 may be equal to the pump resolution or a preset time period. The pump resolution, or the resolution of the pump mechanism, may be an amount or volume of insulin that the pump mechanism delivers upon each actuation. Note the pump resolution may also be referred to as the pump mechanism resolution, the resolution of the pump, or resolution of the pump mechanism and the terms may be used interchangeably. Thepreset time period 411 may be equal to the period of time that the pump mechanism of the medical device takes to output the volume of fluid (i.e., the pump resolution), such aspump mechanism 224 of themedical device 202 ofFIG. 2 , outputs in response to a control actuation command. - The controller may be operable to divide the dosage of insulin by a resolution of the pump mechanism to produce the number of times the pump needs to actuate to output the insulin dosages as shown by the respective time segments in the example graphic 400 of
FIG. 4 . For example, thepump mechanism 224 of themedical device 202 as may be assumed to have a pump resolution of 0.05 Units of insulin that is delivered in 2 seconds, which means that in response to a control actuation command, a pulse of the pump mechanism delivers 0.05 Units of insulin over a time of 2 seconds. The pulse of the pump mechanism may be complete at the end of 2 seconds if no resistance is encountered (such as back pressure from an occlusion or the like). In the case of resistance, the pulse may last longer than 2 seconds due to a mechanical travel limit on the pump mechanism. The 2 seconds may be equal to thepreset time period 411 inFIG. 4 and the 0.05 Units may be viewed as the fixed dosage that the pump mechanism may deliver in response to a control actuation command during the preset time period. The mechanical limit may be based on the travel of a ratchet gear (not shown) as the ratchet gear moves from one gear tooth to another, from one notch to another between gear teeth, or the like. In an example, the fastest time that the ratchet gear can move moves from one gear tooth to another, from one notch to another between gear teeth, or the like may be 2 seconds. The movement in the presence of an occlusion or back pressure may be 5 seconds, 9 seconds or the like. - As shown in
FIG. 4 , each time segment #1-#8 is formed by a preset time period orpulse 411, and a selected additional time period, such as 421. The pulse orpreset time period 411 is equal to 2 seconds which is the time that the pump mechanism takes to output a dose of insulin equal to 0.05 Units. Each pulse 411-418 has a fixed time period that is equal to the time period of the pump resolution. The selectedadditional time period 421 is an amount of time that the controller has calculated to wait until issuing a subsequent actuation command. The selected additional time periods 421-428 may be of equal duration to allow sufficient absorption of the outputted insulin. In the example ofFIG. 4 , each of the time segments #1-#8 is of equal duration. - At 370, the controller may be operable to calculate an output distribution of the dosage of insulin by the pump mechanism by dividing a duration of a control cycle by the number of pump mechanism pulses to obtain an output distribution, such as
output distribution 449 ofFIG. 4 . Theoutput distribution 449 may be, for example, a series of discrete time segments distributed over the duration ofcontrol cycle 444 and during which a partial insulin dose is output by the pump mechanism. Alternatively, theoutput distribution 449 may be a series of partial doses of insulin dosages output at discrete times distributed over thecontrol cycle 444. Theoutput distribution 449 illustrates the distributed output of the dosage of insulin indicated in the control instruction as partial doses of insulin distributed over thecontrol cycle 444 ofFIG. 4 . Theoutput distribution 449 may be used by the controller to determine timing of delivery of the partial doses of the dosage of insulin. For example, each pulse 411-418 may output of a dose of insulin that is an of the dosage of insulin indicated in the control instruction. - In addition to determining the output distribution, the controller also determines the timing of the partial doses of the dosage of insulin (380). For example, the timing of the partial doses of the dosage of insulin may be represented by the selected additional time periods 421-428. Each additional time period 421-428 is a period of time that serves as a delay or a waiting period after completion of a corresponding pulse 411-418.
- Keeping with the example dosage of insulin in the control instruction being 0.4 Units, the controller upon determining the number of pump mechanism pulses needed to deliver the 0.4 Units is 8 may divide the duration of the
control cycle 444 by 8 to determine the duration of each time segment #1-8. As mentioned, a control cycle such as 444 may be 5 minutes or 300 seconds (5×60 seconds) in duration. The duration of each time segment #1-#8, in this example, may be equal to the time period of the control cycle in seconds (i.e., 300) divided by the number of pump mechanism pulses (i.e., 8). In this example, the duration of each time segment #1-#8 may be equal to 37.5 seconds. - Based on this determination the controller generate a respective actuation command to actuate the pump mechanism to output each partial dose of the partial doses distributed over the output distribution (390). For example, the controller may generate a respective actuation command that corresponds to
pulse 411 oftime segment # 1, and at after the 37.5 seconds allocated totime segment # 1, the controller may generate another respective actuation command that corresponds topulse 412 oftime segment # 2. A timer within the controller may be reset or may indicate a start oftime segment # 2. The respective generation of subsequent actuation commands fortime segment # 3,time segment # 4,time segment # 5,time segment # 6,time segment # 7 andtime segment # 8 may be performed until thecontrol cycle 444 is completed. By the completion oftime segment # 8 and the corresponding completion of thecontrol cycle 444, the 0.4 Units of insulin in the dosage of insulin included in the control instruction is output by the pump mechanism. - Recall that under an operation that does not pause to account for pump occlusions, the controller may generate actuation signals that cause the delivery of the instructed 0.4 Units immediately without any pauses at the pump resolution. In such an operation that does not account for pump occlusions, the controller may generate actuation signals every 2 seconds at the start of a control cycle, the pump mechanism may need to receive 8 actuation signals to deliver the instructed 0.4 Units within 16 seconds (i.e., 2 seconds times the 8 actuation signals). The
control cycle 444 may be as long as 5 minutes and the 16 second delivery of insulin may be less than the total time duration oftime segment # 1. - It is also possible for the controller to take different approaches to determining the
output distribution 449 and the time segments #1-#8. - For example, the controller may be operable to determine a number of times the pump mechanism needs to actuate to output the dosage of insulin included in the control instruction (e.g., 8). Using the determined number of times the pump mechanism needs to actuate to output the dosage of insulin, the controller may segment the
control cycle 444 into time segments #1-#8 by dividing a duration of the control cycle 44 by the determined number of times the pump mechanism ought to actuate. The segmentation of the 300 seconds of thecontrol cycle 444 provides eight time segments #1-#8 of 37.5 seconds. As noted, each time segment #1-#8 may include a pump resolution or preset time period and a respectiveadditional time period 421 - In the operational example of
FIG. 3B at 380, each time segment #1-#8 is 37.5 seconds in duration. The controller is operable to generate a respective actuation command that actuates the pump mechanism for each time segment #1-#8. As shown inFIG. 4 , the pump mechanism pulses 411-418 occur at the start of each respective time segment #1-#8. Each pump mechanism pulse, such aspulse 411 oftime segment # 1, pumps 0.05 Units of insulin for 2 seconds and stops, the controller delays the generation of an actuation command for application at the start oftime segment # 2 for 35.5 seconds (i.e., 37.5 seconds minus 2 seconds). The 35.5 seconds may be measured by a clock, a counter or timer accessible by or within the controller. The 35.5 seconds may be the selectedadditional time period 421. An advantage of the selectedadditional time period 421 is that this delay enables the partial dose of insulin to be absorbed within the user and thereby mitigate the effects of any pump occlusion. - In the example of
FIGS. 3B and 4 , after the passing of the selected additional time period (e.g., the delay), the controller causes the actuation of the pump mechanism, which pulses at 412 to output another 0.05 Units of insulin. Since the pump mechanism does not have the ability to gradually deliver 0.05 U, the pump outputs 0.05 Units over the 2 seconds of the preset time period or pulse, then pauses for 35.5 seconds, then repeats. The processes of the examples ofFIG. 1, 3A and 3B enable spreading the 0.4 Units of insulin to be output over a time of the control cycle that is greater much more than the 16 seconds (i.e., 8 pulses to deliver 0.4 units×2 seconds per pulse) that would happen if the selected additional time period was not incorporated to enable absorption of a partial dose of insulin. - In a further example, the pump rate modification may be applied to other insulin deliveries than automated insulin deliveries. For example, user requested boluses can also be delivered at a lower than maximal rate. In the example, if a user requests a bolus of 3 Units, the delivery control application may be operable to cause this delivery can occur via several pump mechanism pulses (i.e., 6) that have a selected additional time period of, for example, 3 seconds between pulses. As a result, the 3 seconds may be combined with the 2 seconds of the pump resolution to provide a time segment of 5 seconds which delivers the requested bolus of 3 Units within 3 seconds to allow for a pump occlusion.
- While the pulse in response to an output of the actuation command at a beginning of each respective time segment of the control cycle is shown in
FIG. 4 , the pulses 411-418 are shown as occurring at the beginning of each time segment #1-#8 inFIG. 4 . Of course, the actuation command may be delivered at other times within the respective time segments so long as the selected additional time periods 421-428 are of sufficient time to allow for absorption of the insulin and mitigate the effects of any pump occlusion or other absorption problems after output of the dosage of insulin. - The foregoing processes used to modify the pump rate of the pump mechanism may be applied in response to a pump occlusion as well as other reasons including physiological reasons such as difficulty in absorption of a particular type of insulin or medication. However, a process for detecting the presence of a pump occlusion may be explained with reference to
FIGS. 5A and 5B . - The following examples may be useful when absorption of the insulin is occurring at a rate that is less than optimum or is occurring due to factors, such as pump occlusion or the like. As discussed above, pump occlusions may occur for a number of reasons. It may be helpful to describe examples of processes and techniques for determining the presence of a pump occlusion with reference to
FIGS. 5A and 5B . -
FIG. 5A illustrates an example of a process for detecting a pump occlusion that may result in a modification of a pump rate. - In the
process 500, a controller of a medical device may be operable to receive a pressure sensor signal from a pressure sensor in a fluid delivery path through which the dosage of insulin is delivered (510). The pressure sensor signal may include a pressure value. The controller may be further operable to determine whether the pressure value exceeds a pressure threshold (520). The pressure threshold, for example, may be equal to an amount of pressure that the pump mechanism experiences when outputting a drug when no form of pump occlusion is present, and the drug is substantially absorbed by bodily tissue at or near an output of a cannula or needle. This may be determined from testing prior to manufacturing of the pump mechanism, for example. The threshold may be stored in a memory of the medical device during manufacture, may be set (or updated) and stored after an initial use of the medical device, or the like. - At 530, in response to the determination that the pressure value exceeds the threshold, the controller may access a lookup table stored in the memory or may communicate with and external device for an additional time increment. In the lookup table example, the lookup table may contain a number of pressure values that exceed the pressure threshold with corresponding additional time increments. The additional time increments may select an additional time increment to be added to the preset time period of the pump mechanism. The controller may be operable to use the additional time increment in the modification of the pump rate (540). As explained in the examples of
FIGS. 3A, 3B and 4 , a preset time period is an amount of time it takes the pump mechanism to output the dosage of insulin after receipt of the actuation command. Instep 540, for example, the controller may be operable to calculate the extended time period or time segment (as in the example ofFIGS. 3A, 3B and 4 ) by adding the selected additional time increment to the preset time period to arrive at the time segment and the modified pump rate. - Alternatively, a process using a pressure to determine the presence of a pump occlusion may be implemented by the controller.
FIG. 5B illustrates another example of a process for detecting a pump occlusion that may result in a modification of a pump rate. - The
process 503 may be implemented by the execution of programming code by the controller of the pump mechanism in response to pressure sensor signals received from a pressure sensor that may be coupled to the pump mechanism and the controller. In the example ofFIG. 5B , the controller may be operable to receive, at 563, a pressure sensor signal from the pressure sensor, which is coupled to a fluid delivery path of the pump mechanism through which the dosage of insulin is output. - At 573, the controller may calculate an amount of delivery back pressure based on the received pressure sensor signal. For example, the controller may monitor the pressure sensor signal received from the pressure sensor at the beginning, during, and/or end of each pulse of the pump mechanism.
- The controller may be operable to determine whether the calculated amount of delivery back pressure exceeds a threshold (583). The controller, for example, may use the respective pressure sensor signals to determine whether the pressure sensor signal is indicating increases in back pressure that are greater than an operation without a pump occlusion.
- In the example, the controller, based on the result of the determination, may generate an indication that the deliver pressure value has increased (593). The programming code executed by the controller may, for example, in response the generated indication may perform pump rate modification processes, such as those discussed with reference to the examples of
FIGS. 3A, 3B and 4 . - The presence of the pressure sensor and the functions provided by delivery control application as described with reference to the earlier examples serves to reduce the buildup of back pressure and thus reduces the increased risk of occlusion that may be caused by a fixed rate of insulin delivery, which improves the safety of the AID system to the users.
-
FIG. 6 illustrates an example of system suitable to implement the processes and techniques described herein. - In the examples of
FIGS. 1, 3A, 3B, 5A and 5B , the example processes may be implemented by programming code, such as a delivery control application, an AP application or automatic insulin deliver (AID) application, or a combination of applications that are executed by a processor. The AP application or the AID application when executed by a processor may utilize inputs and calculations as described with respect to the foregoing examples. - It may be helpful to discuss an example of a drug delivery system that may implement the process example of
FIGS. 1, 3A, 3B, 5A and 5B .FIG. 6 illustrates an example of a drug delivery system suitable for implementing the example processes and techniques described herein including those described with reference toFIGS. 1, 3A, 3B, 5A and 5B . Details of an example of a medical device (such as 202 ofFIG. 2 or 200 ofFIG. 2A ), a wearable drug delivery device, a “drug delivery device,” such as an OmniPod® delivery device provided by Insulet Corp, or the like, are described with reference to the example system ofFIG. 6 . - The
drug delivery system 600 may be an automatic drug delivery system that may include a medical device 602 (also referred to as “a drug delivery device”, “a wearable drug delivery device,” or “a drug delivery device”), a blood glucose sensor 604 (also referred to as “a continuous glucose monitor” or “a blood glucose measurement device”), and a personal diabetes management (PDM)device 606. Thesystem 600, in an example, may also include asmart device 607, which may be operable to communicate with thePDM 606 and other components ofsystem 600 either via a wired or wireless communication link, such as 691, 692 or 693. In a specific example, thesmart device 607 is coupled to thePDM 606 only via awireless communication link 693, which may be a wireless communication link that utilizes the Bluetooth communication protocol or the like. - The
medical device 602 may include acontroller 621, apressure sensor 622, amemory 623, an AP application 629 and adelivery control application 699 stored in thememory 623, apump mechanism 624, acommunication device 626,user interface 627, and apower source 628. The pump mechanism may be operable to deliver a drug, like insulin, at fixed rate of the mech. Typically, pumps are commanded by a controller to deliver insulin at the fixed rate. For example, an ordinary rate for thepump mechanism 624 may be 0.05 Units per 2 seconds or 0.025 Units per second or 6 Units per 5 minutes, where insulin is measured in Units. These mechanical rates are different from physiological rates that may be determined for a patient. For example, the AP algorithm may determine that a user's total daily insulin is 24 Units per 24 hours, which may translate to a physiological rate of 1 unit per hour that may be determined according to a diabetes treatment plan. However, the pump mechanism may be operable to deliver insulin at rates greater than or less than 1 unit per hour. In an example, themedical device 602 may be attached to the body of a user, such as a patient or diabetic via, for example, an adhesive, and may deliver any therapeutic agent, including any drug or medicine, such as insulin, morphine or the like, to the user. Themedical device 602 may, for example, be a wearable device worn by the user. For example, themedical device 602 may be directly coupled to a user (e.g., directly attached to a body part and/or skin of the user via an adhesive or the like). In an example, a surface of themedical device 602 may include an adhesive (not shown) to facilitate attachment to a user. - The
medical device 602 may include a number of components to facilitate automatic delivery of a drug (also referred to as a therapeutic agent) to the user. Themedical device 602 may be operable to store the drug (i.e., insulin) and to provide the drug to the user. Themedical device 602 is often referred to as a pump, or an insulin pump, in reference to the operation of expelling insulin from thereservoir 625 for delivery to the user. While the examples refer to thereservoir 625 storing insulin, thereservoir 625 may be operable to store other drugs or therapeutic agents, such as morphine or the like, that are suitable for automatic delivery. - In various examples, the
medical device 602 may be an automatic, wearable drug delivery device. For example, themedical device 602 may include areservoir 625 for storing the drug (such as insulin), a needle or cannula (not shown) for delivering the drug into the body of the user (which may be done subcutaneously, intraperitoneally, or intravenously), and a pump mechanism (mech.) 624, or other drive mechanism, for transferring the drug from thereservoir 625, through a needle or cannula (not shown), and into the user. Thepump mechanism 624 may be fluidly coupled toreservoir 625, and communicatively coupled to themedical device controller 621. Themedical device 602 may also include apower source 628, such as a battery, a piezoelectric device, or the like, for supplying electrical power to thepump mechanism 624 and/or other components (such as thecontroller 621,memory 623, and the communication device 626) of themedical device 602. Although not shown, an electrical power supply for supplying electrical power may similarly be included in each of thesensor 604, thesmart device 607 and thePDM device 606. - The
blood glucose sensor 604 may be a device communicatively coupled to thePDM processor 661 orcontroller 621 and may be operable to measure a blood glucose value at a predetermined time interval, such as every 5 minutes, or the like. Theblood glucose sensor 604 may provide a number of blood glucose measurement values to the AP applications (e.g., 629, 649, 669, or 679) operating on the respective devices (e.g., 602, 604, 606, or 607). TheAP applications medical device 602 andsensor 604, and manage a personal diabetes treatment program, and provide the functions and services as described herein. - The
medical device 602 may provide the insulin stored inreservoir 625 to the user based on information (e.g., blood glucose measurement values, predicted future blood glucose measurements, evaluations based on a user request for a bolus, pressure sensor signals received from the pressure sensor 622), and the other information provided by thesensor 604,smart device 607, and/or the management device (PDM) 606. For example, themedical device 602 may contain analog and/or digital circuitry that may be implemented as acontroller 621 for controlling the delivery of the drug or therapeutic agent. The circuitry used to implement thecontroller 621 may include discrete, specialized logic and/or components, an application-specific integrated circuit, a microcontroller or processor that executes software instructions, firmware, programming instructions or programming code (enabling, for example, the artificial pancreas application (AP App) 629 as well as the process examples ofFIGS. 1, 3A, 3B, 5A and 5B ) stored inmemory 623, or any combination thereof. For example, thecontroller 621 may execute a control algorithm, such as the artificial pancreas application 629, and other programming code that may make thecontroller 621 operable to cause the pump to deliver doses of the drug or therapeutic agent to a user at predetermined intervals or as needed to bring blood glucose measurement values to a target blood glucose value. In an example, the AP application (App) 629 may include programming code that is operable upon execution by thecontroller 621 to provide the example processes for adjusting or modifying total daily insulin settings, or the like as described with reference toFIGS. 1, 3A, 3B, 5A and 5B . The user preferences for total daily insulin settings may be programmed, for example, into an artificial pancreas application 629 by the user or by a third party (such as a health care provider, medical device manufacturer, or the like) using a wired or wireless link, such as 631, between themedical device 602 and a personaldiabetes management device 606 or other device, such as a computing device at a healthcare provider facility. In an example, the pump ormedical device 602 is communicatively coupled to thePDM processor 661 of the personal diabetes management device via thewireless link 631 or via a wireless link, such as 691 fromsmart device sensor 604. Thepump mechanism 624 of themedical device 602 may be operable to receive an actuation signal from thePDM processor 661, and in response to receiving a command signal or an actuation signal, expel insulin from thereservoir 625 based on the commands from an AP application, such as 669. - The
drug delivery system 600 may be operable to implement the process examples illustrated inFIGS. 1, 3A, 3B, 5A and 5B by executing a delivery control application in cooperation with an AP application. Thedelivery control application 699 or AP application 629 may be operable to receive a signal from thepressure sensor 622. - In an operational example, the
AP application 669 executing in the personaldiabetes management device 606 may be operable to control delivery of insulin to a user. For example, theAP application 669 may be operable to determine timing of an insulin dose and may output a command signal to themedical device 602 that actuates thepump mechanism 624 to deliver an insulin dose. In addition, the AP application (or AID algorithm) 669 when loaded with programmed code that provides instructions for the functionality ofFIGS. 1, 3A, 3B, 5A and 5B . - In the operational example, the AP application or AID algorithm may have requested, via a command signal to the
medical device 602, delivery of an insulin delivery dosage for a current cycle, say every 5 minutes, which is equal to the control cycle of the AP application or AID algorithm. Thecontroller 621 of themedical device 602 may evaluate the requested insulin delivery using thedelivery control application 699. - Continuing with the operational example, the
delivery control application 699 may receive the requesting insulin delivery. For example, the requested insulin delivery dosage (referred to as ID(t)) may be equal to 0.4 Units of insulin as discussed above. In cases where a pump occlusion is not present, thecontroller 621 of themedical device 602 may actuate thepump mechanism 624 to deliver the ID(t) dosage immediately at the mechanical pump rate of 0.05 units every 2 seconds (which will deliver the 0.4 units of insulin in approximately 16 seconds). However, in an example, the pressure sensor signal received from thepressure sensor 622 may have indicated a degree of back pressure, which the delivercontrol application 699 may be operable to interpret as indicating a partial pump occlusion. Thepressure sensor 622 may be operable to provide a signal to thecontroller 621 indicating the partial pump occlusion. Thecontroller 621, in the presence of the indicated partial pump occlusion, may be operable to modify the delivery of the requested insulin delivery by modifying the mechanical pump rate of thepump mechanism 624. Alternatively, thecontroller 621 may automatically extend all requested insulin deliveries over the control cycle regardless of whether there is a pump occlusion or not. - In the presence of the partial pump occlusion, the
controller 621 may modify the delivery of insulin by extending a time interval to deliver the requested insulin delivery (ID(t)) amount. For example, thecontroller 621 may be operable to extend the time interval to fit the control cycle or control cycle, such as 5 minutes, 10 minutes or the like, of the AP application or AID algorithm. Using a 5 minute control cycle and the ID(t) amount as 0.4 Units in an example in which the controller receives a signal from thepressure sensor 622 indicating a pump occlusion, thecontroller 621 may determine a pump rate modification is needed. As a result, instead of the pump delivering the 0.4 U in the 16 seconds that corresponds to a typical drug delivery, the controller modifies the delivery and extends the delivery over the 5 minutes (or 300 seconds (5 minutes×60 seconds/minute)) of the control cycle. For example, the controller may divide the 300 seconds of the control cycle by the number of pump resolution cycles for delivering the 0.4 U of insulin. In this example the number of pump resolution cycles is equal to 8 (i.e., 0.4 Units divided by the pump resolution of 0.05 U) which equals 37.5 seconds (i.e., 300 seconds/8=37.5). - Based on this calculation made by the
controller 621, thecontroller 621 may actuate thepump mechanism 624 to deliver 0.05 U of insulin every 37.5 seconds for the 300 seconds (i.e., the 5 minute control cycle) after which substantially all of the entire amount of the requested insulin delivery ID(t) is output by thepump mechanism 624. - By extending the time interval, the controller may be able to overcome, or at least mitigate, the effects of the pump occlusion. For example, if the pump occlusion is caused by a slow absorption rate of the insulin due to a buildup of scar tissue in or around the infusion site, the slower rate of delivery over the extended time period may enable the insulin to be absorbed in or around the infusion site.
- Bolus dosages may be handled in a similar manner by the
medical device 602. For example, in response to a meal or other event that may cause an increase in blood glucose, a user may request a bolus dosage of insulin. In a hypothetical example, the user may request the delivery of 3 Units of insulin as the bolus dosage. In response to an input by the user or a generated request by the AP application or AID algorithm, the AP application or AID algorithm in thePDM 606 or the like may deliver a control signal to themedical device 602 indicated that a bolus delivery of 3 units is requested. Thecontroller 621 may receive and interpret the control signal to instruct thepump mechanism 624 to deliver a requested insulin delivery (ID(t)) amount of 3 U. In response to the control signal, the controller may divide the ID(t) amount by the pump resolution (e.g., 3 U/0.05) to determine a number of pulses (e.g., 3 U/0.05=60) that the pump mechanism would need to generate to deliver the requested insulin delivery (ID(t)) amount. Without a pump occlusion and the pump operating at the pump resolution of 0.05 U per 2 seconds, thepump mechanism 624 may deliver the ID(t) of 3 U within 120 seconds or 2 minutes (i.e., 60times 2 seconds). However, if a partial pump occlusion is detected by thepressure sensor 622, thecontroller 621 may extend the time interval for delivery of the ID(t). For example, the time for the control cycle may be 5 minutes, the controller may determine the number of seconds in the control cycle (5 minutes time 60 seconds/minute=300 seconds). The 300 seconds is divided by the number of pulses (60) so 5 seconds is the time for the pump to deliver 0.05 U of insulin. In other words, thecontroller 621 commands thepump mechanism 624 to deliver the 0.05 U of insulin over a 5 second period instead of the 2 seconds. - The other devices in the
system 600, such as personaldiabetes management device 606,smart device 607 andsensor 604, may also be operable to perform various functions including controlling themedical device 602. For example, the personaldiabetes management device 606 may include acommunication device 664, aPDM processor 661, and a personal diabetesmanagement device memory 663. The personal diabetesmanagement device memory 663 may store an instance of theAP application 669 that includes programming code, that when executed by thePDM processor 661 provides the process examples described with reference to the examples ofFIGS. 1, 3A, 3B, 5A and 5B . The personal diabetesmanagement device memory 663 may also store programming code for providing the process examples described with reference to the examples ofFIGS. 1, 3A, 3B, 5A and 5B . - The
smart device 607 may be, for example, a smart phone, an Apple Watch®, another wearable smart device, including eyeglasses, provided by other manufacturers, a global positioning system-enabled wearable, a wearable fitness device, smart clothing, or the like. Similar to the personaldiabetes management device 606, thesmart device 607 may also be operable to perform various functions including controlling themedical device 602. For example, thesmart device 607 may include acommunication device 674, aprocessor 671, and amemory 673. Thememory 673 may store an instance of theAP application 679 and/or an instance of an AID application (not shown) that includes programming code for providing the process examples described with reference to the examples ofFIGS. 1, 3A, 3B, 5A and 5B . Thememory 673 may also as store programming code and be operable to store data related to theAP application 679 or an instance of an AID application (not shown). In an operational example, theAP application 679 may be operable to provide functionality similar to or the same the functionality as described with reference to the instance of theAP application 669. - The
sensor 604 ofsystem 600 may be a continuous glucose monitor (CGM) as described above, that may include aprocessor 641, amemory 643, a sensing or measuringdevice 644, and acommunication device 646. Thememory 643 may, for example, store an instance of anAP application 649 as well as other programming code and be operable to store data related to theAP application 649 and process examples described with reference toFIGS. 1, 3A, 3B, 5A and 5B . TheAP application 649 may also include programming code for providing the process examples described with reference to the examples ofFIGS. 1, 3A, 3B, 5A and 5B . - Instructions for determining the delivery of the drug or therapeutic agent (e.g., as a bolus dosage) to the user (e.g., the size and/or timing of any doses of the drug or therapeutic agent) may originate locally by the
medical device 602 or may originate remotely and be provided to themedical device 602. In an example of a local determination of drug or therapeutic agent delivery, programming instructions, such as an instance of the artificial pancreas application 629, stored in thememory 623 that is coupled to themedical device 602 may be used to make determinations by themedical device 602. In addition, themedical device 602 may be operable to communicate with the cloud-basedservices 611 via thecommunication device 626 and thecommunication link 688. In an example, thesystem 600 may include one or more components operable to implement the process examples ofFIGS. 1, 3A, 3B, 5A and 5B . - Alternatively, the remote instructions may be provided to the
medical device 602 over a wired or wireless link (such as 631) by the personal diabetes management device (PDM) 606, which has aPDM processor 661 that executes an instance of theartificial pancreas application 669, or the smart device 607 (via communication link 691), which has aprocessor 671 that executes an instance of theartificial pancreas application 669 as well as other programming code for controlling various devices, such as themedical device 602,smart device 607 and/orsensor 604. In an example, the send a message to a server, for example, in thecloud services 611 or the like, requesting downloading of the one or more cost functions to a personal diabetes management (PDM) 606 orsmart device 607. Themedical device 602 may execute any received instructions (originating internally or from the personal diabetes management device 606) for the delivery of the drug or therapeutic agent to the user. In this way, the delivery of the drug or therapeutic agent to a user may be automatic. - In various examples, the
medical device 602 may communicate via awireless link 631 with the personaldiabetes management device 606. The personaldiabetes management device 606 may be an electronic device such as, for example, a smart phone, a tablet, a dedicated diabetes therapy personal diabetes management device, or the like. The personaldiabetes management device 606 may be a wearable wireless accessory device. Thewireless communication links wireless communication links medical device 602, the personaldiabetes management device 606 andsensor 604 based on, for example, Bluetooth®, Wi-Fi®, a near-field communication standard, a cellular standard, or any other wireless optical or radio-frequency protocol. - The
sensor 604 may be a glucose sensor operable to measure blood glucose and output a blood glucose value or data that is representative of a blood glucose value. For example, thesensor 604 may be a glucose monitor or a continuous glucose monitor (CGM). Thesensor 604 may include aprocessor 641, amemory 643, a sensing/measuring device 644, andcommunication device 646. Thecommunication device 646 ofsensor 604 may include one or more sensing elements, an electronic transmitter, receiver, and/or transceiver for communicating with the personaldiabetes management device 606 over awireless link 632 or withmedical device 602 over thelink 608. The sensing/measuring device 644 may include one or more sensing elements, such as a glucose measurement, heart rate monitor, or the like. Theprocessor 641 may include discrete, specialized logic and/or components, an application-specific integrated circuit, a microcontroller or processor that executes software instructions, firmware, programming instructions stored in memory (such as memory 643), or any combination thereof. For example, thememory 643 may store an instance of anAP application 649 that is executable by theprocessor 641. - Although the
sensor 604 is depicted as separate from themedical device 602, in various examples, thesensor 604 andmedical device 602 may be incorporated into the same unit. That is, in various examples, thesensor 604 may be a part of themedical device 602 and contained within the same housing of the medical device 602 (e.g., thesensor 604 may be positioned within or embedded within the medical device 602). Glucose monitoring data (e.g., measured blood glucose values) determined by thesensor 604 may be provided to themedical device 602,smart device 607 and/or the personaldiabetes management device 606 and may be used to perform the functions and deliver doses of insulin for automatic delivery of insulin by themedical device 602 as described with reference to the examples ofFIGS. 1, 3A, 3B, 5A and 5B . - The
sensor 604 may also be coupled to the user by, for example, adhesive or the like and may provide information or data on one or more medical conditions and/or physical attributes of the user. The information or data provided by thesensor 604 may be used to adjust drug delivery operations of themedical device 602. - In an example, the personal
diabetes management device 606 may be a mobile computing device operable to manage a personal diabetes treatment plan via an AP application or an AID algorithm. The personaldiabetes management device 606 may be used to program or adjust operation of themedical device 602 and/or thesensor 604. The personaldiabetes management device 606 may be any portable electronic, computing device including, for example, a dedicated controller, such asPDM processor 661, a smartphone, or a tablet. In an example, the personal diabetes management device (PDM) 606 may include aPDM processor 661, a personal diabetesmanagement device memory 663, and acommunication device 664. The personaldiabetes management device 606 may contain analog and/or digital circuitry that may be implemented as a PDM processor 661 (or controller) for executing processes to manage a user's blood glucose levels and for controlling the delivery of the drug or therapeutic agent to the user. ThePDM processor 661 may also be operable to execute programming code stored in the personal diabetesmanagement device memory 663. For example, the personal diabetesmanagement device memory 663 may be operable to store an artificial pancreas (AP)application 669 that may be executed by thePDM processor 661. ThePDM processor 661 may when executing theartificial pancreas application 669 may be operable to perform various functions, such as those described with respect to the examples inFIGS. 1, 3A, 3B, 5A and 5B . Thewireless communication device 664 may be a device, such as a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols. For example, thecommunication device 664 may include a cellular transceiver and a Bluetooth transceiver that enables the personaldiabetes management device 606 to communicate with a data network (not shown) via the cellular transceiver and with thesensor 604 and themedical device 602. The respective transceivers ofcommunication device 664 may be operable to transmit signals containing information useable by or generated by the AP application or the like. Thecommunication devices medical device 602,sensor 604 andSmart device 607 may also be operable to transmit signals containing information useable by or generated by the AP application or the like. - The
medical device 602 may communicate with thesensor 604 over awireless link 608 and may communicate with the personaldiabetes management device 606 over awireless link 631. Thesensor 604 and the personaldiabetes management device 606 may communicate over awireless link 632. Thesmart device 607, when present, may communicate with themedical device 602, thesensor 604 and the personaldiabetes management device 606 overwireless communication links wireless communication links wireless communication links respective communication devices medical device 602 and/or the personaldiabetes management device 606 may include auser interface user interface devices - In various examples, the
drug delivery system 600 may implement the artificial pancreas (AP) algorithm (and/or provide AP functionality) to govern or control automatic delivery of insulin to a user (e.g., to maintain euglycemia—a normal level of glucose in the blood). The AP application (or an AID algorithm) may be implemented by themedical device 602 and/or thesensor 604. The AP application may be operable to determine an initial total daily insulin dosage as described with reference to the examples ofFIGS. 1, 2, 4 and 5 , as well as the times and incremental dosages of insulin delivery. In various examples, the AP application (or the AID algorithm) may determine the times and dosages for delivery based on information known about the user, such as the user's sex, age, weight, or height, and/or on information gathered about a physical attribute or condition of the user (e.g., from the sensor 604). For example, the AP application may determine an appropriate delivery of insulin based on glucose level monitoring of the user through thesensor 604. The AP application may also allow the user to adjust insulin delivery. For example, the AP application may allow the user to issue (e.g., via an input) commands to themedical device 602, such as a command to deliver an insulin bolus. In some examples, different functions of the AP application may be distributed among two or more of the personaldiabetes management device 606, themedical device 602 or thesensor 604. In other examples, the different functions of the AP application may be performed by one device, such the personaldiabetes management device 606, themedical device 602 or thesensor 604. - As described herein, the
drug delivery system 600 or any component thereof, such as the medical device may be considered to provide AP functionality or to implement an AP application. Accordingly, references to the AP application (e.g., functionality, operations, or capabilities thereof) are made for convenience and may refer to and/or include operations and/or functionalities of thedrug delivery system 600 or any constituent component thereof (e.g., themedical device 602 and/or the personal diabetes management device 606). Thedrug delivery system 600—for example, as an insulin delivery system implementing an AP application—may be considered to be a drug delivery system or an AP application-based delivery system that uses sensor inputs (e.g., data collected by the sensor 604). - In an example, one or more of the devices, 602, 604, 606 or 607 may be operable to communicate via a
wireless communication link 688 with cloud-basedservices 611. The cloud-basedservices 611 may utilize servers and data storage (not shown). Thecommunication link 688 may be a cellular link, a Wi-Fi link, a Bluetooth link, or a combination thereof, that is established between therespective devices system 600. The data storage provided by the cloud-basedservices 611 may store insulin delivery history related to the user, cost function data related to general delivery of insulin to users, or the like. In addition, the cloud-basedservices 611 may process anonymized data from multiple users to provide generalized information related to the various parameters used by the AP application. - In an example, the
device 602 includes acommunication device 664, which as described above may be a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols, such as Bluetooth, Wi-Fi, a near-field communication standard, a cellular standard, that may enable the respective device to communicate with the cloud-basedservices 611. For example, outputs from thesensor 604 or themedical device 602 may be transmitted to the cloud-basedservices 611 for storage or processing via the transceivers ofcommunication device 664. Similarly,medical device 602, personaldiabetes management device 606 andsensor 604 may be operable to communicate with the cloud-basedservices 611 via thecommunication link 688. - In an example, the respective receiver or transceiver of each respective device, 602, 606 or 607, may be operable to receive signals containing respective blood glucose measurement values of the number of blood glucose measurement values that may be transmitted by the
sensor 604. The respective processor of eachrespective device diabetes management device 606, theSmart device 607, orsensor 604 may be operable to transmit, via a transceiver implemented by a respective communication device, 664, 674, 646, a control signal for receipt by a medical device. In the example, the control signal may indicate an amount of insulin to be expelled by themedical device 602. - Various operational scenarios and examples of processes performed by the
system 600 are described herein. For example, thesystem 600 may be operable to implement the process examples ofFIGS. 1, 4A, 4B, 5A and 5B . - The techniques described herein for providing functionality to set an adjusted total daily insulin factor and determine whether the adjusted total daily insulin factor exceeds a fixed algorithm delivery threshold. In response to a result of the determination, set a total daily insulin dosage using the attained information and obtain blood glucose measurement values over a period of time. Based on the obtained blood glucose measurement values, a level of glycated hemoglobin of a user may be determined. The set total daily insulin dosage may be modified to provide a modified total daily insulin dosage in response to the determined level of glycated hemoglobin. A control signal including the modified total daily insulin dosage may be output instructing a controller to actuate delivery of insulin according to the modified total daily insulin dosage.
- For example, the
system 600 or any component thereof may be implemented in hardware, software, or any combination thereof. Software related implementations of the techniques described herein may include, but are not limited to, firmware, application specific software, or any other type of computer readable instructions that may be executed by one or more processors. Hardware related implementations of the techniques described herein may include, but are not limited to, integrated circuits (ICs), application specific ICs (ASICs), field programmable arrays (FPGAs), and/or programmable logic devices (PLDs). In some examples, the techniques described herein, and/or any system or constituent component described herein may be implemented with a processor executing computer readable instructions stored on one or more memory components. - In addition, or alternatively, while the examples may have been described with reference to a closed loop algorithmic implementation, variations of the disclosed examples may be implemented to enable open loop use. The open loop implementations allow for use of different modalities of delivery of insulin such as smart pen, syringe or the like. For example, the disclosed delivery control application, AP application and algorithms may be operable to perform various functions related to open loop operations, such as modification of a pump mechanism rate or the like. Similarly, a dosage amount of insulin may be received by the AP application or algorithm from a user via a user interface. Other open-loop actions may also be implemented by adjusting user settings or the like in an AP application or algorithm.
- Some examples of the disclosed device may be implemented, for example, using a storage medium, a computer-readable medium, or an article of manufacture which may store an instruction or a set of instructions that, if executed by a machine (i.e., processor or microcontroller), may cause the machine to perform a method and/or operation in accordance with examples of the disclosure. Such a machine may include, for example, any suitable processing platform, computing platform, computing device, processing device, computing system, processing system, computer, processor, or the like, and may be implemented using any suitable combination of hardware and/or software. The computer-readable medium or article may include, for example, any suitable type of memory unit, memory, memory article, memory medium, storage device, storage article, storage medium and/or storage unit, for example, memory (including non-transitory memory), removable or non-removable media, erasable or non-erasable media, writeable or re-writeable media, digital or analog media, hard disk, floppy disk, Compact Disk Read Only Memory (CD-ROM), Compact Disk Recordable (CD-R), Compact Disk Rewriteable (CD-RW), optical disk, magnetic media, magneto-optical media, removable memory cards or disks, various types of Digital Versatile Disk (DVD), a tape, a cassette, or the like. The instructions may include any suitable type of code, such as source code, compiled code, interpreted code, executable code, static code, dynamic code, encrypted code, programming code, and the like, implemented using any suitable high-level, low-level, object-oriented, visual, compiled and/or interpreted programming language. The non-transitory computer readable medium embodied programming code may cause a processor when executing the programming code to perform functions, such as those described herein.
- Certain examples of the present disclosure were described above. It is, however, expressly noted that the present disclosure is not limited to those examples, but rather the intention is that additions and modifications to what was expressly described herein are also included within the scope of the disclosed examples. Moreover, it is to be understood that the features of the various examples described herein were not mutually exclusive and may exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the disclosed examples. In fact, variations, modifications, and other implementations of what was described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the disclosed examples. As such, the disclosed examples are not to be defined only by the preceding illustrative description.
- Program aspects of the technology may be thought of as “products” or “articles of manufacture” typically in the form of executable code and/or associated data that is carried on or embodied in a type of non-transitory, machine readable medium. Storage type media include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming. It is emphasized that the Abstract of the Disclosure is provided to allow a reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. In addition, in the foregoing Detailed Description, various features are grouped together in a single example for streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed examples require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed example. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate example. In the appended claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein,” respectively. Moreover, the terms “first,” “second,” “third,” and so forth, are used merely as labels and are not intended to impose numerical requirements on their objects.
- The foregoing description of example examples has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the present disclosure to the precise forms disclosed. Many modifications and variations are possible in light of this disclosure. It is intended that the scope of the present disclosure be limited not by this detailed description, but rather by the claims appended hereto. Future filed applications claiming priority to this application may claim the disclosed subject matter in a different manner and may generally include any set of one or more limitations as variously disclosed or otherwise demonstrated herein.
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/945,246 US11684716B2 (en) | 2020-07-31 | 2020-07-31 | Techniques to reduce risk of occlusions in drug delivery systems |
US18/316,703 US20230277766A1 (en) | 2020-07-31 | 2023-05-12 | Techniques to reduce risk of occlusions in drug delivery systems |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/945,246 US11684716B2 (en) | 2020-07-31 | 2020-07-31 | Techniques to reduce risk of occlusions in drug delivery systems |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/316,703 Continuation US20230277766A1 (en) | 2020-07-31 | 2023-05-12 | Techniques to reduce risk of occlusions in drug delivery systems |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220031944A1 true US20220031944A1 (en) | 2022-02-03 |
US11684716B2 US11684716B2 (en) | 2023-06-27 |
Family
ID=80003933
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/945,246 Active 2041-08-28 US11684716B2 (en) | 2020-07-31 | 2020-07-31 | Techniques to reduce risk of occlusions in drug delivery systems |
US18/316,703 Pending US20230277766A1 (en) | 2020-07-31 | 2023-05-12 | Techniques to reduce risk of occlusions in drug delivery systems |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/316,703 Pending US20230277766A1 (en) | 2020-07-31 | 2023-05-12 | Techniques to reduce risk of occlusions in drug delivery systems |
Country Status (1)
Country | Link |
---|---|
US (2) | US11684716B2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018093727A1 (en) * | 2016-11-15 | 2018-05-24 | Insulet Corporation | Basal insulin management |
Family Cites Families (571)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US303013A (en) | 1884-08-05 | Pen-holder | ||
US5338157B1 (en) | 1992-09-09 | 1999-11-02 | Sims Deltec Inc | Systems and methods for communicating with ambulat |
US5935099A (en) | 1992-09-09 | 1999-08-10 | Sims Deltec, Inc. | Drug pump systems and methods |
US2797149A (en) | 1953-01-08 | 1957-06-25 | Technicon International Ltd | Methods of and apparatus for analyzing liquids containing crystalloid and non-crystalloid constituents |
US3631847A (en) | 1966-03-04 | 1972-01-04 | James C Hobbs | Method and apparatus for injecting fluid into the vascular system |
US3634039A (en) | 1969-12-22 | 1972-01-11 | Thomas L Brondy | Blood testing machine |
US3841328A (en) | 1972-08-04 | 1974-10-15 | J Jensen | Airplane hijacking injector |
US3812843A (en) | 1973-03-12 | 1974-05-28 | Lear Siegler Inc | Method and apparatus for injecting contrast media into the vascular system |
US4146029A (en) | 1974-04-23 | 1979-03-27 | Ellinwood Jr Everett H | Self-powered implanted programmable medication system and method |
US3963380A (en) | 1975-01-06 | 1976-06-15 | Thomas Jr Lyell J | Micro pump powered by piezoelectric disk benders |
CA1040271A (en) | 1975-01-22 | 1978-10-10 | Anthony M. Albisser | Artificial beta cell |
US4245634A (en) | 1975-01-22 | 1981-01-20 | Hospital For Sick Children | Artificial beta cell |
US4055175A (en) | 1976-05-07 | 1977-10-25 | Miles Laboratories, Inc. | Blood glucose control apparatus |
US4151845A (en) | 1977-11-25 | 1979-05-01 | Miles Laboratories, Inc. | Blood glucose control apparatus |
US4559037A (en) | 1977-12-28 | 1985-12-17 | Siemens Aktiengesellschaft | Device for the pre-programmable infusion of liquids |
US4373527B1 (en) | 1979-04-27 | 1995-06-27 | Univ Johns Hopkins | Implantable programmable medication infusion system |
DE3023211A1 (en) | 1979-06-28 | 1981-01-22 | Ti Fords Ltd | METHOD AND DEVICE FOR DETERMINING AN AQUEOUS LIQUID IN BOTTLES AND CONTAINERS |
US4403984A (en) | 1979-12-28 | 1983-09-13 | Biotek, Inc. | System for demand-based adminstration of insulin |
AU546785B2 (en) | 1980-07-23 | 1985-09-19 | Commonwealth Of Australia, The | Open-loop controlled infusion of diabetics |
US4559033A (en) | 1980-10-27 | 1985-12-17 | University Of Utah Research Foundation | Apparatus and methods for minimizing peritoneal injection catheter obstruction |
JPS57211361A (en) | 1981-06-23 | 1982-12-25 | Terumo Corp | Liquid injecting apparatus |
IT1142930B (en) | 1981-11-04 | 1986-10-15 | Luigi Bernardi | PORTABLE APPARATUS THAT INFUSES INSULIN ON THE BASIS OF GLYCEMIC DETECTION |
US4529401A (en) | 1982-01-11 | 1985-07-16 | Cardiac Pacemakers, Inc. | Ambulatory infusion pump having programmable parameters |
US4526568A (en) | 1982-09-29 | 1985-07-02 | Miles Laboratories, Inc. | Diagnostic method and apparatus for clamping blood glucose concentration |
US4464170A (en) | 1982-09-29 | 1984-08-07 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
US4624661A (en) | 1982-11-16 | 1986-11-25 | Surgidev Corp. | Drug dispensing system |
IT1170375B (en) | 1983-04-19 | 1987-06-03 | Giuseppe Bombardieri | Implantable device for measuring body fluid parameters |
US4573968A (en) | 1983-08-16 | 1986-03-04 | Ivac Corporation | Infusion and blood chemistry monitoring system |
US4781693A (en) | 1983-09-02 | 1988-11-01 | Minntech Corporation | Insulin dispenser for peritoneal cavity |
US4743243A (en) | 1984-01-03 | 1988-05-10 | Vaillancourt Vincent L | Needle with vent filter assembly |
US4685903A (en) | 1984-01-06 | 1987-08-11 | Pacesetter Infusion, Ltd. | External infusion pump apparatus |
DE3584880D1 (en) | 1984-06-29 | 1992-01-23 | Baxter Int | METHOD AND DEVICE FOR CONTROLLING THE TAKING AND SUBSEQUENT INFUSION OF BLOOD. |
US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
US4778451A (en) | 1986-03-04 | 1988-10-18 | Kamen Dean L | Flow control system using boyle's law |
US5349852A (en) | 1986-03-04 | 1994-09-27 | Deka Products Limited Partnership | Pump controller using acoustic spectral analysis |
AT384737B (en) | 1986-04-04 | 1987-12-28 | Thoma Dipl Ing Dr Techn Herwig | DEVICE FOR CONTINUOUSLY DELIVERING LIQUID MEDICINAL PRODUCTS |
US4731726A (en) | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
US4981140A (en) | 1986-09-12 | 1991-01-01 | Philip Wyatt | Method and apparatus for arterial and venous blood sampling |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
US4976720A (en) | 1987-01-06 | 1990-12-11 | Advanced Cardiovascular Systems, Inc. | Vascular catheters |
AT391998B (en) | 1987-02-02 | 1990-12-27 | Falko Dr Skrabal | Device for determining the concentration of at least one medicinal substance in living organisms |
GB8710610D0 (en) | 1987-05-05 | 1987-06-10 | British Res Agricult Eng | Rotor assemblies |
US4940527A (en) | 1987-06-01 | 1990-07-10 | Abbott Laboratories | Two-part test cartridge for centrifuge |
US5207642A (en) | 1987-08-07 | 1993-05-04 | Baxter International Inc. | Closed multi-fluid delivery system and method |
US4925444A (en) | 1987-08-07 | 1990-05-15 | Baxter Travenol Laboratories, Inc. | Closed multi-fluid delivery system and method |
US4919596A (en) | 1987-12-04 | 1990-04-24 | Pacesetter Infusion, Ltd. | Fluid delivery control and monitoring apparatus for a medication infusion system |
US4994047A (en) | 1988-05-06 | 1991-02-19 | Menlo Care, Inc. | Multi-layer cannula structure |
JP2755654B2 (en) | 1988-07-07 | 1998-05-20 | 住友ベークライト株式会社 | Glucose concentration responsive insulin release device |
US4854170A (en) | 1988-10-12 | 1989-08-08 | Separation Technology, Inc. | Apparatus and method for using ultrasound to determine hematocrit |
US5153827A (en) | 1989-01-30 | 1992-10-06 | Omni-Flow, Inc. | An infusion management and pumping system having an alarm handling system |
US6262798B1 (en) | 1992-09-29 | 2001-07-17 | Board Of Regents, The University Of Texas System | Method and apparatus for direct spectrophotometric measurements in unaltered whole blood |
MX173202B (en) | 1989-03-17 | 1994-02-08 | Baxter Int | PLACE TO PLACE INJECTIONS WITH PRE-CUT AND SHARP CANNULA |
US5134079A (en) | 1989-03-27 | 1992-07-28 | International Technidyne Corp. | Fluid sample collection and delivery system and methods particularly adapted for body fluid sampling |
CA1328359C (en) | 1989-03-27 | 1994-04-12 | Michael D. Mintz | Fluid sample collection and delivery system and methods particularly adapted for body fluid sampling |
US5102406A (en) | 1989-06-02 | 1992-04-07 | Arnold Victor A | Device and method for avoiding contamination of multi-dose medicament vials |
US5716343A (en) | 1989-06-16 | 1998-02-10 | Science Incorporated | Fluid delivery apparatus |
US4975581A (en) | 1989-06-21 | 1990-12-04 | University Of New Mexico | Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids |
US5007286A (en) | 1989-08-03 | 1991-04-16 | Malcolm Robert G | Solid-state transducer based dynamic fluid flow sensing system |
US5109850A (en) | 1990-02-09 | 1992-05-05 | Massachusetts Institute Of Technology | Automatic blood monitoring for medication delivery method and apparatus |
JPH0451966A (en) | 1990-06-19 | 1992-02-20 | Toichi Ishikawa | Medical fluid continuous injector |
US5125415A (en) | 1990-06-19 | 1992-06-30 | Smiths Industries Medical Systems, Inc. | Syringe tip cap with self-sealing filter |
US5176662A (en) | 1990-08-23 | 1993-01-05 | Minimed Technologies, Ltd. | Subcutaneous injection set with improved cannula mounting arrangement |
US5165406A (en) | 1990-09-13 | 1992-11-24 | Via Medical Corporation | Electrochemical sensor apparatus and method |
TW279133B (en) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
US5468727A (en) | 1990-12-13 | 1995-11-21 | Board Of Regents, The University Of Texas System | Methods of normalizing metabolic parameters in diabetics |
US5061424A (en) | 1991-01-22 | 1991-10-29 | Becton, Dickinson And Company | Method for applying a lubricious coating to an article |
US5273517A (en) | 1991-07-09 | 1993-12-28 | Haemonetics Corporation | Blood processing method and apparatus with disposable cassette |
JPH05209826A (en) | 1991-10-04 | 1993-08-20 | Perkin Elmer Corp:The | Spectral comparison method and apparatus |
US5244463A (en) | 1991-12-06 | 1993-09-14 | Block Medical, Inc. | Programmable infusion pump |
DE4141944C2 (en) | 1991-12-19 | 1995-06-08 | Hansa Metallwerke Ag | Device for the contactless control of a sanitary fitting |
EP0549341A1 (en) | 1991-12-24 | 1993-06-30 | W.R. Grace & Co.-Conn. | Hollow fiber plasma sampler |
US5421812A (en) | 1992-03-04 | 1995-06-06 | Cobe Laboratories, Inc. | Method and apparatus for controlling concentrations in tubing system |
US5377674A (en) | 1992-05-08 | 1995-01-03 | Kuestner; J. Todd | Method for non-invasive and in-vitro hemoglobin concentration measurement |
US5385539A (en) | 1992-06-30 | 1995-01-31 | Advanced Haemotechnologies | Apparatus for monitoring hematocrit levels of blood |
US5342298A (en) | 1992-07-31 | 1994-08-30 | Advanced Cardiovascular Systems, Inc. | Automated fluid pressure control system |
US5330634A (en) | 1992-08-28 | 1994-07-19 | Via Medical Corporation | Calibration solutions useful for analyses of biological fluids and methods employing same |
US5232439A (en) | 1992-11-02 | 1993-08-03 | Infusion Technologies Corporation | Method for pumping fluid from a flexible, variable geometry reservoir |
US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
DE4336336A1 (en) | 1992-11-23 | 1994-05-26 | Lang Volker | Cassette infusion system |
US5299571A (en) | 1993-01-22 | 1994-04-05 | Eli Lilly And Company | Apparatus and method for implantation of sensors |
US5257980A (en) | 1993-04-05 | 1993-11-02 | Minimed Technologies, Ltd. | Subcutaneous injection set with crimp-free soft cannula |
DE69430152T2 (en) | 1993-06-25 | 2002-10-31 | Edward W Stark | Method and device for measuring glucose-related substances |
DK88893D0 (en) | 1993-07-30 | 1993-07-30 | Radiometer As | A METHOD AND APPARATUS FOR DETERMINING THE CONTENT OF A CONSTITUENT OF BLOOD OF AN INDIVIDUAL |
US5389078A (en) | 1993-10-06 | 1995-02-14 | Sims Deltec, Inc. | Programmable infusion pump for administering medication to patients |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
US5411889A (en) | 1994-02-14 | 1995-05-02 | Nalco Chemical Company | Regulating water treatment agent dosage based on operational system stresses |
EP0672427A1 (en) | 1994-03-17 | 1995-09-20 | Siemens-Elema AB | System for infusion of medicine into the body of a patient |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
DE4415896A1 (en) | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
US5685859A (en) | 1994-06-02 | 1997-11-11 | Nikomed Aps | Device for fixating a drainage tube and a drainage tube assembly |
US5700695A (en) | 1994-06-30 | 1997-12-23 | Zia Yassinzadeh | Sample collection and manipulation method |
US5505709A (en) | 1994-09-15 | 1996-04-09 | Minimed, Inc., A Delaware Corporation | Mated infusion pump and syringe |
CA2159052C (en) | 1994-10-28 | 2007-03-06 | Rainer Alex | Injection device |
IE72524B1 (en) | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
US5484044A (en) | 1994-11-07 | 1996-01-16 | Mario Sergio Helmeister | Device for the automatic control of vehicular brake systems on hills |
US5685844A (en) | 1995-01-06 | 1997-11-11 | Abbott Laboratories | Medicinal fluid pump having multiple stored protocols |
DE19500529C5 (en) | 1995-01-11 | 2007-11-22 | Dräger Medical AG & Co. KG | Control unit for a ventilator |
US5697899A (en) | 1995-02-07 | 1997-12-16 | Gensia | Feedback controlled drug delivery system |
WO1996025186A2 (en) | 1995-02-07 | 1996-08-22 | Gensia, Inc. | Feedback controlled drug delivery system |
US5741228A (en) | 1995-02-17 | 1998-04-21 | Strato/Infusaid | Implantable access device |
US5665065A (en) | 1995-05-26 | 1997-09-09 | Minimed Inc. | Medication infusion device with blood glucose data input |
US5584813A (en) | 1995-06-07 | 1996-12-17 | Minimed Inc. | Subcutaneous injection set |
US5655530A (en) | 1995-08-09 | 1997-08-12 | Rio Grande Medical Technologies, Inc. | Method for non-invasive blood analyte measurement with improved optical interface |
US7016713B2 (en) | 1995-08-09 | 2006-03-21 | Inlight Solutions, Inc. | Non-invasive determination of direction and rate of change of an analyte |
US6240306B1 (en) | 1995-08-09 | 2001-05-29 | Rio Grande Medical Technologies, Inc. | Method and apparatus for non-invasive blood analyte measurement with fluid compartment equilibration |
US5879310A (en) | 1995-09-08 | 1999-03-09 | Integ, Inc. | Body fluid sampler |
US5693018A (en) | 1995-10-11 | 1997-12-02 | Science Incorporated | Subdermal delivery device |
US6072180A (en) | 1995-10-17 | 2000-06-06 | Optiscan Biomedical Corporation | Non-invasive infrared absorption spectrometer for the generation and capture of thermal gradient spectra from living tissue |
US6058934A (en) | 1995-11-02 | 2000-05-09 | Chiron Diagnostics Corporation | Planar hematocrit sensor incorporating a seven-electrode conductivity measurement cell |
US5800405A (en) | 1995-12-01 | 1998-09-01 | I-Flow Corporation | Syringe actuation device |
WO1997022291A1 (en) | 1995-12-19 | 1997-06-26 | Abbott Laboratories | Device for the detection of analyte and administration of a therapeutic substance |
US6040578A (en) | 1996-02-02 | 2000-03-21 | Instrumentation Metrics, Inc. | Method and apparatus for multi-spectral analysis of organic blood analytes in noninvasive infrared spectroscopy |
FI118509B (en) | 1996-02-12 | 2007-12-14 | Nokia Oyj | A method and apparatus for predicting blood glucose levels in a patient |
US5703364A (en) | 1996-02-15 | 1997-12-30 | Futrex, Inc. | Method and apparatus for near-infrared quantitative analysis |
US5801057A (en) | 1996-03-22 | 1998-09-01 | Smart; Wilson H. | Microsampling device and method of construction |
US5865806A (en) | 1996-04-04 | 1999-02-02 | Becton Dickinson And Company | One step catheter advancement automatic needle retraction system |
SE9602298D0 (en) | 1996-06-11 | 1996-06-11 | Siemens Elema Ab | Arrangement for analyzing body fluids |
ATE241405T1 (en) | 1996-07-03 | 2003-06-15 | Altea Therapeutics Corp | MULTIPLE MECHANICAL MICROPERFORATION OF SKIN OR MUCOUS MEASURES |
WO1998001071A1 (en) | 1996-07-08 | 1998-01-15 | Animas Corporation | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
US5758643A (en) | 1996-07-29 | 1998-06-02 | Via Medical Corporation | Method and apparatus for monitoring blood chemistry |
US5755682A (en) | 1996-08-13 | 1998-05-26 | Heartstent Corporation | Method and apparatus for performing coronary artery bypass surgery |
US5804048A (en) | 1996-08-15 | 1998-09-08 | Via Medical Corporation | Electrode assembly for assaying glucose |
US5932175A (en) | 1996-09-25 | 1999-08-03 | Via Medical Corporation | Sensor apparatus for use in measuring a parameter of a fluid sample |
US5714123A (en) | 1996-09-30 | 1998-02-03 | Lifescan, Inc. | Protective shield for a blood glucose strip |
EP0952858B1 (en) | 1996-11-22 | 2005-01-12 | Therakos, Inc. | Integrated cassette for valving, pumping and controlling movement of fluids |
US6071249A (en) | 1996-12-06 | 2000-06-06 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
US5947911A (en) | 1997-01-09 | 1999-09-07 | Via Medical Corporation | Method and apparatus for reducing purge volume in a blood chemistry monitoring system |
EP0958499B1 (en) | 1997-01-17 | 2002-08-07 | Metracor Technologies Inc | Method for calibrating sensors used in diagnostic testing |
US5851197A (en) | 1997-02-05 | 1998-12-22 | Minimed Inc. | Injector for a subcutaneous infusion set |
ATE227844T1 (en) | 1997-02-06 | 2002-11-15 | Therasense Inc | SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION |
US6979309B2 (en) | 1997-02-14 | 2005-12-27 | Nxstage Medical Inc. | Systems and methods for performing blood processing and/or fluid exchange procedures |
ATE306844T1 (en) | 1997-02-27 | 2005-11-15 | Terumo Cardiovascular Sys | CASSETTE FOR MEASURING BLOOD PARAMETERS |
US6741877B1 (en) | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US6161028A (en) | 1999-03-10 | 2000-12-12 | Optiscan Biomedical Corporation | Method for determining analyte concentration using periodic temperature modulation and phase detection |
US6270455B1 (en) | 1997-03-28 | 2001-08-07 | Health Hero Network, Inc. | Networked system for interactive communications and remote monitoring of drug delivery |
US5871470A (en) | 1997-04-18 | 1999-02-16 | Becton Dickinson And Company | Combined spinal epidural needle set |
US6285448B1 (en) | 1997-05-05 | 2001-09-04 | J. Todd Kuenstner | Clinical analyte determination by infrared spectroscopy |
US6050978A (en) | 1997-05-09 | 2000-04-18 | Becton Dickinson And Company | Needleless valve connector |
US7267665B2 (en) | 1999-06-03 | 2007-09-11 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US5954643A (en) | 1997-06-09 | 1999-09-21 | Minimid Inc. | Insertion set for a transcutaneous sensor |
US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US6500150B1 (en) | 1997-06-16 | 2002-12-31 | Elan Pharma International Limited | Pre-filled drug-delivery device and method of manufacture and assembly of same |
US5948695A (en) | 1997-06-17 | 1999-09-07 | Mercury Diagnostics, Inc. | Device for determination of an analyte in a body fluid |
US6071292A (en) | 1997-06-28 | 2000-06-06 | Transvascular, Inc. | Transluminal methods and devices for closing, forming attachments to, and/or forming anastomotic junctions in, luminal anatomical structures |
US6115673A (en) | 1997-08-14 | 2000-09-05 | Instrumentation Metrics, Inc. | Method and apparatus for generating basis sets for use in spectroscopic analysis |
US7010336B2 (en) | 1997-08-14 | 2006-03-07 | Sensys Medical, Inc. | Measurement site dependent data preprocessing method for robust calibration and prediction |
US5858005A (en) | 1997-08-27 | 1999-01-12 | Science Incorporated | Subcutaneous infusion set with dynamic needle |
US6200287B1 (en) | 1997-09-05 | 2001-03-13 | Gambro, Inc. | Extracorporeal blood processing methods and apparatus |
US6102872A (en) | 1997-11-03 | 2000-08-15 | Pacific Biometrics, Inc. | Glucose detector and method |
US5964718A (en) | 1997-11-21 | 1999-10-12 | Mercury Diagnostics, Inc. | Body fluid sampling device |
US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6159192A (en) | 1997-12-04 | 2000-12-12 | Fowles; Thomas A. | Sliding reconstitution device with seal |
US5971941A (en) | 1997-12-04 | 1999-10-26 | Hewlett-Packard Company | Integrated system and method for sampling blood and analysis |
US6579690B1 (en) | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
DE19756872B4 (en) | 1997-12-19 | 2005-06-02 | Siemens Ag | Device for administering an infusion and / or perfusion to a patient |
AU2005399A (en) | 1997-12-19 | 1999-07-12 | Amira Medical | Embossed test strip system |
US6244776B1 (en) | 1998-01-05 | 2001-06-12 | Lien J. Wiley | Applicators for health and beauty products |
SE523080C2 (en) | 1998-01-08 | 2004-03-23 | Electrolux Ab | Docking system for self-propelled work tools |
DE69838526T2 (en) | 1998-02-05 | 2008-07-03 | Biosense Webster, Inc., Diamond Bar | Device for releasing a drug in the heart |
US6728560B2 (en) | 1998-04-06 | 2004-04-27 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
US6721582B2 (en) | 1999-04-06 | 2004-04-13 | Argose, Inc. | Non-invasive tissue glucose level monitoring |
US6126637A (en) | 1998-04-15 | 2000-10-03 | Science Incorporated | Fluid delivery device with collapsible needle cover |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6283944B1 (en) | 1998-04-30 | 2001-09-04 | Medtronic, Inc. | Infusion systems with patient-controlled dosage features |
ATE246356T1 (en) | 1998-05-13 | 2003-08-15 | Cygnus Therapeutic Systems | DEVICE FOR PREDICTING PHYSIOLOGICAL MEASUREMENTS |
US6662030B2 (en) | 1998-05-18 | 2003-12-09 | Abbott Laboratories | Non-invasive sensor having controllable temperature feature |
US6312888B1 (en) | 1998-06-10 | 2001-11-06 | Abbott Laboratories | Diagnostic assay for a sample of biological fluid |
US6226082B1 (en) | 1998-06-25 | 2001-05-01 | Amira Medical | Method and apparatus for the quantitative analysis of a liquid sample with surface enhanced spectroscopy |
US6214629B1 (en) | 1998-08-06 | 2001-04-10 | Spectral Diagnostics, Inc. | Analytical test device and method for use in medical diagnoses |
US5993423A (en) | 1998-08-18 | 1999-11-30 | Choi; Soo Bong | Portable automatic syringe device and injection needle unit thereof |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6949081B1 (en) | 1998-08-26 | 2005-09-27 | Non-Invasive Technology, Inc. | Sensing and interactive drug delivery |
US6087182A (en) | 1998-08-27 | 2000-07-11 | Abbott Laboratories | Reagentless analysis of biological samples |
DE19840965A1 (en) | 1998-09-08 | 2000-03-09 | Disetronic Licensing Ag | Device for self-administration of a product fluid |
US6402689B1 (en) | 1998-09-30 | 2002-06-11 | Sicel Technologies, Inc. | Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors |
US6326160B1 (en) | 1998-09-30 | 2001-12-04 | Cygnus, Inc. | Microprocessors for use in a device for predicting physiological values |
US6157041A (en) | 1998-10-13 | 2000-12-05 | Rio Grande Medical Technologies, Inc. | Methods and apparatus for tailoring spectroscopic calibration models |
EP1128860B1 (en) | 1998-11-20 | 2004-06-23 | Novo Nordisk A/S | Injection needle |
DK1144028T3 (en) | 1998-11-30 | 2004-10-18 | Novo Nordisk As | A system for assisting a user during medical self-treatment, wherein said self-treatment comprises a plurality of actions |
US6540672B1 (en) | 1998-12-09 | 2003-04-01 | Novo Nordisk A/S | Medical system and a method of controlling the system for use by a patient for medical self treatment |
US6077055A (en) | 1998-12-03 | 2000-06-20 | Sims Deltec, Inc. | Pump system including cassette sensor and occlusion sensor |
US6128519A (en) | 1998-12-16 | 2000-10-03 | Pepex Biomedical, Llc | System and method for measuring a bioanalyte such as lactate |
US6200338B1 (en) | 1998-12-31 | 2001-03-13 | Ethicon, Inc. | Enhanced radiopacity of peripheral and central catheter tubing |
US6280381B1 (en) | 1999-07-22 | 2001-08-28 | Instrumentation Metrics, Inc. | Intelligent system for noninvasive blood analyte prediction |
US6531095B2 (en) | 1999-02-11 | 2003-03-11 | Careside, Inc. | Cartridge-based analytical instrument with optical detector |
EP1135052A1 (en) | 1999-02-12 | 2001-09-26 | Cygnus, Inc. | Devices and methods for frequent measurement of an analyte present in a biological system |
US20010034023A1 (en) | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
US6669663B1 (en) | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
US6334851B1 (en) | 1999-05-10 | 2002-01-01 | Microfab Technologies, Inc. | Method for collecting interstitial fluid from the skin |
US6835553B2 (en) | 1999-05-11 | 2004-12-28 | M-Biotech, Inc. | Photometric glucose measurement system using glucose-sensitive hydrogel |
US6546268B1 (en) | 1999-06-02 | 2003-04-08 | Ball Semiconductor, Inc. | Glucose sensor |
US7806886B2 (en) | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
WO2001003572A1 (en) | 1999-07-08 | 2001-01-18 | Steffen Leonhardt | Device for measuring the blood-sugar level in humans |
US6512937B2 (en) | 1999-07-22 | 2003-01-28 | Sensys Medical, Inc. | Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction |
US6697654B2 (en) | 1999-07-22 | 2004-02-24 | Sensys Medical, Inc. | Targeted interference subtraction applied to near-infrared measurement of analytes |
US6196046B1 (en) | 1999-08-25 | 2001-03-06 | Optiscan Biomedical Corporation | Devices and methods for calibration of a thermal gradient spectrometer |
US6261065B1 (en) | 1999-09-03 | 2001-07-17 | Baxter International Inc. | System and methods for control of pumps employing electrical field sensing |
EP1103796B1 (en) | 1999-11-19 | 2003-10-08 | ESEC Trading S.A. | Sensor for the detection of a predetermined level in a container |
US6470279B1 (en) | 1999-11-23 | 2002-10-22 | James Samsoondar | Method for calibrating spectrophotometric apparatus with synthetic fluids to measure plasma and serum analytes |
WO2001043643A1 (en) | 1999-12-16 | 2001-06-21 | Alza Corporation | Device for enhancing transdermal flux of sampled agents |
US6477901B1 (en) | 1999-12-21 | 2002-11-12 | Integrated Sensing Systems, Inc. | Micromachined fluidic apparatus |
US6813519B2 (en) | 2000-01-21 | 2004-11-02 | Medtronic Minimed, Inc. | Ambulatory medical apparatus and method using a robust communication protocol |
US6895263B2 (en) | 2000-02-23 | 2005-05-17 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US6751490B2 (en) | 2000-03-01 | 2004-06-15 | The Board Of Regents Of The University Of Texas System | Continuous optoacoustic monitoring of hemoglobin concentration and hematocrit |
US6375627B1 (en) | 2000-03-02 | 2002-04-23 | Agilent Technologies, Inc. | Physiological fluid extraction with rapid analysis |
US6572542B1 (en) | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
AU2001242610A1 (en) | 2000-03-28 | 2001-10-08 | Elan Pharma International Limited | Device for measuring a volume of drug |
US6485465B2 (en) | 2000-03-29 | 2002-11-26 | Medtronic Minimed, Inc. | Methods, apparatuses, and uses for infusion pump fluid pressure and force detection |
IT1314759B1 (en) | 2000-05-08 | 2003-01-03 | Menarini Farma Ind | INSTRUMENTATION FOR MEASUREMENT AND CONTROL OF THE CONTENT OF GLUCOSIOLACTATE OR OTHER METABOLITES IN BIOLOGICAL FLUIDS |
WO2001088510A2 (en) | 2000-05-18 | 2001-11-22 | Argose, Inc. | Pre-and post-processing of spectral data for calibration using multivariate analysis techniques |
US6699221B2 (en) | 2000-06-15 | 2004-03-02 | Vincent L. Vaillancourt | Bloodless catheter |
WO2002017210A2 (en) | 2000-08-18 | 2002-02-28 | Cygnus, Inc. | Formulation and manipulation of databases of analyte and associated values |
US6475196B1 (en) | 2000-08-18 | 2002-11-05 | Minimed Inc. | Subcutaneous infusion cannula |
IL138073A0 (en) | 2000-08-24 | 2001-10-31 | Glucon Inc | Photoacoustic assay and imaging system |
DK1335764T3 (en) | 2000-09-08 | 2007-10-01 | Insulet Corp | Patient infusion apparatus and system |
US6575905B2 (en) | 2000-09-22 | 2003-06-10 | Knobbe, Lim & Buckingham | Method and apparatus for real-time estimation of physiological parameters |
US6553841B1 (en) | 2000-09-26 | 2003-04-29 | Helix Technology Corporation | Pressure transducer assembly |
US7460130B2 (en) | 2000-09-26 | 2008-12-02 | Advantage 3D Llc | Method and system for generation, storage and distribution of omni-directional object views |
CA2423717A1 (en) | 2000-10-04 | 2002-04-11 | Insulet Corporation | Data collection assembly for patient infusion system |
US20120191052A1 (en) | 2000-10-06 | 2012-07-26 | Ip Holdings, Inc. | Intelligent activated skin patch system |
DE60135042D1 (en) | 2000-11-09 | 2008-09-04 | Insulet Corp | Device for the transcutaneous delivery of drugs |
WO2002043866A2 (en) | 2000-12-01 | 2002-06-06 | Burstein Technologies, Inc. | Apparatus and methods for separating components of particulate suspension |
US6645142B2 (en) | 2000-12-01 | 2003-11-11 | Optiscan Biomedical Corporation | Glucose monitoring instrument having network connectivity |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
JP4996015B2 (en) | 2001-03-12 | 2012-08-08 | メディキット株式会社 | Indwelling catheter |
US7139598B2 (en) | 2002-04-04 | 2006-11-21 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using tissue fluorescence |
US6865408B1 (en) | 2001-04-11 | 2005-03-08 | Inlight Solutions, Inc. | System for non-invasive measurement of glucose in humans |
US7043288B2 (en) | 2002-04-04 | 2006-05-09 | Inlight Solutions, Inc. | Apparatus and method for spectroscopic analysis of tissue to detect diabetes in an individual |
US6574490B2 (en) | 2001-04-11 | 2003-06-03 | Rio Grande Medical Technologies, Inc. | System for non-invasive measurement of glucose in humans |
US7756558B2 (en) | 2004-05-24 | 2010-07-13 | Trutouch Technologies, Inc. | Apparatus and methods for mitigating the effects of foreign interferents on analyte measurements in spectroscopy |
US6748250B1 (en) | 2001-04-27 | 2004-06-08 | Medoptix, Inc. | Method and system of monitoring a patient |
US6837988B2 (en) | 2001-06-12 | 2005-01-04 | Lifescan, Inc. | Biological fluid sampling and analyte measurement devices and methods |
US6890291B2 (en) | 2001-06-25 | 2005-05-10 | Mission Medical, Inc. | Integrated automatic blood collection and processing unit |
US20030208113A1 (en) | 2001-07-18 | 2003-11-06 | Mault James R | Closed loop glycemic index system |
US6544212B2 (en) | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
US6687620B1 (en) | 2001-08-01 | 2004-02-03 | Sandia Corporation | Augmented classical least squares multivariate spectral analysis |
US6788965B2 (en) | 2001-08-03 | 2004-09-07 | Sensys Medical, Inc. | Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes |
EP1428013A4 (en) | 2001-08-14 | 2007-10-31 | Purdue Research Foundation | Measuring a substance in a biological sample |
US20040147034A1 (en) | 2001-08-14 | 2004-07-29 | Gore Jay Prabhakar | Method and apparatus for measuring a substance in a biological sample |
US6678542B2 (en) | 2001-08-16 | 2004-01-13 | Optiscan Biomedical Corp. | Calibrator configured for use with noninvasive analyte-concentration monitor and employing traditional measurements |
US6827702B2 (en) | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
US6740072B2 (en) | 2001-09-07 | 2004-05-25 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
US20030144582A1 (en) | 2001-09-07 | 2003-07-31 | Carl Cohen | Portable non-invasive glucose monitor |
US8152789B2 (en) | 2001-10-23 | 2012-04-10 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
FI20011918A0 (en) | 2001-10-01 | 2001-10-01 | Mirhava Ltd | Automatic vascular connection control device |
AU2002341372A1 (en) | 2001-10-09 | 2003-04-22 | Glucon Inc. | Method and apparatus for determining absorption of electromagnetic radiation by a material |
US6989891B2 (en) | 2001-11-08 | 2006-01-24 | Optiscan Biomedical Corporation | Device and method for in vitro determination of analyte concentrations within body fluids |
US7061593B2 (en) | 2001-11-08 | 2006-06-13 | Optiscan Biomedical Corp. | Device and method for in vitro determination of analyte concentrations within body fluids |
US6958809B2 (en) | 2001-11-08 | 2005-10-25 | Optiscan Biomedical Corporation | Reagent-less whole-blood glucose meter |
US7050157B2 (en) | 2001-11-08 | 2006-05-23 | Optiscan Biomedical Corp. | Reagent-less whole-blood glucose meter |
US20030175806A1 (en) | 2001-11-21 | 2003-09-18 | Peter Rule | Method and apparatus for improving the accuracy of alternative site analyte concentration measurements |
US6862534B2 (en) | 2001-12-14 | 2005-03-01 | Optiscan Biomedical Corporation | Method of determining an analyte concentration in a sample from an absorption spectrum |
US7139593B2 (en) | 2001-12-14 | 2006-11-21 | Samsung Electronics Co., Ltd. | System and method for improving performance of an adaptive antenna array in a vehicular environment |
US7009180B2 (en) | 2001-12-14 | 2006-03-07 | Optiscan Biomedical Corp. | Pathlength-independent methods for optically determining material composition |
US7204823B2 (en) | 2001-12-19 | 2007-04-17 | Medtronic Minimed, Inc. | Medication delivery system and monitor |
US6985870B2 (en) | 2002-01-11 | 2006-01-10 | Baxter International Inc. | Medication delivery system |
AU2003200359A1 (en) | 2002-02-11 | 2003-08-28 | Bayer Healthcare, Llc | Non-invasive System for the Determination of Analytes in Body Fluids |
US20030212379A1 (en) | 2002-02-26 | 2003-11-13 | Bylund Adam David | Systems and methods for remotely controlling medication infusion and analyte monitoring |
US20080172026A1 (en) | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having a suspension bolus |
US6878136B2 (en) | 2002-02-28 | 2005-04-12 | Medical Product Specialists | Huber needle with anti-rebound safety mechanism |
US7500949B2 (en) | 2002-03-01 | 2009-03-10 | Medtronic Minimed, Inc. | Multilumen catheter |
GB0206792D0 (en) | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
US7027848B2 (en) | 2002-04-04 | 2006-04-11 | Inlight Solutions, Inc. | Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte |
US20050238507A1 (en) | 2002-04-23 | 2005-10-27 | Insulet Corporation | Fluid delivery device |
US6960192B1 (en) | 2002-04-23 | 2005-11-01 | Insulet Corporation | Transcutaneous fluid delivery system |
US6758835B2 (en) | 2002-05-01 | 2004-07-06 | Medtg, Llc | Disposable needle assembly having sensors formed therein permitting the simultaneous drawing and administering of fluids and method of forming the same |
US7175606B2 (en) | 2002-05-24 | 2007-02-13 | Baxter International Inc. | Disposable medical fluid unit having rigid frame |
US20040010207A1 (en) | 2002-07-15 | 2004-01-15 | Flaherty J. Christopher | Self-contained, automatic transcutaneous physiologic sensing system |
US7018360B2 (en) | 2002-07-16 | 2006-03-28 | Insulet Corporation | Flow restriction system and method for patient infusion device |
US8512276B2 (en) | 2002-07-24 | 2013-08-20 | Medtronic Minimed, Inc. | System for providing blood glucose measurements to an infusion device |
US7278983B2 (en) | 2002-07-24 | 2007-10-09 | Medtronic Minimed, Inc. | Physiological monitoring device for controlling a medication infusion device |
US7404796B2 (en) | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
AU2003278798A1 (en) | 2002-09-12 | 2004-04-30 | Children's Hospital Medical Center | Method and device for painless injection of medication |
US20040051368A1 (en) | 2002-09-17 | 2004-03-18 | Jimmy Caputo | Systems and methods for programming pumps |
US7128727B2 (en) | 2002-09-30 | 2006-10-31 | Flaherty J Christopher | Components and methods for patient infusion device |
US7144384B2 (en) | 2002-09-30 | 2006-12-05 | Insulet Corporation | Dispenser components and methods for patient infusion device |
US7025744B2 (en) | 2002-10-04 | 2006-04-11 | Dsu Medical Corporation | Injection site for male luer or other tubular connector |
DK1575656T3 (en) | 2002-10-11 | 2009-09-14 | Becton Dickinson Co | Insulin delivery system with sensor |
US7029443B2 (en) | 2002-10-21 | 2006-04-18 | Pacesetter, Inc. | System and method for monitoring blood glucose levels using an implantable medical device |
US7248912B2 (en) | 2002-10-31 | 2007-07-24 | The Regents Of The University Of California | Tissue implantable sensors for measurement of blood solutes |
US6931328B2 (en) | 2002-11-08 | 2005-08-16 | Optiscan Biomedical Corp. | Analyte detection system with software download capabilities |
US20040133166A1 (en) | 2002-11-22 | 2004-07-08 | Minimed Inc. | Methods, apparatuses, and uses for infusion pump fluid pressure and force detection |
US7142814B2 (en) | 2002-12-11 | 2006-11-28 | Shary Nassimi | Automatic Bluetooth inquiry mode headset |
US20040122353A1 (en) | 2002-12-19 | 2004-06-24 | Medtronic Minimed, Inc. | Relay device for transferring information between a sensor system and a fluid delivery system |
EP1578262A4 (en) | 2002-12-31 | 2007-12-05 | Therasense Inc | Continuous glucose monitoring system and methods of use |
KR100521855B1 (en) | 2003-01-30 | 2005-10-14 | 최수봉 | Control method of insulin pump by bluetooth protocol |
US8016798B2 (en) | 2003-02-24 | 2011-09-13 | Integrated Sensing Systems, Inc. | Fluid delivery system and sensing unit therefor |
US7354429B2 (en) | 2003-05-27 | 2008-04-08 | Integrated Sensing Systems, Inc. | Device and method for detecting and treating chemical and biological agents |
US9872890B2 (en) | 2003-03-19 | 2018-01-23 | Paul C. Davidson | Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
JP4091865B2 (en) | 2003-03-24 | 2008-05-28 | 日機装株式会社 | Drug injection device |
US20040204868A1 (en) | 2003-04-09 | 2004-10-14 | Maynard John D. | Reduction of errors in non-invasive tissue sampling |
EP1620715A1 (en) | 2003-04-15 | 2006-02-01 | Optiscan Biomedical Corporation | Sample element for use in material analysis |
US7271912B2 (en) | 2003-04-15 | 2007-09-18 | Optiscan Biomedical Corporation | Method of determining analyte concentration in a sample using infrared transmission data |
CA2520880A1 (en) | 2003-04-18 | 2004-11-04 | Insulet Corporation | User interface for infusion pump remote controller and method of using the same |
US20040241736A1 (en) | 2003-05-21 | 2004-12-02 | Hendee Shonn P. | Analyte determinations |
US7258673B2 (en) | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
BRPI0411212A (en) | 2003-06-09 | 2006-07-18 | Nipro Diabetes Systems Inc | liquid release system |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
WO2005007223A2 (en) | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
CN1905835B (en) | 2003-09-11 | 2011-11-30 | 赛拉诺斯股份有限公司 | Medical device for analyte monitoring and drug delivery |
DE10346167A1 (en) | 2003-10-01 | 2005-05-25 | Merck Patent Gmbh | Shiny black interference pigments |
US7320676B2 (en) | 2003-10-02 | 2008-01-22 | Medtronic, Inc. | Pressure sensing in implantable medical devices |
KR100567837B1 (en) | 2003-10-24 | 2006-04-05 | 케이제이헬스케어 주식회사 | Insulin pump combined with mobile which detects a blood glucose, network system for transmitting control imformation of the insulin pump |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
WO2006053007A2 (en) | 2004-11-09 | 2006-05-18 | Angiotech Biocoatings Corp. | Antimicrobial needle coating for extended infusion |
EP3263032B1 (en) | 2003-12-09 | 2024-01-24 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US20050137573A1 (en) | 2003-12-19 | 2005-06-23 | Animas Corporation | System, method, and communication hub for controlling external infusion device |
WO2005089103A2 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
CN102886101B (en) | 2004-03-08 | 2015-10-28 | 艾科医疗系统公司 | The apparatus for electrically mediated delivery of therapeutic agents improved |
EP1735729A2 (en) | 2004-03-26 | 2006-12-27 | Novo Nordisk A/S | Device for displaying data relevant for a diabetic patient |
US20060009727A1 (en) | 2004-04-08 | 2006-01-12 | Chf Solutions Inc. | Method and apparatus for an extracorporeal control of blood glucose |
US20080051764A1 (en) | 2004-04-19 | 2008-02-28 | Board Of Regents, The University Of Texas System | Physiological Monitoring With Continuous Treatment |
WO2005110601A1 (en) | 2004-05-07 | 2005-11-24 | Optiscan Biomedical Corporation | Sample element with separator |
WO2005113036A1 (en) | 2004-05-13 | 2005-12-01 | The Regents Of The University Of California | Method and apparatus for glucose control and insulin dosing for diabetics |
US20050261660A1 (en) | 2004-05-24 | 2005-11-24 | Choi Soo B | Method for controlling insulin pump using Bluetooth protocol |
GB2446321B8 (en) | 2004-07-13 | 2011-03-02 | Waters Investments Ltd | High pressure pump controller. |
US7291107B2 (en) | 2004-08-26 | 2007-11-06 | Roche Diagnostics Operations, Inc. | Insulin bolus recommendation system |
US20060229531A1 (en) | 2005-02-01 | 2006-10-12 | Daniel Goldberger | Blood monitoring system |
US20070191716A1 (en) | 2004-09-29 | 2007-08-16 | Daniel Goldberger | Blood monitoring system |
US7608042B2 (en) | 2004-09-29 | 2009-10-27 | Intellidx, Inc. | Blood monitoring system |
US7388202B2 (en) | 2004-10-21 | 2008-06-17 | Optiscan Biomedical Corporation | Method and apparatus for determining an analyte concentration in a sample having interferents |
WO2006069102A1 (en) | 2004-12-21 | 2006-06-29 | E.I. Dupont De Nemours And Company | Process for forming a patterned fluoropolymer film on a substrate |
US20060167350A1 (en) | 2005-01-27 | 2006-07-27 | Monfre Stephen L | Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction |
US7547281B2 (en) | 2005-02-01 | 2009-06-16 | Medtronic Minimed, Inc. | Algorithm sensor augmented bolus estimator for semi-closed loop infusion system |
US20060235348A1 (en) | 2005-02-14 | 2006-10-19 | Callicoat David N | Method of extracting and analyzing the composition of bodily fluids |
US7722537B2 (en) | 2005-02-14 | 2010-05-25 | Optiscan Biomedical Corp. | Method and apparatus for detection of multiple analytes |
US20060189926A1 (en) | 2005-02-14 | 2006-08-24 | Hall W D | Apparatus and methods for analyzing body fluid samples |
US20070083160A1 (en) | 2005-10-06 | 2007-04-12 | Hall W D | System and method for assessing measurements made by a body fluid analyzing device |
US8251907B2 (en) | 2005-02-14 | 2012-08-28 | Optiscan Biomedical Corporation | System and method for determining a treatment dose for a patient |
US7785258B2 (en) | 2005-10-06 | 2010-08-31 | Optiscan Biomedical Corporation | System and method for determining a treatment dose for a patient |
US20060204535A1 (en) | 2005-02-25 | 2006-09-14 | Johnson Johnnie M | Cell-friendly cannula and needle |
WO2007059476A2 (en) | 2005-11-15 | 2007-05-24 | Luminous Medical, Inc. | Blood analyte determinations |
US20090054753A1 (en) | 2007-08-21 | 2009-02-26 | Mark Ries Robinson | Variable Sampling Interval for Blood Analyte Determinations |
JP5001934B2 (en) | 2005-04-15 | 2012-08-15 | バイエル・ヘルスケア・エルエルシー | Non-invasive system and method for measuring body glucose |
US20060253085A1 (en) | 2005-05-06 | 2006-11-09 | Medtronic Minimed, Inc. | Dual insertion set |
EP1881786B1 (en) | 2005-05-13 | 2017-11-15 | Trustees of Boston University | Fully automated control system for type 1 diabetes |
US7509156B2 (en) | 2005-05-18 | 2009-03-24 | Clarian Health Partners, Inc. | System for managing glucose levels in patients with diabetes or hyperglycemia |
ATE451132T1 (en) | 2005-05-26 | 2009-12-15 | Infusion Systems Llc | IMPLANTABLE INFUSION DEVICE WITH MULTIPLE CONTROLLED FLUID OUTLETS |
EP1728468A1 (en) | 2005-06-04 | 2006-12-06 | Roche Diagnostics GmbH | Evaluation of blood glucose concentration values for adaptation of insulin dosage |
US20060276771A1 (en) | 2005-06-06 | 2006-12-07 | Galley Paul J | System and method providing for user intervention in a diabetes control arrangement |
US20070060869A1 (en) | 2005-08-16 | 2007-03-15 | Tolle Mike C V | Controller device for an infusion pump |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US7704457B2 (en) | 2005-11-18 | 2010-04-27 | Patton Charles J | Automatic, field portable analyzer using discrete sample aliquots |
US20080200838A1 (en) | 2005-11-28 | 2008-08-21 | Daniel Goldberger | Wearable, programmable automated blood testing system |
US20070129690A1 (en) | 2005-12-02 | 2007-06-07 | Joel Rosenblatt | Catheter with polymeric coating |
US8666760B2 (en) | 2005-12-30 | 2014-03-04 | Carefusion 303, Inc. | Medication order processing and reconciliation |
US20070173974A1 (en) | 2006-01-25 | 2007-07-26 | Chyi-Yeu Lin | Device and method for interacting with autonomous robot |
BRPI0708063A2 (en) | 2006-02-17 | 2011-05-17 | Alan L Buchman | catheter cleaning devices |
US20070197163A1 (en) | 2006-02-23 | 2007-08-23 | Research In Motion Limited | Combination modes for network connection management |
US8478557B2 (en) | 2009-07-31 | 2013-07-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
US20070249007A1 (en) | 2006-04-20 | 2007-10-25 | Rosero Spencer Z | Method and apparatus for the management of diabetes |
NZ573499A (en) | 2006-05-09 | 2011-08-26 | Axela Inc | Automated analyzer for assaying analytes in liquids using light diffraction |
US20070282269A1 (en) | 2006-05-31 | 2007-12-06 | Seattle Medical Technologies | Cannula delivery apparatus and method for a disposable infusion device |
WO2007143225A2 (en) | 2006-06-07 | 2007-12-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
CN101489603A (en) | 2006-06-30 | 2009-07-22 | 诺沃-诺迪斯克有限公司 | Perfusion device with compensation of medical infusion during wear-time |
US7682338B2 (en) | 2006-08-23 | 2010-03-23 | Medtronic Minimed, Inc. | Infusion medium delivery system, device and method with needle inserter and needle inserter device and method |
US9056165B2 (en) | 2006-09-06 | 2015-06-16 | Medtronic Minimed, Inc. | Intelligent therapy recommendation algorithm and method of using the same |
WO2008029403A1 (en) | 2006-09-06 | 2008-03-13 | Medingo Ltd. | Fluid delivery system with optical sensing of analyte concentration levels |
US8561614B2 (en) | 2006-09-28 | 2013-10-22 | Covidien Lp | Multi-layer cuffs for medical devices |
GB2443260C (en) | 2006-10-26 | 2017-11-29 | Cellnovo Ltd | Micro-valve |
GB2456681B (en) | 2006-10-26 | 2009-11-11 | Starbridge Systems Ltd | Pump |
US8377040B2 (en) | 2006-11-06 | 2013-02-19 | Becton, Dickinson And Company | Extravascular system venting |
US20080214919A1 (en) | 2006-12-26 | 2008-09-04 | Lifescan, Inc. | System and method for implementation of glycemic control protocols |
US7946985B2 (en) | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
US7734323B2 (en) | 2007-01-24 | 2010-06-08 | Smiths Medical Asd, Inc. | Correction factor testing using frequent blood glucose input |
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
WO2008124478A1 (en) | 2007-04-04 | 2008-10-16 | Pronia Medical Systems, Llc | Systems, methods, and computer program product for improved management of medical procedures for patients on medical protocols |
US20080269723A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
US20080269714A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
WO2008133702A1 (en) | 2007-04-30 | 2008-11-06 | Medtronic Minimed, Inc. | Needle inserting and fluid flow connection for infusion medium delivery system |
US8417311B2 (en) | 2008-09-12 | 2013-04-09 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
ES2576639T3 (en) | 2007-06-20 | 2016-07-08 | F.Hoffmann-La Roche Ag | Method and device to assess the ratio of carbohydrates to insulin |
US10350354B2 (en) | 2007-06-21 | 2019-07-16 | Roche Diagnostics Operations, Inc. | Device and method for preventing hypoglicemia |
US8078787B2 (en) | 2007-06-22 | 2011-12-13 | Apple Inc. | Communication between a host device and an accessory via an intermediate device |
EP2171630A1 (en) | 2007-06-27 | 2010-04-07 | F. Hoffmann-Roche AG | System and method for developing patient specific therapies based on modeling of patient physiology |
US20090036753A1 (en) | 2007-07-31 | 2009-02-05 | King Allen B | Continuous glucose monitoring-directed adjustments in basal insulin rate and insulin bolus dosing formulas |
US7717903B2 (en) | 2007-09-06 | 2010-05-18 | M2 Group Holdings, Inc. | Operating an infusion pump system |
US7935076B2 (en) | 2007-09-07 | 2011-05-03 | Asante Solutions, Inc. | Activity sensing techniques for an infusion pump system |
US20090069743A1 (en) | 2007-09-11 | 2009-03-12 | Baxter International Inc. | Infusion therapy sensor system |
WO2009039214A2 (en) | 2007-09-17 | 2009-03-26 | Satish Sundar | High precision infusion pumps |
EP2351932B1 (en) | 2007-10-02 | 2014-08-20 | Emerson Climate Technologies, Inc. | Compressor having improved valve plate |
EP2205147A1 (en) | 2007-10-10 | 2010-07-14 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
DE102007049446A1 (en) | 2007-10-16 | 2009-04-23 | Cequr Aps | Catheter introducer |
US7695434B2 (en) | 2007-10-19 | 2010-04-13 | Lifescan Scotland, Ltd. | Medical device for predicting a user's future glycemic state |
US20100262117A1 (en) | 2007-11-02 | 2010-10-14 | University Of Virginia Patent Foundation | Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing |
WO2009066287A2 (en) | 2007-11-21 | 2009-05-28 | Medingo Ltd. | Hypodermic optical monitoring of bodily analyte |
US20100256593A1 (en) | 2007-11-21 | 2010-10-07 | Ofer Yodfat | Analyte Monitoring and Fluid Dispensing System |
US7918825B2 (en) | 2007-11-29 | 2011-04-05 | Insulet Corporation | Interfacing a prefilled syringe with an infusion pump to fill the infusion pump |
WO2009075925A1 (en) | 2007-12-13 | 2009-06-18 | Shaya Steven A | Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
DE112009005510A5 (en) | 2008-01-31 | 2013-06-20 | Fisher-Rosemount Systems, Inc. | Robust adaptive model predictive controller with tuning to compensate for model mismatch |
EP2359880A3 (en) | 2008-02-04 | 2011-09-21 | Nilimedix Ltd. | Drug delivery system with wireless monitor |
US20090221890A1 (en) | 2008-02-28 | 2009-09-03 | Daniel Saffer | Diabetes Management System |
DK2252956T3 (en) | 2008-03-03 | 2019-03-25 | Hoffmann La Roche | INSULIN PUMP WITH REPLACEMENT OPPORTUNITIES |
WO2009114718A2 (en) | 2008-03-12 | 2009-09-17 | University Of Miami | Methods and assays for detecting and treating hypoglycemia |
JP5506780B2 (en) | 2008-04-09 | 2014-05-28 | エフ.ホフマン−ラ ロシュ アーゲー | System, apparatus and method for delivering fluid |
TWI394580B (en) | 2008-04-28 | 2013-05-01 | Halozyme Inc | Super fast-acting insulin compositions |
US8140275B2 (en) | 2008-07-18 | 2012-03-20 | Insulet Corporation | Calculating insulin on board for extended bolus being delivered by an insulin delivery device |
US8734422B2 (en) | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US8622988B2 (en) | 2008-08-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Variable rate closed loop control and methods |
EP2323720A4 (en) | 2008-09-09 | 2013-04-10 | Pulmonx Corp | Systems and methods for inhibiting secretion flow into a functional assessment catheter |
GB2464114B (en) | 2008-10-02 | 2012-06-13 | Cellnovo Ltd | Linear capacitive displacement sensor |
US9409052B2 (en) | 2008-10-03 | 2016-08-09 | Adidas Ag | Program products, methods, and systems for providing location-aware fitness monitoring services |
WO2010041261A1 (en) | 2008-10-09 | 2010-04-15 | Medingo Ltd. | Skin securable drug delivery device with a shock absorbing protective shield |
US20100174228A1 (en) | 2008-10-24 | 2010-07-08 | Bruce Buckingham | Hypoglycemia prediction and control |
US8613719B2 (en) | 2008-11-03 | 2013-12-24 | Calibra Medical, Inc. | Dosage sensing unit with tactile feedback |
US8352290B2 (en) | 2008-11-07 | 2013-01-08 | Curlin Medical Inc. | Method of automatically programming an infusion pump |
US9370621B2 (en) | 2008-12-16 | 2016-06-21 | Medtronic Minimed, Inc. | Needle insertion systems and methods |
US9375529B2 (en) | 2009-09-02 | 2016-06-28 | Becton, Dickinson And Company | Extended use medical device |
WO2010097796A1 (en) | 2009-02-26 | 2010-09-02 | Mor Research Applications Ltd. | Method and system for automatic monitoring of diabetes related treatments |
GR1007310B (en) | 2009-03-09 | 2011-06-10 | Αχιλλεας Τσουκαλης | Implantable biosensor with automatic calibration |
US8172798B2 (en) | 2009-05-12 | 2012-05-08 | Sigma International General Medical Apparatus LLC | System and method for managing infusion therapies |
US8597274B2 (en) | 2009-05-22 | 2013-12-03 | Abbott Diabetes Care Inc. | Usability features for integrated insulin delivery system |
EP2433235A2 (en) | 2009-05-22 | 2012-03-28 | Abbott Diabetes Care, Inc. | Safety features for integrated insulin delivery system |
US9579456B2 (en) | 2009-05-22 | 2017-02-28 | Abbott Diabetes Care Inc. | Methods for reducing false hypoglycemia alarm occurrence |
JP2012527981A (en) | 2009-05-29 | 2012-11-12 | ユニバーシティ オブ バージニア パテント ファウンデーション | System coordinator and module architecture for open-loop and closed-loop control of diabetes |
US9687194B2 (en) | 2009-06-17 | 2017-06-27 | Medtronic Minimed, Inc. | Closed-loop glucose and/or insulin control system |
AU2010278894B2 (en) | 2009-07-30 | 2014-01-30 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US8547239B2 (en) | 2009-08-18 | 2013-10-01 | Cequr Sa | Methods for detecting failure states in a medicine delivery device |
US8900190B2 (en) | 2009-09-02 | 2014-12-02 | Medtronic Minimed, Inc. | Insertion device systems and methods |
DK2475356T3 (en) | 2009-09-08 | 2019-06-17 | Hoffmann La Roche | Devices, systems and methods for adjusting fluid supply parameters |
US20110099507A1 (en) | 2009-10-28 | 2011-04-28 | Google Inc. | Displaying a collection of interactive elements that trigger actions directed to an item |
US9858386B2 (en) | 2009-11-02 | 2018-01-02 | Universita Degli Studi Di Padova | Method to recalibrate continuous glucose monitoring data on-line |
JP5595513B2 (en) | 2009-11-12 | 2014-09-24 | アカシア ファーマ リミテッド | Use of bethanechol for the treatment of xerostomia |
US20110124996A1 (en) | 2009-11-20 | 2011-05-26 | Roche Diagnostics Operations, Inc. | Diabetes health management systems and methods |
US8613724B2 (en) | 2009-12-31 | 2013-12-24 | DEKA Products Limted Partnership | Infusion pump assembly |
US8348898B2 (en) | 2010-01-19 | 2013-01-08 | Medimop Medical Projects Ltd. | Automatic needle for drug pump |
US10911515B2 (en) | 2012-05-24 | 2021-02-02 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
US9662438B2 (en) | 2010-02-05 | 2017-05-30 | Deka Products Limited Partnership | Devices, methods and systems for wireless control of medical devices |
EP2531237A1 (en) | 2010-02-05 | 2012-12-12 | Sanofi-Aventis Deutschland GmbH | Medicated module with time lock |
IL211800A (en) | 2010-03-21 | 2014-03-31 | Isaac Zukier | Device for injecting fluids or gels |
US8810394B2 (en) | 2010-04-16 | 2014-08-19 | Medtronic, Inc. | Reservoir monitoring for implantable fluid delivery devices |
EP2575935B2 (en) | 2010-06-07 | 2023-08-23 | Amgen Inc. | Drug delivery device |
EP2397181B1 (en) | 2010-06-18 | 2014-01-15 | F. Hoffmann-La Roche AG | Insertion device having a permanently locking rotating needle cover |
US20110313680A1 (en) | 2010-06-22 | 2011-12-22 | Doyle Iii Francis J | Health Monitoring System |
CA2808457C (en) | 2010-08-17 | 2018-09-04 | University Of Florida Research Foundation, Inc. | Intelligent drug and/or fluid delivery system to optimize medical treatment or therapy using pharmacodynamic and/or pharmacokinetic data |
US9132233B2 (en) | 2010-08-26 | 2015-09-15 | B. Braun Melsungen Ag | Infusion control device |
US9498573B2 (en) | 2010-09-24 | 2016-11-22 | Perqflo, Llc | Infusion pumps |
EP2436412A1 (en) | 2010-10-04 | 2012-04-04 | Unomedical A/S | A sprinkler cannula |
CA2816388C (en) | 2010-10-12 | 2016-12-06 | The Regents Of The University Of California | Maintaining multiple defined physiological zones using model predictive control |
US9211378B2 (en) | 2010-10-22 | 2015-12-15 | Cequr Sa | Methods and systems for dosing a medicament |
CA3040486A1 (en) | 2011-02-09 | 2012-08-16 | Becton, Dickinson And Company | Insulin infusion set |
CN203609736U (en) | 2011-02-09 | 2014-05-28 | 贝克顿·迪金森公司 | Infusion device with automatic insertion and introducer needle retraction |
CN203724531U (en) | 2011-02-09 | 2014-07-23 | 贝克顿·迪金森公司 | Infusion device |
US8852152B2 (en) | 2011-02-09 | 2014-10-07 | Asante Solutions, Inc. | Infusion pump systems and methods |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
KR101836957B1 (en) | 2011-03-01 | 2018-03-09 | 제이디에스 테라퓨틱스, 엘엘씨 | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
US10010273B2 (en) | 2011-03-10 | 2018-07-03 | Abbott Diabetes Care, Inc. | Multi-function analyte monitor device and methods of use |
US9028410B2 (en) | 2011-04-08 | 2015-05-12 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US20120271655A1 (en) | 2011-04-19 | 2012-10-25 | Yishai Knobel | Methods and Systems for Enabling Applications on a Mobile Computing Device to Access Data Associated with a Peripheral Medical Device |
US8308680B1 (en) | 2011-04-26 | 2012-11-13 | Medtronic Minimed, Inc. | Selective alarms for an infusion device |
CA2834555A1 (en) | 2011-05-05 | 2012-11-08 | Eksigent Technologies, Llc | System and method of differential pressure control of a reciprocating electrokinetic pump |
US9075900B2 (en) | 2011-05-18 | 2015-07-07 | Exco Intouch | Systems, methods and computer program products for providing compliant delivery of content, applications and/or solutions |
BR112013033254A2 (en) | 2011-06-23 | 2017-03-01 | Univ Virginia Patent Foundation | system for managing patient glycemic control and computer readable non-transient storage media |
CN104023785B (en) | 2011-11-22 | 2017-03-01 | 贝克顿·迪金森公司 | There is the delivery system of delay device |
EP2902064B1 (en) | 2011-12-07 | 2018-07-04 | Becton, Dickinson and Company | Needle shielding assemblies and infusion devices for use therewith |
US20130178791A1 (en) | 2012-01-09 | 2013-07-11 | Jonathan C. Javitt | Method and system for detecting and treating biological and chemical warfare agents |
CA3154910A1 (en) | 2012-03-07 | 2013-09-12 | Deka Products Limited Partnership | Infusion pump assembly |
US9463280B2 (en) | 2012-03-26 | 2016-10-11 | Medimop Medical Projects Ltd. | Motion activated septum puncturing drug delivery device |
EP3549524B1 (en) | 2012-03-30 | 2023-01-25 | Insulet Corporation | Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith |
WO2013177565A1 (en) | 2012-05-25 | 2013-11-28 | Amylin Pharmaceuticals, Llc | Insulin-pramlintide compositions and methods for making and using them |
WO2013182321A1 (en) | 2012-06-09 | 2013-12-12 | Roche Diagnostics Gmbh | Disposable inserter for use with a medical device |
US20130338576A1 (en) | 2012-06-15 | 2013-12-19 | Wayne C. Jaeschke, Jr. | Portable infusion pump with pressure and temperature compensation |
ES2869202T3 (en) | 2012-06-18 | 2021-10-25 | Fresenius Kabi Deutschland Gmbh | Cannula line system for the puncture of central subcutaneous access lines |
US9757510B2 (en) | 2012-06-29 | 2017-09-12 | Animas Corporation | Method and system to handle manual boluses or meal events for closed-loop controllers |
US10130767B2 (en) | 2012-08-30 | 2018-11-20 | Medtronic Minimed, Inc. | Sensor model supervisor for a closed-loop insulin infusion system |
JP6073478B2 (en) | 2012-08-30 | 2017-02-01 | メドトロニック ミニメド インコーポレイテッド | System and method for controlling an insulin infusion device |
AU2015200834B2 (en) | 2012-08-30 | 2016-07-14 | Medtronic Minimed, Inc. | Safeguarding techniques for a closed-loop insulin infusion system |
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US20150213217A1 (en) | 2012-09-13 | 2015-07-30 | Parkland Center For Clinical Innovation | Holistic hospital patient care and management system and method for telemedicine |
CN105264924B (en) | 2012-11-12 | 2019-04-02 | 埃姆皮公司 | For the wireless pairing of electro photoluminescence and the system and method for communication |
US9253433B2 (en) | 2012-11-27 | 2016-02-02 | International Business Machines Corporation | Method and apparatus for tagging media with identity of creator or scene |
TWM452390U (en) | 2012-12-11 | 2013-05-01 | Dongguan Masstop Liquid Crystal Display Co Ltd | Active capacitive stylus |
US20140276536A1 (en) | 2013-03-14 | 2014-09-18 | Asante Solutions, Inc. | Infusion Pump System and Methods |
US9907909B2 (en) | 2012-12-20 | 2018-03-06 | Animas Corporation | Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas |
WO2014109898A1 (en) | 2013-01-14 | 2014-07-17 | The Regents Of University Of California | Model-based personalization scheme of an artificial pancreas for type i diabetes applications |
KR102212020B1 (en) | 2013-01-14 | 2021-02-05 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type i diabetes applications |
US10573413B2 (en) | 2013-03-14 | 2020-02-25 | Roche Diabetes Care, Inc. | Method for the detection and handling of hypoglycemia |
US20160038673A1 (en) | 2013-03-15 | 2016-02-11 | Animas Corporation | Insulin time-action model |
CN105142695B (en) | 2013-03-15 | 2020-06-02 | 安进公司 | Body contour adaptable autoinjector device |
US10016561B2 (en) | 2013-03-15 | 2018-07-10 | Tandem Diabetes Care, Inc. | Clinical variable determination |
US9795737B2 (en) | 2013-03-15 | 2017-10-24 | Animas Corporation | Method and system for closed-loop control of an artificial pancreas |
WO2014172467A1 (en) | 2013-04-16 | 2014-10-23 | Smartloop Llc | Discretionary insulin delivery systems and methods |
US10003545B2 (en) | 2013-04-26 | 2018-06-19 | Roche Diabetes Care, Inc. | Mobile phone application for diabetes care with medical feature activation |
CN105228675B (en) | 2013-05-31 | 2018-04-27 | 瓦莱里塔斯公司 | Fluid delivery system with the pre-filled cylinder of insertable |
JP2016530905A (en) | 2013-06-21 | 2016-10-06 | フレゼニウス ヴィアル エスアーエスFresenius Vial SAS | Method and control device for controlling administration of insulin to a patient |
CA2918332C (en) | 2013-07-18 | 2023-08-08 | Parkland Center For Clinical Innovation | Patient care surveillance system and method |
WO2015009385A1 (en) | 2013-07-19 | 2015-01-22 | Dexcom, Inc. | Time averaged basal rate optimizer |
WO2015056259A1 (en) | 2013-10-14 | 2015-04-23 | Dreamed-Diabetes Ltd. | System and method for improved artificial pancreas management |
EP2862586B1 (en) | 2013-10-21 | 2021-09-01 | F. Hoffmann-La Roche AG | Control unit for infusion pump units, including a controlled intervention unit |
US10517892B2 (en) | 2013-10-22 | 2019-12-31 | Medtronic Minimed, Inc. | Methods and systems for inhibiting foreign-body responses in diabetic patients |
JP6855244B2 (en) | 2013-10-31 | 2021-04-07 | デックスコム・インコーポレーテッド | Adaptive interface for continuous monitoring devices |
US10311972B2 (en) | 2013-11-11 | 2019-06-04 | Icu Medical, Inc. | Medical device system performance index |
CN105899127B (en) | 2013-11-14 | 2019-09-24 | 加州大学董事会 | Blood glucose rate rise detection device: the diet detection module for health monitoring systems |
BR112016012539B1 (en) | 2013-12-01 | 2021-11-30 | Becton, Dickinson And Company | APPARATUS FOR PRODUCING A STERILE CONNECTION, MEDICAL DEVICE AND METHOD FOR CREATING A STERILE CONNECTION WITH A FLUID IN A CONTAINER |
US9849240B2 (en) | 2013-12-12 | 2017-12-26 | Medtronic Minimed, Inc. | Data modification for predictive operations and devices incorporating same |
US20150173674A1 (en) | 2013-12-20 | 2015-06-25 | Diabetes Sentry Products Inc. | Detecting and communicating health conditions |
JP6137338B2 (en) | 2013-12-25 | 2017-05-31 | 富士通株式会社 | Pairing processing device, pairing processing method, and pairing processing program |
US9486571B2 (en) | 2013-12-26 | 2016-11-08 | Tandem Diabetes Care, Inc. | Safety processor for wireless control of a drug delivery device |
WO2015103543A1 (en) | 2014-01-03 | 2015-07-09 | University Of Virginia Patent Foundation | Central data exchange node for system monitoring and control of blood glucose levels in diabetic patients |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
US9399096B2 (en) | 2014-02-06 | 2016-07-26 | Medtronic Minimed, Inc. | Automatic closed-loop control adjustments and infusion systems incorporating same |
US10773032B2 (en) | 2014-03-14 | 2020-09-15 | Shl Medical Ag | Monitoring device |
US10034976B2 (en) | 2014-03-24 | 2018-07-31 | Medtronic Minimed, Inc. | Fluid infusion patch pump device with automatic fluid system priming feature |
CN106456067A (en) | 2014-06-06 | 2017-02-22 | 德克斯康公司 | Fault discrimination and responsive processing based on data and context |
US9656017B2 (en) | 2014-06-20 | 2017-05-23 | Howard E. Greene | Infusion delivery devices and methods |
AU2015284181B2 (en) | 2014-06-30 | 2020-05-07 | Icu Medical, Inc. | Infusion pump error display |
CN106714874B (en) | 2014-08-06 | 2019-10-08 | 加利福尼亚大学董事会 | Rolling time horizon state initialization device for control applications |
US9717845B2 (en) | 2014-08-19 | 2017-08-01 | Medtronic Minimed, Inc. | Geofencing for medical devices |
PT3185934T (en) | 2014-08-28 | 2018-10-19 | Unl Holdings Llc | Skin sensors for drug delivery devices |
JP6734262B2 (en) | 2014-09-15 | 2020-08-05 | サノフイSanofi | Skin-wearable drug delivery device including contact sensor |
US20160082187A1 (en) | 2014-09-23 | 2016-03-24 | Animas Corporation | Decisions support for patients with diabetes |
US10529454B2 (en) | 2014-10-17 | 2020-01-07 | Bradley E. Kahlbaugh | Human metabolic condition management |
US9943645B2 (en) | 2014-12-04 | 2018-04-17 | Medtronic Minimed, Inc. | Methods for operating mode transitions and related infusion devices and systems |
US10307535B2 (en) | 2014-12-19 | 2019-06-04 | Medtronic Minimed, Inc. | Infusion devices and related methods and systems for preemptive alerting |
US9775957B2 (en) | 2015-01-16 | 2017-10-03 | Becton, Dickinson And Company | Smart module for injection devices |
JP2018505756A (en) | 2015-02-18 | 2018-03-01 | インシュレット コーポレイション | Fluid delivery and infusion device and method of use thereof |
US10569014B2 (en) | 2015-03-02 | 2020-02-25 | Amgen Inc. | Device and method for making aseptic connections |
US10646650B2 (en) | 2015-06-02 | 2020-05-12 | Illinois Institute Of Technology | Multivariable artificial pancreas method and system |
JP6853198B2 (en) | 2015-06-28 | 2021-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | Speed-weighted model predictive control of artificial pancreas for application to type 1 diabetes |
US10463297B2 (en) | 2015-08-21 | 2019-11-05 | Medtronic Minimed, Inc. | Personalized event detection methods and related devices and systems |
EP3371770A4 (en) | 2015-11-04 | 2019-04-24 | Bayer Healthcare LLC | Barcode database and software update system |
US10716896B2 (en) | 2015-11-24 | 2020-07-21 | Insulet Corporation | Wearable automated medication delivery system |
US10413665B2 (en) | 2015-11-25 | 2019-09-17 | Insulet Corporation | Wearable medication delivery device |
US10248839B2 (en) | 2015-11-30 | 2019-04-02 | Intel Corporation | Locating objects within depth images |
CA2994015A1 (en) | 2015-12-18 | 2017-06-22 | Dexcom, Inc. | Data backfilling for continuous glucose monitoring |
US10987468B2 (en) | 2016-01-05 | 2021-04-27 | Bigfoot Biomedical, Inc. | Operating multi-modal medicine delivery systems |
US9980140B1 (en) | 2016-02-11 | 2018-05-22 | Bigfoot Biomedical, Inc. | Secure communication architecture for medical devices |
US10792423B2 (en) | 2016-04-13 | 2020-10-06 | The Trustees Of The University Of Pennsylvania | Methods, systems, and computer readable media for physiology parameter-invariant meal detection |
AU2017259158B2 (en) | 2016-05-02 | 2022-07-28 | Dexcom, Inc. | System and method for providing alerts optimized for a user |
EP3871708A3 (en) | 2016-05-26 | 2022-01-19 | Insulet Corporation | Wearable drug delivery system comprising a prefilled cartridge |
US10332632B2 (en) | 2016-06-01 | 2019-06-25 | Roche Diabetes Care, Inc. | Control-to-range failsafes |
WO2018009614A1 (en) | 2016-07-06 | 2018-01-11 | President And Fellows Of Harvard College | Event-triggered model predictive control for embedded artificial pancreas systems |
US10052441B2 (en) | 2016-08-02 | 2018-08-21 | Becton, Dickinson And Company | System and method for measuring delivered dose |
US11202579B2 (en) | 2016-08-08 | 2021-12-21 | Zoll Medical Corporation | Wrist-worn device for coordinating patient care |
KR102494011B1 (en) | 2016-09-09 | 2023-01-31 | 덱스콤, 인크. | Systems and methods for CGM-based bolus calculators for display and presentation to drug delivery devices |
US10987032B2 (en) | 2016-10-05 | 2021-04-27 | Cláudio Afonso Ambrósio | Method, system, and apparatus for remotely controlling and monitoring an electronic device |
US10561788B2 (en) | 2016-10-06 | 2020-02-18 | Medtronic Minimed, Inc. | Infusion systems and methods for automated exercise mitigation |
US11097051B2 (en) | 2016-11-04 | 2021-08-24 | Medtronic Minimed, Inc. | Methods and apparatus for detecting and reacting to insufficient hypoglycemia response |
US10854322B2 (en) | 2016-12-21 | 2020-12-01 | Medtronic Minimed, Inc. | Infusion systems and methods for patient activity adjustments |
US11534548B2 (en) | 2016-12-30 | 2022-12-27 | Medtrum Technologies Inc. | System and method for a closed loop control in an artificial pancreas |
US10583250B2 (en) | 2017-01-13 | 2020-03-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
US10881792B2 (en) | 2017-01-13 | 2021-01-05 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
EP3568859A1 (en) | 2017-01-13 | 2019-11-20 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
CA3046354A1 (en) | 2017-01-17 | 2018-07-26 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and event detection |
US11197949B2 (en) | 2017-01-19 | 2021-12-14 | Medtronic Minimed, Inc. | Medication infusion components and systems |
JP2020511202A (en) | 2017-02-15 | 2020-04-16 | ユニヴァーシティー オブ ヴァージニア パテント ファンデーション ドゥーイング ビジネス アズ ユニヴァーシティー オブ ヴァージニア ライセンシング アンド ヴェンチャーズ グループ | System, method and computer readable medium for basal rate profile adaptation algorithm for closed loop artificial pancreas system |
US10729849B2 (en) | 2017-04-07 | 2020-08-04 | LifeSpan IP Holdings, LLC | Insulin-on-board accounting in an artificial pancreas system |
EP3970611B1 (en) | 2017-05-05 | 2023-12-06 | Ypsomed AG | Closed loop control of physiological glucose |
WO2019005686A1 (en) | 2017-06-26 | 2019-01-03 | Abbott Diabetes Care Inc. | Artificial pancreas integrated cgm architectures and designs |
US20210193285A1 (en) | 2017-10-19 | 2021-06-24 | Dreamed Diabetes Ltd. | A system and method for use in disease treatment management |
EP3707820A4 (en) | 2017-11-08 | 2021-08-11 | General Vibration Corporation | Coherent phase switching and modulation of a linear actuator array |
US11197964B2 (en) | 2017-12-12 | 2021-12-14 | Bigfoot Biomedical, Inc. | Pen cap for medication injection pen having temperature sensor |
CA3085930A1 (en) | 2017-12-21 | 2019-06-27 | Eli Lilly And Company | Closed loop control of physiological glucose |
EP3788628A1 (en) | 2018-05-04 | 2021-03-10 | Insulet Corporation | Safety constraints for a control algorithm-based drug delivery system |
AU2019288473A1 (en) | 2018-06-22 | 2020-12-10 | Ypsomed Ag | Insulin and pramlintide delivery systems, methods, and devices |
AU2018264051B2 (en) | 2018-08-09 | 2020-03-26 | Final Bell Brand Co. | A vaporization device, method of using the device, a charging case, a kit, and a vibration assembly |
US11628251B2 (en) | 2018-09-28 | 2023-04-18 | Insulet Corporation | Activity mode for artificial pancreas system |
US11097052B2 (en) | 2018-09-28 | 2021-08-24 | Medtronic Minimed, Inc. | Insulin infusion device with configurable target blood glucose value for automatic basal insulin delivery operation |
US10894126B2 (en) | 2018-09-28 | 2021-01-19 | Medtronic Minimed, Inc. | Fluid infusion system that automatically determines and delivers a correction bolus |
US20220054748A1 (en) | 2018-10-15 | 2022-02-24 | President And Fellows Of Harvard College | Control model for artificial pancreas |
EP3998943A4 (en) | 2019-07-16 | 2023-09-06 | Beta Bionics, Inc. | Blood glucose control system |
MX2022001442A (en) | 2019-08-02 | 2022-02-22 | Abbott Diabetes Care Inc | Systems, devices, and methods relating to medication dose guidance. |
US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
US20220023536A1 (en) | 2020-07-22 | 2022-01-27 | Insulet Corporation | Open-loop insulin delivery basal parameters based on insulin delivery records |
-
2020
- 2020-07-31 US US16/945,246 patent/US11684716B2/en active Active
-
2023
- 2023-05-12 US US18/316,703 patent/US20230277766A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018093727A1 (en) * | 2016-11-15 | 2018-05-24 | Insulet Corporation | Basal insulin management |
Also Published As
Publication number | Publication date |
---|---|
US11684716B2 (en) | 2023-06-27 |
US20230277766A1 (en) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11801344B2 (en) | Blood glucose rate of change modulation of meal and correction insulin bolus quantity | |
US11986630B2 (en) | Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk | |
EP4069082B1 (en) | Techniques and devices providing adaptivity and personalization in diabetes treatment | |
EP4231308A2 (en) | Adaptive duration of insulin action for use in insulin on board calculations | |
US11684716B2 (en) | Techniques to reduce risk of occlusions in drug delivery systems | |
US20220168505A1 (en) | Device and methods for a simple meal announcement for automatic drug delivery system | |
US20210228804A1 (en) | Meal insulin determination for improved post prandial response | |
US20230061740A1 (en) | Methods and systems for managing fluid pump delivery impediments | |
EP4084007A1 (en) | Devices and methods for initialization of drug delivery devices using measured analyte sensor information | |
EP4039293A1 (en) | Techniques and devices for adaptation of maximum drug delivery limits | |
EP4261835A1 (en) | System and method for creating or adjusting manual basal profiles | |
EP4369350A1 (en) | Maximum subcutaneous insulin absorption rates to calculate effective insulin-on-board in automated insulin delivery systems | |
US20240000347A1 (en) | System and method for evaluating risk of hypoglycemia or hyperglycemia | |
US20230248909A1 (en) | Techniques for determining medication correction factors in automatic medication delivery systems | |
US20220241504A1 (en) | Systems and methods for incorporating co-formulations of insulin in an automatic insulin delivery system | |
US20240075208A1 (en) | Method for detecting occlusions in a fluid path using blood glucose readings | |
WO2024081559A1 (en) | System and method for determining the effect of ingestion of meals of varying carbohydrate content | |
WO2024118292A1 (en) | Medicament injection pen with automatic dosing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: INSULET CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHENG, YIBIN;O'CONNOR, JASON;LEE, JOON BOK;SIGNING DATES FROM 20200729 TO 20200731;REEL/FRAME:053378/0590 |
|
AS | Assignment |
Owner name: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT, MARYLAND Free format text: SECURITY AGREEMENT SUPPLEMENT FOR INTELLECTUAL PROPERTY;ASSIGNOR:INSULET CORPORATION;REEL/FRAME:061951/0977 Effective date: 20220627 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |